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Proteins, with their ability to perform a variety of highly specific biological functions, have emerged as an
important class of therapeutics. However, to fully harness their therapeutic potential, proteins often need to be
optimized by molecular engineering; therapeutic efficacy can be improved by modulating protein properties
such as binding affinity/specificity, half-life, bioavailability, and immunogenicity. In this work, we first present
an introductory example in which a mechanistic mathematical model was used to improve target selection for
directed evolution of an aglycosylated Fc domain of an antibody to enhance phagocytosis of tumor cells.
Several aspects of directed evolution experimental methods were then optimized. A model-guided ligation
strategy was developed to maximize ligation yield in DNA library construction, and this design tool is freely
available through a web server. Streamlined protocols for mRNA display and ribosome display, which are
powerful in vitro selection methods, were also created to allow robust selection of a variety of therapeutic
proteins, including monomeric Fc domains, designed ankyrin repeat proteins, a single-chain insulin analog
(SCI-57), and leptin. Anti-ICAM-1 scFv antibody fragments were also optimized for ribosome display by
grafting complementarity determining regions onto a stable human framework. In addition to engineering the
proteins themselves, effective delivery systems are essential for maximizing the therapeutic benefit of these
proteins in a clinical setting. We therefore also developed a novel oral delivery platform based on the food-
grade bacterium Lactococcus lactis. SCI-57, leptin, and SCI-57-leptin fusion proteins have been successfully
secreted from this host in vitro and preliminary studies in a diabetic mouse model show reduced glucose levels
after oral administration of L. lactis secreting SCI-57. We then further improved the secretion potential of this
host through directed evolution of a L. lactis signal peptide. In summary, our studies have provided important
advances to the field of protein engineering through the development of mechanistic mathematical models,
streamlined experimental methodologies, and polypeptides with improved properties. This work has also
opened up the possibility of systemic delivery of protein therapeutics using live microorganisms.
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ABSTRACT 
IMPROVING PROTEIN THERAPEUTICS THROUGH QUANTITATIVE 
MOLECULAR ENGINEERING APPROACHES AND A CELL-BASED ORAL 
DELIVERY PLATFORM 
Daphne T. W. Ng 
Casim A. Sarkar, Ph.D. 
 
Proteins, with their ability to perform a variety of highly specific biological functions, 
have emerged as an important class of therapeutics. However, to fully harness their 
therapeutic potential, proteins often need to be optimized by molecular engineering; 
therapeutic efficacy can be improved by modulating protein properties such as binding 
affinity/specificity, half-life, bioavailability, and immunogenicity. In this work, we first 
present an introductory example in which a mechanistic mathematical model was used to 
improve target selection for directed evolution of an aglycosylated Fc domain of an 
antibody to enhance phagocytosis of tumor cells. Several aspects of directed evolution 
experimental methods were then optimized. A model-guided ligation strategy was 
developed to maximize ligation yield in DNA library construction, and this design tool is 
freely available through a web server. Streamlined protocols for mRNA display and 
ribosome display, which are powerful in vitro selection methods, were also created to 
allow robust selection of a variety of therapeutic proteins, including monomeric Fc 
domains, designed ankyrin repeat proteins, a single-chain insulin analog (SCI-57), and 
vii 
 
leptin. Anti-ICAM-1 scFv antibody fragments were also optimized for ribosome display 
by grafting complementarity determining regions onto a stable human framework. In 
addition to engineering the proteins themselves, effective delivery systems are essential 
for maximizing the therapeutic benefit of these proteins in a clinical setting. We therefore 
also developed a novel oral delivery platform based on the food-grade bacterium 
Lactococcus lactis. SCI-57, leptin, and SCI-57-leptin fusion proteins have been 
successfully secreted from this host in vitro and preliminary studies in a diabetic mouse 
model show reduced glucose levels after oral administration of L. lactis secreting SCI-57. 
We then further improved the secretion potential of this host through directed evolution 
of a L. lactis signal peptide. In summary, our studies have provided important advances 
to the field of protein engineering through the development of mechanistic mathematical 
models, streamlined experimental methodologies, and polypeptides with improved 
properties. This work has also opened up the possibility of systemic delivery of protein 
therapeutics using live microorganisms. 
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CHAPTER 1 
Introduction 
1.1 Protein therapeutics 
Proteins, encoded by 25,000–40,000 different genes in the human genome1,2, comprise 
one of the most diverse classes of biological macromolecules. They perform a variety of 
important biochemical tasks in the body, including catalysis and cellular signaling, and 
they also serve mechanical and structural roles. There is increasing interest in harnessing 
the potential of proteins to develop new therapeutics, which have traditionally been 
dominated by small molecules
3
. Protein therapeutics can offer a range of highly specific 
and complex functions that cannot be achieved by small molecules
4
, thus providing novel 
treatments to alleviate diseases. Proteins with catalytic activity can replace or augment 
natural enzymes or they can provide entirely novel functions; proteins with specific 
binding properties can block the functions of their targets or they can be used to deliver a 
cytotoxic or effector payload to specific cells
4
. Today, there are over 200 approved 
protein therapeutics in the market
5
, with many more promising ones in development. 
Among the approved therapeutics are blood factors, thrombolytics and anticoagulants, 
hormones, growth factors, interferons and interleukins, vaccines, and monoclonal 
antibody-based products to treat a variety of diseases such as hemophilia, myocardial 
infarction, diabetes, anemia, hepatitis, rheumatoid arthritis, and cancer
5
. 
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Since the approval of the first recombinant protein therapeutic human insulin in 
1982
6
, advances in recombinant protein technology have largely fueled the popularity of 
protein therapeutics in the past few decades. It is now possible to circumvent the 
inefficient and costly purification of proteins from natural sources and to produce highly 
pure proteins efficiently and in large quantities in the laboratory. Recombinant proteins 
can be produced from a variety of host systems including bacteria, yeast, insect cells, 
mammalian cells, and transgenic animals and plants, each of which offers differing 
advantages in production cost and processing (e.g. post-translational modifications)
4
. 
Perhaps more importantly, another major advantage that recombinant protein technology 
offers is the ability to modify or create novel protein properties
7
, which is often necessary 
in the development and optimization of protein therapeutics for specific clinical 
applications.  
 
1.2 Improving protein therapeutics through molecular engineering 
Paralleling the increasing popularity of protein-based therapeutics, the field of protein 
engineering has rapidly emerged since the 1980s
7
. Protein engineering has greatly 
expanded the repertoire of proteins available for therapeutic purposes. The majority of 
protein drugs consist of monoclonal antibodies
8
, in which the Fab region enables high- 
affinity target binding and the Fc region modulates immunological effector functions and 
significantly extends circulatory half-life in vivo
9
. Monoclonal antibodies have been 
traditionally produced from hybridomas, but recombinant DNA technology now allows 
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chimerization and humanization of monoclonal antibodies to reduce immunogenicity and 
also enables display libraries to be constructed and screened in order to further improve 
affinities and specificities
8
. In addition, natural ligands and receptors represent another 
important class of protein therapeutics; these proteins are utilized for their innate ability 
to interact with high affinity and specificity with targets in the body, but they are often 
further engineered to create custom therapeutics with optimized properties
10
. A new 
generation of potential therapeutics includes engineered protein scaffolds, which are 
typically derived from stable, soluble, and easily expressed monomeric proteins that can 
overcome the limitations posed by antibodies or natural proteins
11
. More than 50 such 
alternative protein scaffolds have been proposed, including Affibodies
12
, Monobodies
13
, 
and designed ankyrin repeat proteins (DARPins)
14
, most of which have been engineered 
to interact with different molecules of interest. 
Additional engineering efforts are motivated by limitations in current protein 
therapeutics, including their high production costs, large sizes with limited tissue 
penetration and localization, inability to cross epithelial and endothelial structures, and 
rapid degradation by proteases and clearance from the body
7
. Drug potency can be 
improved by increasing affinity and specificity for protein binders or catalytic activity for 
enzymes and also by augmenting half-life and bioavailability by reducing clearance and 
decreasing degradation
9. In addition, immunogenicity can be alleviated by “humanizing” 
drugs
15
, and production costs can be reduced in some cases by eliminating glycosylation 
and/or disulfide bonds to allow production in lower organisms and simplify downstream 
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purification. Furthermore, the host itself can be engineered to increase protein expression 
levels. 
  Protein engineering efforts have relied on two complementary approaches, 
rational design and directed evolution. In rational design, detailed knowledge of protein 
structure and function are used to “design” new proteins or to improve the properties of 
existing proteins. Computational algorithms are often used to aid rational design, by 
sampling the amino acid sequence in protein structure-function space. The “design cycle” 
often includes iterating between molecular modeling and experimental construction and 
analysis of the designed protein until the desired properties are achieved
16
. This 
hypothesis-driven manipulation of proteins is direct and inexpensive, and it has achieved 
success when structural knowledge of the protein is available
17
. However, the need for 
detailed structural information and computational complexity in predicting the 
combinatorial effects of multiple mutations has prevented the rational design of many 
interesting proteins. Directed evolution, on the other hand, works by mimicking the 
natural evolutionary process involving repeated cycles of mutation and selection in order 
to evolve molecules with desired properties. This method is indirect and more labor-
intensive, and the combinatorial nature of the sequence space can give an astronomically 
large number of possible polypeptide sequences
18
. However, given that minimal 
structural information is required and powerful screening and selection techniques are 
now available, directed evolution has become a popular and effective protein engineering 
approach. 
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1.3 Directed evolution 
Directed evolution consists of iterative cycles of diversity generation and selection to 
evolve proteins with new and improved properties (Fig. 1.1). The starting template is 
usually chosen based on its “proximity” to the desired function19, and a library of mutants 
is constructed “around” the parent molecule to sample the surrounding sequence space. 
Alternatively, a naïve synthetic library built on a stable scaffold can be used as the 
starting material. To generate molecular diversity, different randomization methods can 
be employed. Error-prone PCR is frequently used to introduce random point mutations, 
as point mutations can often act alone or synergistically to give rise to new, unexpected 
functions. Taq polymerase with mutagenic buffer
20,21
 or nucleotide triphosphate 
analogs
22
, or other error-prone DNA polymerases can be used. This method can sample a 
broad spectrum of sequence space, but sampling cannot be done exhaustively as the 
number of possible mutations far exceeds the upper limit of any current screening or 
selection capabilities. Saturation mutagenesis, on the other hand, can efficiently sample a 
highly focused region of sequence space, often a “hot spot” which is typically around the 
active site of an enzyme or binding site of a protein. A saturation mutagenesis library is 
usually constructed using degenerate oligonucleotides
23
 or primers synthesized with 
trinucleotide phosphoramidites
24
. A third method, DNA shuffling, allows in vitro 
homologous recombination of selected mutant genes
25,26
. This method can be used 
together with error-prone PCR and/or saturation mutagenesis to recombine beneficial 
mutations from different parents and allow the further separation of beneficial mutational 
combinations from neutral or deleterious ones. 
6 
 
 
Figure 1.1. Schematic overview of directed evolution. Directed evolution starts with a parent molecule 
with functions to be optimized, or a naïve molecule for evolving new properties. Libraries of new 
molecules are generated by incorporating mutations at various sites, which are then subjected to functional 
assays to screen or select for mutants with desired properties. Central to the functional assays in all directed 
evolution methodologies is the ability to couple phenotype (selected property) to genotype (nucleotide 
sequence) in order to determine the sequences of improved variants. The best clones are used for the next 
iteration of mutation and selection or they are subjected to analysis once the engineering objective is met
19
. 
 
 With the library of mutants in hand, a functional assay is needed to find the subset 
of mutants that contain the properties of interest. Screening methodologies involve direct 
functional evaluation of each individual clone, usually with low to medium throughput 
(10
2
 to 10
6
 clones/round). Screening is straightforward and can utilize almost any 
biochemical or biophysical detection method
27
. Selection methods, on the other hand, 
allow much higher numbers of variants (10
6
 to > 10
12
 clones/round) to be filtered, but 
carefully designed assays are needed to select, retain, and amplify clones with the desired 
properties while minimizing false positives arising from the indirect nature of most 
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selections. Nevertheless, the advantage of sampling a much larger fraction of sequence 
space might justify the efforts in setting up such selections
27
. 
In the case of directed protein evolution, the available methodologies ensure 
physical linkage of the displayed phenotype (desired protein property) and the genotype 
(cDNA or mRNA encoding the variant) to allow recovery and identification of mutant 
sequences after screening or selection. Depending on the protein of interest and the 
properties to be engineered, in vivo display techniques (e.g., phage display
28
 and yeast 
surface display
29
) or in vitro display techniques (e.g., mRNA display
30
 and ribosome 
display
31
) can be employed. We focused our investigation on two powerful in vitro 
display technologies, ribosome display and mRNA display, as their cell-free nature 
enables selections on the largest possible libraries to date (up to 10
14
 members). 
Ribosome display involves in vitro translation of mRNA sequences lacking stop codons 
to generate ternary complexes in which each mRNA and its corresponding protein are 
noncovalently associated via a stalled ribosome
32
. mRNA display uses an mRNA-DNA-
puromycin fusion as its template for in vitro translation, which results in a covalent 
puromycin linkage between the mRNA and the corresponding nascent peptide
33
. Unlike 
in vivo display methods, which rely on a transformation step to incorporate the library 
into display formats
34
, ribosome display and mRNA display are performed entirely in 
vitro, so the theoretical limit to library size is the amount of translation mixture that can 
be physically accommodated in a tube. Another advantage is that in vitro display allows 
easy introduction of additional diversity between generations because the PCR step, often 
used to add diversity, is inherent to these methods
35
. 
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Finally, in all directed evolution methods, screened or selected clones with 
desired properties are obtained and their sequences are analyzed to identify beneficial 
mutations. These variants can either be used as the starting template for the next round of 
evolution or further analyzed once the engineering objective is fulfilled
19
. 
 
1.4 The role of mathematical modeling in directed evolution 
The success of directed evolution experiments is directly impacted by the ability to 
construct and propagate a high-quality library of variants. Since each library member 
represents a unique combination of properties, any loss due to insufficient sampling or 
inefficient experimental procedures could be detrimental to the identification of improved 
variants through a series of screenings or selections. Furthermore, each round of directed 
evolution is extremely labor intensive, so the higher the enrichment ratio per round, the 
faster the engineering objective can be fulfilled. Once clones with beneficial properties 
have been identified, performing additional experiments to trace the source of these 
properties to specific mutations can provide tremendous mechanistic insight into the 
sequence-structure-function relationship of the protein and aid further engineering efforts. 
Due to the combinatorial nature of mutants and complexity of selection assays, statistical 
and quantitative approaches are very useful in guiding and optimizing directed evolution 
experiments and in evaluating the multitude of mutational effects both during and after 
the selection process. 
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 Various computational tools have enabled construction of highly guided 
libraries
36
, and statistical analyses have allowed estimation of the completeness and 
diversity of library assembled using various library construction methods
37,38
. Not only 
can quantitative approaches allow higher quality libraries to be constructed to maximize 
variants containing beneficial mutations, but knowledge of the frequency and location of 
mutations within the ensemble of variants can help guide sampling and selection 
procedures
39–46
. Mathematical models have also been developed to optimize screening 
and selection parameters in order to maximize enrichment of desired properties
47,48
. 
Depending on the choice of assay, the optimal experimental conditions are often non-
intuitive, and conventional wisdom can misguide the selection efforts
48
. In many cases, 
the optimal experimental parameters can be identified through simple mathematical 
analyses without the need for extensive experimental trial-and-error, which can then be 
incorporated into suitable screening and selection assays
47–49
. In addition, data-driven 
models that employ multivariate statistical techniques to model protein sequence-activity 
relationships (ProSAR) can guide the evolutionary process
50
. ProSAR classifies 
individual mutations as beneficial, neutral, or deleterious, which informs the design of 
subsequent libraries
51–56
. Finally, mechanistic models have been used to relate 
biochemical properties to desired protein functions to explain experimental observations 
and provide insights into future engineering efforts
57–60
. Molecular-level kinetic models 
can also be incorporated into systems-level pharmacokinetic/pharmacodynamic models to 
investigate physiological effects arising from changes in molecular properties, providing 
a more holistic approach in the development of new protein therapeutics
61
. 
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1.5 The significance and bottlenecks for oral delivery 
Although the tools for protein engineering have grown at a rapid rate, the methods for 
delivering protein drugs have remained similar despite much research. For decades, 
proteins have been administered by subcutaneous, intramuscular, or intravenous 
injections
62
. These invasive methods lead to poor patient compliance and complications 
at injection sites, such as pain, irritation, infection, and tissue damage
63
. While many life-
saving drugs have been administered through injections, other potential therapeutics for a 
variety of chronic or non-lethal diseases are not entering the clinic due to barriers in 
administration and dosage requirement. Depending on the injection type, medical 
personnel might need to administer the drug, which becomes impractical for short-acting 
therapeutics that require multiple injections per day. Injection also brings about a social 
stigma and poor patient acceptance, and missed doses can have deleterious health 
outcomes
62
. Thus, non-invasive approaches such as pulmonary, transdermal, or oral 
delivery are more preferable. Oral delivery, in particular, has been the route of choice for 
the majority of small-molecule drugs. This mode of administration is easy to use, widely 
accepted, and can prevent the problems and side effects associated with injections
63
. 
Patient compliance is also significantly improved, which often leads to improved health 
outcomes
64
, especially for chronic illnesses. Moreover, for some proteins (e.g., insulin), 
oral delivery offers an additional advantage of more accurately recapitulating normal 
physiology. After absorption in the intestine, orally delivered insulin reaches the portal 
system, more closely approximating what occurs in a non-diabetic individual
65
. 
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 Despite the many advantages of oral delivery, this route of administration is not 
yet feasible for most proteins due to low bioavailability
66
. The first reason is poor 
stability due to low pH of the gastric fluid and enzymatic degradation at multiple sites 
along the gastrointestinal tract
67
. Protein drugs administered orally are subjected to pre-
systemic degradation, first encountering pepsin in the stomach, then pancreatic proteases 
such as trypsin, α-chymotrypsin, and elastase in the intestinal lumen, and proteolytic 
enzymes associated with enterocytes
68
. The second reason for low bioavailability is due 
to poor penetration of the intestinal wall to reach systemic circulation
67
. The intestine is 
lined with closely packed epithelial cells, which form tight junctions that keep out most 
macromolecules (e.g., proteins) to prevent absorption of unwanted and potentially 
harmful molecules
68
 (Fig. 1.2). The transcellular route of absorption, which requires large 
hydrophilic therapeutic proteins to cross by passive diffusion, is extremely difficult. The 
alternative, paracellular route through tight junctions, is also not feasible for molecules 
with the physical dimensions of proteins
69
. By comparison, small-molecule drugs, usually 
with molecular weight less than 500 Da, can engage both pathways
68
. 
 
Figure 1.2. Pathways of intestinal drug absorption. The intestine is tightly packed with intestinal epithelial 
cells, which form tight junctions. (1) Transcellular diffusion involves diffusion through both the apical and 
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basolateral plasma membranes of the epithelial cells, which is difficult for large, highly charged molecules. 
(2) Paracellular diffusion involves diffusion through the aqueous intercellular space between adjacent 
epitheial cells. However, a group of interacting transmembrane and cytosolic proteins (tight junctions) is 
selectively permeable to only small, hydrophilic molecules. (3) Carrier-mediated transcellular transport 
actively transports specifically recognized molecules across the epithelial cells. 
 
To increase oral bioavailability, various strategies have been developed. 
Approaches involving permeation enhancers or protease inhibitors as additives could be 
effective, but their long-term use remains questionable because of possible absorption of 
unwanted molecules and disturbance of the digestion of nutritive proteins
70
. Another 
strategy involves encapsulating protein drugs in microparticles, nanoparticles, or 
liposomes to protect the therapeutics from enzymatic digestion. However, there are 
concerns regarding the stability of proteins during the processing, release, and storage of 
these formulations as well as the fate of synthetic particles
70
. It is also necessary to 
consider the use of a delivery carrier system to cross the intestinal barrier. A class of cell-
penetrating peptides, such as TAT, penetratin, and oligoarginine, have been used to 
internalize different biomolecules into cells
71–73
. But such peptide-cell interactions are 
non-specific and may cause undesired toxicity
74
. Harnessing endogenous intestinal 
transport systems, a potentially safer and more practical strategy, has also been used to 
increase intestinal absorption of peptides and proteins. For example, the transferrin 
receptor and vitamin B12 receptor have been utilized to transport transferrin- and vitamin 
B12-conjugated drugs respectively
75,76
; however, such approaches might interfere with 
normal absorption of these nutrients. Therefore, further improvements in oral delivery 
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strategies are necessary to elicit maximum benefit from the current and next generations 
of protein therapeutics. 
 
1.6 Significance of research 
Development of new protein therapeutics requires parallel efforts in many different areas, 
and this work has contributed in three major directions. First, our molecular engineering 
efforts have brought about important improvements in display technologies and in the 
properties of several different classes of proteins that are commonly used as therapeutic 
modalities. Two central streamlined display platforms, mRNA display and ribosome 
display, have been developed for monoclonal antibodies and Fc domains, natural ligands, 
and alternative scaffolds such as DARPins. Many important protein properties were 
examined, including aglycosylation to remove glycan heterogeneity and enable facile 
engineering of novel effector functions, disulfide bond removal for easier protein 
production, fusion to the Fc domain of an antibody to increase half-life and 
bioavailability, antibody humanization to reduce immunogenicity, utilization of single-
chain analogs of heterodimeric proteins for increased stability, and engineered signal 
peptides for improved protein secretion. Two of the engineering strategies resulted in 
improvements over existing molecules: (1) grafting the complementarity determining 
regions (CDRs) of an anti-ICAM-1 single-chain variable fragment (scFv) into a stable 
framework improved its biophysical properties and (2) directed evolution of a signal 
peptide enhanced protein secretion from Lactococcus lactis. 
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 Second, our mathematical modeling efforts can be used in a broad spectrum of 
applications to guide directed evolution experiments. For library construction, an 
experimentally validated, easily parameterized thermodynamic model was developed to 
optimize ligation reactions and provide general insights. A free, web-based ligation 
calculator was subsequently developed to allow facile and customized optimization of 
ligation reactions by the scientific community. In addition, mechanistic models were 
developed to explain and guide two different directed evolution experiments. The 
relationship between mRNA folding and translation/secretion efficiencies was 
quantitatively explained in the first model, which was successfully used to explain and 
quantify the effects of silent mutations in signal peptides. Our second model provides 
mechanistic insight into how IgG Fc receptor affinity relates to effector functions in 
phagocytic cells. The identification of a dominant allele that has largely been overlooked 
in triggering phagocytosis will be vital to future Fc engineering efforts. 
 Third, our novel cell-based delivery platform using L. lactis offers an alternative 
approach in addressing some of the bottlenecks in oral delivery. This food-grade 
bacterium was successfully used to secrete bioactive proteins both in vitro and in vivo. 
One of the major hurdles in oral delivery of proteins, proteolytic degradation, can be 
attenuated since recombinant protein is locally produced by the bacteria in the intestine. 
Ongoing work to conjugate protein therapeutics to a viable transcytosis partner may 
overcome the other major problem of poor absorption. This work opens up the possibility 
of systemic delivery of protein therapeutics via oral administration using live 
microorganisms. 
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1.7 Chapter layout 
We start by presenting in Chapter 2 an introductory example of an application in which 
directed evolution was used to engineer a useful protein therapeutic. The Fc domain of an 
IgG antibody was aglycosylated and evolved to achieve increased affinity to activating 
Fcγ receptors for an enhanced immune response. We developed a mathematical model to 
help explain how receptor affinities and contradictory signaling relate to improved 
antibody dependent cell-mediated phagocytosis (ADCP). We have also provided 
guidelines for future engineering of Fc domains with enhanced effector functions by 
identifying a new target allele for improving ADCP. 
The following three chapters describe our optimizations and selections in various 
directed evolution applications. In Chapter 3, initial library construction for generation of 
diversity in directed evolution experiments was examined, and a model-guided ligation 
strategy is shown to be beneficial in optimizing assembly of DNA libraries. We 
demonstrated that display vectors should be redesigned to utilize Type IIS restriction sites 
to improve ligation yield, and we developed an easily parameterized thermodynamic 
model and accompanying web-based ligation calculator to predict product distributions. 
General insights and guidelines were provided for optimizing ligation reactions for both 
in vivo and in vitro display methodologies. A high-quality library would benefit the most 
from an effective selection procedure, and we present a streamlined mRNA display 
protocol in Chapter 4. We tested the procedure by performing affinity selection against 
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Her2 using binary DARPin libraries. An enrichment factor of up to two orders of 
magnitude per selection round was achieved. Display of monomeric IgG Fc domains 
using this new protocol is also discussed. In Chapter 5, other scaffold and therapeutic 
proteins, such as ankyrin repeat proteins, a single-chain insulin analog, leptin, and scFv 
against ICAM-1 were displayed using an updated version of ribosome display. CDR 
grafting into stable human frameworks, which is traditionally used to humanize 
antibodies to reduce immunogenicity for therapeutic purposes, was shown to be an 
effective strategy for engineering antibodies with higher thermodynamic stability and 
more efficient folding. 
Although advances in biomolecular engineering are critical to improving the 
potencies of therapeutic proteins, an effective oral delivery system is also necessary to 
maximize the therapeutic benefit for proteins such as insulin. We propose a novel oral 
delivery platform utilizing the food-grade bacterium L. lactis in Chapters 6 and 7. In 
Chapter 6, L. lactis was used to successfully secrete a single-chain insulin, leptin, and 
insulin-leptin fusion proteins. Preliminary in vivo experiments in which insulin-secreting 
bacteria have been orally delivered into diabetic mice also show promising results. In 
Chapter 7, we further exploit the secretion capability of L. lactis by performing directed 
evolution on its major signal peptide. Saturation mutagenesis was used to generate 
diversity and the subsequent signal peptides were screened for enhanced secretion. 
Engineered signal peptides were identified that can replace wild-type signal peptides in 
many biotechnological and clinical applications of L. lactis. 
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CHAPTER 2 
Mathematical modeling improves target identification for 
enhancing phagocytosis with engineered, aglycosylated IgGs 
(Adapted from Jung S. T. et al. (2013) Effective phagocytosis of low Her2 tumor cell 
lines with engineered, aglycosylated IgG displaying high FcγRIIa affinity and selectivity, 
ACS Chemical Biology, Volume 8, Issue 2, 368-375.) 
 
2.1 Introduction 
Antibodies trigger a wide array of responses in leukocytes by linking cellular targets on 
pathogens with Fc γ receptors (FcγRs) expressed on the surface of macrophages, 
granulocytes, dendritic cells, natural killer (NK) cells, and B cells. In humans, the binding 
of immune complexes (ICs) to activating receptors FcγRI, FcγRIIa, and FcγRIIIa initiates 
signaling through intracellular immunoreceptor tyrosine-based activation motifs (ITAMs) 
to effect potent antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-
dependent cell-mediated phagocytosis (ADCP), degranulation, T cell proliferation, and 
cytokine release responses
1
. Activation is moderated by the binding of ICs to the sole 
inhibitory receptor, FcγRIIb, inducing immunoreceptor tyrosine-based inhibitory motif 
(ITIM) signaling that leads to anti-inflammatory responses
2
. The affinity of IgG 
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antibodies for activating and inhibitory FcγRs depends on subclass, glycosylation state, 
and other more subtle effects such as Fc allotype
3
. IgG1 is the most commonly used 
isotype for therapeutic applications and engages all of the activating receptors, as well as 
the inhibitory FcγRIIb3. There is evidence that the ratio of binding affinities of IgG1 in 
solution for activating and inhibitory FcγRs (A/I ratio) plays a significant role in 
determining the extent of effector functions displayed by immune cells
4–6
. However, 
since signaling by FcγR receptors requires interactions with multivalent ICs, other 
parameters such as avidity of the ICs and expression level and cell surface distribution of 
the FcγRs on effector cells likely impact the nature of the response in addition to the A/I 
ratio. 
 There are two common polymorphisms in each of the FcγRIIIa and FcγRIIa 
subclasses that also affect the binding affinity to IgG1 antibodies
3
. Engagement of 
FcγRIIIa is considered important for the recruitment of NK effector cells that do not 
express the inhibitory receptor FcγRIIb7. Lymphoma patients expressing the high affinity 
FcγRIIIa allotype, FcγRIIIa-V158, show improved clinical outcomes when treated with 
anti-CD20 (rituximab) compared to patients homozygous for the low affinity FcγRIIIa-
F158 allele
8,9
. Amino acid substitutions and engineering of the glycan appended to N297 
of the Fc have been employed successfully to enhance affinity toward both FcγRIIIa 
alleles
10,11
. MGAH22, an Fc engineered Her2-specific antibody that shows improved 
clearance of medium and low Her2-expressing cancer cells, is under phase I clinical 
evaluation
12
. Likewise, the defucosylated antibody GA201 (anti-EGFR) that exhibits 
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about 50-fold higher FcγRIIIa-V158 affinity is in phase I/II studies for high EGFR 
expressing solid tumors
13
. 
 Expression of the high affinity FcγRIIa-H131 allele correlates with improved 
clinical response rates following treatment with trastuzumab, rituximab, or 
cetuximab
9,14,15. Conversely, individuals homozygous for FcγRIIa-R131 have an 
increased risk of bacterial infection and autoimmunity due to the low affinity interaction 
with IgGs impairing immune complex clearance
16–19. Because the low affinity FcγRIIa-
R131 allele occurs at a frequency between 0.47–0.57 in African Americans, 0.45–0.53 in 
Caucasians, and 0.19–0.45 in Asians, the engineering of antibodies that can enhance 
responses in patients bearing the FcγRIIa-R131 allele is of significant mechanistic and 
clinical interest
19–21. Engagement of FcγRIIa is particularly important for phagocytosis of 
tumor cells by macrophages, which were recently shown to comprise almost 20% of 
infiltrating leukocytes in breast cancer biopsies
22
. 
 Attempts to engineering IgG1 antibodies with FcγRIIa selectivity have led either 
to increased affinity for both FcγRIIa and FcγRIIb and/or relatively modest 
improvements in the A/I ratio (< 6-fold change compared to wild-type)
10,23,24
. Two 
predominant issues complicate the engineering of antibodies that display optimal 
FcγRIIa/FcγRIIb selectivity and FcγRIIa affinity for enhanced phagocytic potential: First, 
FcγRIIa shares 96% amino acid identity with FcγRIIb, and therefore the generation of Fc 
ligands that discriminate between the two is challenging
7
. Second, because of the avidity 
effects involved in the interaction of antibody-decorated tumors with effector cells it is 
26 
 
not easy to determine a priori whether high affinity to FcγRIIa, or a higher A/I ratio, or 
both are needed to enhance phagocytosis. 
 Typically, the interaction of antibodies with cognate FcγRs is critically dependent 
on N-linked glycosylation at residue N297 in the Fc
25
. Aglycosylated antibodies show 
nearly complete loss of FcγR binding and effector functions24,26,27. Contrary to previous 
findings
28
, recent analysis of aglycosylated, bacterially expressed human Fc domains 
suggested that the absence of the glycan increases the conformational flexibility around 
the CH2-CH3 hinge and that the “closed conformations” (reduced CH2 distances) 
observed in prior aglycosylated crystal structures are likely due to crystal packing 
effects
29
. Screening of very large combinatorial libraries by bacterial display led to the 
isolation of the aglycosylated Fc5 variants, which has high affinity toward FcγRI26 and 
displays a CH2 distance intermediate between those of fully glycosylated and 
aglycosylated Fc domains. Collectively, these findings suggest that the high flexibility of 
aglycosylated Fcs might allow for the identification of amino acid substitutions that 
stabilize conformers not accessible to glycosylated antibodies. So far, aglycosylated 
antibodies have been used for applications where inflammatory engagement of FcγRs or 
C1q complement proteins is undesirable
30
. Yet the generation of aglycosylated antibodies 
with unique affinities and selectivities may open the possibility for a new class of 
therapeutics with intriguing biological properties. We hypothesized that such 
substitutions might confer unusually high FcγRIIa affinity and selectivity with respect to 
binding to the highly homologous FcγRIIb for improved phagocytic potentiation.  
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The presence of both activating and inhibitory FcγRs allows effector cells to 
generate, suppress, and fine tune their responses based on the occupancy of these 
receptors
31
. Given the multitude of receptor complexes that can arise during engagement 
of effector cells, it is difficult to intuit how these receptor signals, often conflicting in 
nature, result in a specific cellular response. Mathematical modeling can provide a 
quantitative framework for better understanding this nuanced regulation
32
. We developed 
a mathematical model to link biomolecular interactions at the cell surface (IgG binding to 
Fcγ receptor subunits) to cellular response (ADCP). Experimental results with our novel 
Fc variants, which have altered receptor-binding properties and varied cellular responses, 
were used for model parameterization and validation. The model provides insights into 
the molecular determinants of strong ADCP and suggests general design rules for further 
improving the efficacy of Fc variants that elicit this cellular response. 
This work has been performed in close collaboration with George Georgiou’s 
laboratory at the University of Texas at Austin. All of the experimental work has been 
performed by our collaborators and all of the computational work has been performed by 
us. Using a new library screening system, an engineered trastuzumab variant displaying > 
160-fold increased affinity for the FcγRIIa-R131 allele and a > 25 increase in A/I ratio 
compared to clinical grade glycosylated trastuzumab (Herceptin) has been isolated. This 
engineered trastuzumab was shown to elicit markedly increased ADCP with human 
macrophages as effector cells relative to Herceptin for both +3 (SKOV-3) and +2 (MDA-
MB-453) Her2 expressing cell lines
33
. A mathematical model has been developed to 
provide design criteria for further improving the efficacy of Fc variants by elucidating a 
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mechanism that links their FcγRIIa/FcγRIIb binding to activation of phagocytosis. To the 
best of our knowledge, this is the first report of an aglycosylated antibody that binds to 
FcγRs with affinity and selectivity that far exceed those of clinically used glycosylated 
antibodies or of any engineered glycosylated mutants reported thus far, engineered either 
through mutagenesis programs or via glycoengineering
10,11,23,34
. 
 
2.2 Experimental methods and results 
2.2.1 Development of a bacterial display system for IgG having a free Fc domain 
To discover new aglycosylated Fc mutants, a bacterial display system has been developed 
in which full length IgG1 antibodies are tethered to the inner membrane of E. coli, 
leaving the Fc domain free to interact with fluorescently labeled FcγRs. Full length IgG1 
display system was used to accurately capture the conformational and steric effects 
present when antibodies interact with Fc binding ligands (Fig. 2.1). For this purpose, the 
light chain (L chain) was fused at the N-terminal with the PelB leader peptide and the 
first 6 amino acids of the E. coli inner membrane lipoprotein NlpA, which anchor it to the 
periplasmic side of the bacterial inner membrane
35
. To avoid steric constrains that might 
arise if both L chains of an IgG molecule are membrane-anchored, the plasmid was 
designed to express NlpA anchored L chain (VL-Cκ) as well as unanchored L chain from 
the same promoter. Heavy chain polypeptides secreted into the periplasm assemble either 
with (i) two unanchored L chains, (ii) a membrane-anchored and an unanchored L chain, 
or (iii) two membrane-anchored L chains. The unanchored IgG in the periplasm is 
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preferentially released from the bacteria following spheroplasting, whereas anchored IgG 
comprising one membrane-anchored and one unanchored L chain (or two membrane-
anchored L chains) is retained on the surface of the spheroplasts. The Fc domain in the 
membrane-anchored IgG is free to interact with exogenously added, fluorescently labeled 
FcγRs for fluorescence activated cell sorting analysis (FACS) and library screening. To 
validate the IgG display strategy, the H and L chains of AglycoT-Fc5 (aglycosylated 
trastuzumab with E382V/M428I
26
) and AglycoT-Fc2a (aglycosylated trastuzumab with 
S298G/T299A
24
) were cloned separately and expressed in E. coli. Under optimized 
culture conditions, AglycoT-Fc5 expressing spheroplasts displayed high fluorescence 
following labeling with FcγRI-FITC, whereas spheroplasts expressing AglycoT-Fc2a 
could be labeled selectively with FcγRIIa-GST/anti-GST-FITC36. In both instances, a 
large increase in fluorescent signal was observed relative to the negative control, 
indicating that inner membrane-anchored IgG display is well suited for the engineering of 
aglycosylated antibody Fc variants that bind to other Fc receptors (FcγRI, FcγRIIa, 
FcγRIIb, FcγRIIIa/b, or FcRn). 
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Figure 2.1. Schematic of a covalently anchored, full-length IgG1 display system for Fc engineering. 
Schematic diagram showing the display of full length IgG1 by NlpA tethering to inner membrane via a 
single membrane-anchored light chain. Soluble fluorescent FcγRIIa-R131-GST and non-fluorescent 
FcγRIIb-GST can then compete for binding to full length library variants on the surface of bacterial 
spheroplasts before FACS sorting. 
 
2.2.2 Isolation and characterization of aglycosylated IgG variants displaying high 
affinity and binding selectivity toward the FcγRIIa-R131 allele 
An IgG that combined mutations from both Fc5 and Fc2a (E382V/M428I/ 
S298G/T299A) was constructed and shown to display binding affinity to both FcγRI and 
FcγRIIa/FcγRIIb comparable to that of Fc5 and Fc2a, respectively, when expressed as 
individual variants
36
. SPR analysis of the purified AglycoT-Fc5-2a revealed that binding 
to FcγRI was significantly reduced relative to Herceptin (11-fold decrease or a 3-fold 
decrease relative to AglycoT-Fc5). Interestingly, this antibody showed a small (40%) but 
reproducible increase in the selectivity for FcγRIIa-R131 allele relative to FcγRIIb (AIIa-
R131/I ratio) when compared to Herceptin and an even more significant increase in AIIa-
R131/I relative to AglycoT-Fc2a (Table 2.1). Therefore, AglycoT-Fc5-2a was used as a 
template for random mutagenesis and the isolation of variants that exhibit improved 
binding to the low affinity FcγRIIa-R131 allele and simultaneously increased AIIa‑R131/I 
ratios.  
 
Table 2.1. SPR analysis showing kinetic on and off rates and affinity for glycosylated herceptin and 
aglycosylated trastuzumab Fc variants binding to FcγRIIa-R131, FcγRIIa-H131, FcγRIIb and FcγRI. 
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Variant FcγR kon (M
-1
 s
-1
) koff (s
-1
) KD (µM) A/I ratio 
KD relative 
to Herceptin 
Herceptin FcγRI 1.8 x 105 2.7 x 10-4 0.0015 a  1 
 FcγRIIa-H131 7.2 x 105 8.5 x 10-2 0.12 11 1 
 FcγRIIa-R131 1.2 x 105 3.7 x 10-2 0.31 4.2 1 
 FcγRIIb 2.8 x 104 3.8 x 10-2 1.3  1 
AglycoT-Fc5-2a FcγRI 1.5 x 105 2.3 x 10-3 0.016  0.096 
 FcγRIIa-H131 3.1 x 105 1.2 x 10-1 0.37 4.3 0.32 
 FcγRIIa-R131 1.3 x 105 3.6 x 10-2 0.27 5.9 1.1 
 FcγRIIb 5.8 x 104 9.1 x 10-2 1.6  0.81 
AglycoT-Fc1001 FcγRI 4.3 x 105 3.3 x 10-2 0.077  0.020 
 FcγRIIa-H131 2.6 x 105 5.4 x 10-2 0.20 2.4 0.60 
 FcγRIIa-R131 2.6 x 105 3.9 x 10-3 0.015 31 21 
 FcγRIIb 2.9 x 104 1.3 x 10-2 0.47  2.8 
AglycoT-Fc1002 FcγRI N/A N/A N/A  N/A 
 FcγRIIa-H131 1.5 x 105 2.8 x 10-2 0.19 10 0.63 
 FcγRIIa-R131 1.8 x 105 4.0 x 10-2 0.22 8.6 1.4 
 FcγRIIb 2.0 x 104 3.9 x 10-2 1.9  0.68 
AglycoT-Fc1003 FcγRI N/A N/A N/A  N/A 
 FcγRIIa-H131 3.3 x 105 5.9 x 10-2 0.18 5.6 0.67 
 FcγRIIa-R131 2.6 x 105 3.2 x 10-2 0.12 8.3 2.6 
 FcγRIIb 3.8 x 104 3.8 x 10-2 1  1.3 
AglycoT-Fc1004 FcγRI 4.0 x 105 2.6 x 10-2 0.064  0.024 
 FcγRIIa-H131 5.3 x 105 1.1 x 10-2 0.021 9.5 5.7 
 FcγRIIa-R131 3.2 x 105 6.2 x 10-4 0.0019 105 163 
 FcγRIIb 2.5 x 104 4.9 x 10-3 0.2  6.5 
 
a 
Affinity reported in a previous study
26
, using the same method.
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A library of random mutations in the Fc domain of AglycoT-Fc5-2a was created 
by error prone PCR to yield 4.8×10
9
 transformants. Cells were incubated with a 
progressively increasing excess of unlabeled FcγRIIb-GST (extracellular domain of 
FcγRIIb fused with glutathione-S-transferase (GST) from Schistosoma japonicum), over 
highly homologous fluorescent FcγRIIa-R131-GST-Alexa488 conjugate to help enrich 
variants displaying improved FcγRIIa-R131/FcγRIIb selectivity. After five rounds of 
sorting, four individual clones showing markedly improved fluorescence upon incubation 
with 20 nM FcγRIIa-R131-GST-Alexa-488 and 100 nM of FcγRIIb-GST relative to 
spheroplasted cells expressing AglycoT-Fc5-2a were isolated (Fig. 2.2A). Cells 
expressing the clone termed AglycoT-Fc1001 (S298G, T299A, H268P, E294K, N361S 
and E382V, M428L (Fig. 2.2B)) exhibited the highest fluorescence under these 
conditions (Fig. 2.2D). Interestingly, the best performing variant in ADCP assays, 
AglycoT-Fc1004 (S298G, T299A, N390D, E382V, M428L (Fig. 2.2C)) showed the 
lowest fluorescent signal (Fig. 2.2D). Expression differences between the Fc1001 and 
Fc1004 variants are likely to be responsible for the qualitative difference between FACS 
signal and FcγRIIa binding; this can be addressed by two color sorting that also monitors 
antibody expression. Note that in AglycoT-Fc5-2a, residue M428 had been mutated to 
Ile, which was further changed to a Leu in AglycoT-Fc1004 and the three other selected 
clones pointing to the functional significance of this residue for effector FcγR binding 
(Fig. 2.2A).  
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Figure 2.2. Isolated Fc variants. (A) Sequences and corresponding FACS signals for isolated Fc variants. 
Mutations isolated in (B) AglycoT-FC1001 and (C) AglycoT-Fc1004 are shown on the 3D structure of an 
aglycosylated IgG1 Fc (PDB code: 3S7G). Yellow = AglycoT-Fc2a base mutations, blue = AglycoT-Fc5 
base mutations, red = AglycoT-Fc1001 mutations and purple = AglycoT-Fc1004. (D) Fluorescent 
histogram of variant binding to 30 nM FcγRIIa as detected by secondary goat anti‐GST‐FITC diluted 1:200 
from a 1 mg/ml stock. 
 
The four IgG variants corresponding to the sequences encoded by the highest 
fluorescence clones isolated by FACS were expressed in HEK293F cells to limit 
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endotoxin contamination and purified. All IgGs contained the S298G/T299A mutations 
that block glycosylation at N297 and thus do not bind Concanavalin A. Binding of 
dimeric purified GST fusions of FcγRIIa-H131, FcγRIIa-R131, and FcγRIIb to each IgG 
variant was determined by SPR analysis (Table 2.1). A bivalent binding model was used 
to fit the sensorgram curves and obtain monomeric binding constants in accordance with 
earlier studies
37
. This methodology resulted in equilibrium dissociation values, kon and 
koff rate constants for the binding of Herceptin and the various mutant Fcs to FcγRs that 
were in excellent agreement with the recent comprehensive binding data of all human 
IgG subclasses to effector FcγRs3. AglycoT-Fc1004 IgG displayed the highest affinity for 
both FcγRIIa polymorphisms: a remarkable 163-fold improvement in KD for the low 
affinity FcγRIIa-R131 relative to Herceptin and a more modest 5.7-fold affinity 
improvement for the high affinity FcγRIIa-H131 allele. The large increase in affinity 
toward FcγRIIa-R131 is consistent with the use of this receptor polymorphism for FACS 
screening. While AglycoT-Fc1004 showed somewhat higher affinity toward the 
inhibitory FcγRIIb, the much greater increase in FcγRIIa-R131 affinity resulted in 25-
fold improvement in AIIa‑R131/I selectivity compared to Herceptin and a 16-fold increase 
in selectivity relative to its parental variant, AglycoT-Fc5-2a. AglycoT-Fc1001 displayed 
21-fold higher FcγRIIa-R131 affinity than Herceptin and an AIIa‑R131/I of 7.5 (5.3-fold 
increase relative to AglycoFc5-2a). The two other IgGs isolated from the screening 
displayed only marginal increases in FcγRIIa-R131 binding and lower affinity toward the 
FcγRIIa-H131 allele. 
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The binding kinetics of the two highest affinity clones AglycoT-Fc1004 and 
AglycoT-Fc1001 and their parental AglcycoT-Fc5-2a toward FcγRI were evaluated by 
SPR, and the data were fit with a 1:1 Langmuir binding model
37
 (Table 2.1). AglycoT-
Fc5-2a displayed a 10-fold decrease in FcγRI binding compared to Herceptin, which was 
further reduced in AglycoT-Fc1004 and AglycoT-Fc1001 to almost a 50-fold lower level. 
Evidently, the S298G/T299A mutations that conferred binding to FcγRIIa and FcγRIIb to 
aglycosylated IgGs suppressed the ability of the Fc5 amino acid substitutions to bind 
FcγRI. AglycoT-Fc1004 has only two amino acid substitutions in the CH3 domain 
(N390D, M428L) yet has 5-fold lower KD for FcγRI relative to its parental AglycoT-Fc5-
2a template. Our data show that the reason for the decreased FcγRI affinity of AglycoT-
Fc1004 results from the N390D mutation and the subtle change I428L (compared to 
I428M in the parental antibody Fc5-2a). Both of these mutations are in the CH3 domain, 
which is distal to the FcγR binding epitope, underscoring the significance of 
conformational flexibility in these interactions. This finding is consistent with the recent 
structural data that indicates in the absence of glycosylation the Fc domain displays a 
high degree of conformational flexibility and our hypothesis that mutations within the 
CH3 domain can stabilize particular conformers with unusual FcγR binding properties29. 
In particular, M428L is located near the hinge region of the CH2 and CH3 domains 
where this mutation likely influences the local conformation and favorably impacts the 
binding of antibodies to FcRn
38
. 
The isolated IgGs displayed no binding to either of the two FcγRIIIa 
polymorphisms (F158 and V158) as determined by ELISA
36
. Interestingly, both 
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AglycoT-Fc1001 and AglycoT-Fc1004 showed higher binding to the neonatal Fc 
receptor, FcRn, at endosomal pH 6.0 but not at physiological pH
36
. This was most likely 
the consequence of the M428L mutation, which had been shown earlier to improve 
binding affinity for FcRn at pH 6.0 by 11-fold and thus confer extended IgG serum 
persistence and pharmacokinetics in animal models
38
. 
 
2.2.2 Enhanced ADCP of low and medium Her2
+
 cell lines 
Surface expression of Her2 on SKBR-3, SKOV-3, and MDA-MB-453 Her2
+
 cells 
was evaluated by FACS following incubation with Herceptin and a fluorescently labeled 
secondary antibody. SKBR-3 cells showed a 2-fold higher FACS signal relative to 
SKOV-3, which in turn had a 2-fold greater Her2 binding signal compared to that of 
MDA-MB-453 cells (Fig. 2.3A). These results are consistent with the total Her2 
expression in these cell lines as determined by Western blotting
39
.  
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Figure 2.3. Expression level of Her2 and FcγR on tumor cell lines and macrophages for ADCP assay. (A) 
Her2 expression level on tumor cell lines used for ADCP was confirmed by labeling with 10 µg/ml 
Herceptin or IgG1 pooled from human serum followed by fluorescent donkey anti-human IgG (H+L) FITC 
Fab at a 1:50 dilution. Bars are labeled with the immunohistochemical staining category assigned to each 
tumor cell line
33. (B) FcγR counts on macrophages were determined using a fluorescent Quantum Simply 
Cellular bead assay. Macrophages were labeled with 20 µg/ml anti-FcγRI-FITC, 10 µg/ml anti-FcγRIIa-
FITC, 1 µg/ml 2B6-N287D-FITC and 20 µg/ml anti-FcγRIII-FITC. (C) Schematic diagram showing the 
experimental workflow of the ADCP analysis. 
 
CD14
+
 CD11b
+
 macrophages were prepared from pooled PBMCs (peripheral 
blood mononuclear cells) following cultivation with GM-CSF cytokine
23
. The surface 
densities of FcγRI, FcγRIIa, FcγRIIb, and FcγRIII on macrophages were determined by 
FACS. We observed high FcγRI, FcγRIIa, and FcγRIIb levels in macrophages prepared 
at different times and from different pooled PBMC fractions (Fig. 2.3B). Notably, the 
level of FcγRI (CD64) was comparable to that of FcγRIIa and FcγRIIb, in contrast to an 
earlier report that showed low level FcγRI expression in human macrophages23. 
ADCP was determined by incubating PKH67 labeled, IgG opsonized tumor cells 
with macrophages at a low (1:5 MDA-MB-453 or 1:10 SKOV-3) ratio of target to 
effector cells (Fig. 2.3C). The numbers of CD11b
+
 CD14
+
 macrophages that stained with 
PKH67 (arising from associated/ingested tumor cells) were determined by FACS
23
 and 
fluorescence microscopy. As a positive control we used glycosylated trastuzumab with 
the mutation G236A (GlycoT-G236A), which has been reported to confer the highest 
AIIa-R131/I and AIIa-H131/I ratios reported in the literature (5.5 and 5.7, respectively, relative 
to wild-type IgG) and to mediate increased macrophage mediated ADCP of EpCAM
+
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LS180 cells
23
. We found that AglycoT-Fc1004 internalized approximately 75% more 
tumor cells (P < 0.01) relative to Herceptin and 40% more relative to its glycosylated, Fc 
engineered GlycoT-G236A variant (Fig. 2.4). Equally importantly, AglycoT-Fc1004 
displayed the same high level of ADCP with both the SKOV-3 and with the even lower 
Her2 expressing MDA-MB-453 cell line. These two cell lines correspond to 
approximately +3 and +2 Her2
+
 tumor cells, respectively, which have been shown to be 
recalcitrant to Herceptin treatment
40,41
. Consequently, AglycoT-Fc1004 may provide the 
opportunity to treat patients having tumors with Her2 moderate or low expression that do 
not respond well to Herceptin. We expect binding to the low affinity FcγRIIa-R131 
polymorphism to be particularly desirable since therapeutic responses in patients that are 
homozygotic or heterozygotic for this allele show poorer responses to anti-neoplastic 
antibodies
9,14,15
. On the other hand, AglycoT-Fc1001 could not induce phagocytosis of 
tumor cells above background for either cell line. Likewise, the addition of 2B6, an 
antagonistic FcγRIIb antibody, had no significant effect on ADCP with any of the 
engineered antibodies tested or with Herceptin, suggesting that tumor cell surface-bound 
ICs likely displace 2B6 from FcγRIIb allowing ITIM mediated signaling to occur. 
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Figure 2.4. ADCP mediated by macrophages with various Fc variants. Human monocyte derived 
macrophages were used with (A) +3 Her2
+
 SKOV-3 ovarian cancer and (B) +2 Her2
+
 MDA-MB-453 
breast cancer tumor cell lines as target cells. 
**
 Welch’s t test P < 0.01 for samples compared to No Ab 
negative control, 
##
 Welch’s t test P < 0.01 for samples relative to G236A positive control. 
 
2.3 Computational methods 
2.3.1 Parameters and schematic of the mathematical model 
A mathematical model was developed to better understand the interaction between Her2-
expressing cells (SKOV-3 or MDA-MD-453) and macrophages, and to predict the 
relative level of ADCP based on the KD values of the Fc variants to the different FcγRIIs 
(Table 2.1). Model nomenclature and parameter values are provided in Table 2.2. 
 
Table 2.2. Parameters used to generate FcγRIIa/b activation model. 
Parameter Description Value Reference 
    
Physical parameters 
SK_dia Diameter of SKOV-3 cell 10 µm Zhang et al.
42
 
MD_dia Diameter of MDA-MB-453 cell 10 µm Rhodes et al., 
Zhang et al.
33,42
 
Mac_dia Diameter of macrophage 21 µm Krombach et al.
43
 
Cell_gap Gap distance between SKOV-3/MDA-MB-453 cell 
and macrophage 
12 nm Pease et al., 
Sondermann et al. 
44,45
 
Contact_area Contact area of FcγRII receptors on macrophage 104.7 µm2 Kuo and 
Lauffenburger, 
Heiple et al., 
Tolentino et al.
46–48
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Expression level parameters 
SK_HER2 HER2 expression level on SKOV-3 7.36 x 10
5
 Costantini et al., 
Xu et al.
49,50
 
MD_HER2 HER2 expression level on MDA-MB-453 4.00 x 10
5
 Costantini et al., 
Xu et al.
49,50
 
Mac_IIaH Number of FcγRIIa-H131 on macrophage 171271 This work 
Mac_IIaR Number of FcγRIIa-R131 on macrophage 171271 This work 
Mac_IIb Number of FcγRIIb on macrophage 291150 This work 
[IgG]s Free serum IgG concentration 10 µM This work 
[L0]SK SKOV-3 Her2-bound IgG effective concentration 342.2 µM This work 
[L0]MD MDA-MB-453 Her2-bound IgG effective 
concentration 
176.2 µM This work 
    
Affinity parameters 
Kdiff Equilibrium constant for partitioning of FcγRII 
receptors in/out of contact area on macrophage 
16.64 This work 
Kcross Equilibrium dissociation constant for the 
crosslinking of FcγRII receptors 
2500/µm
2
 This work 
KD_IIa_IgG Equilibrium dissociation constant between serum 
IgG and FcγRIIa-H131/FcγRIIa-R131 
0.72 µM Maenaka et al.
51
 
KD_IIb_IgG Equilibrium dissociation constant between serum 
IgG and FcγRIIb 
2.4 µM Maenaka et al.
51
 
KD_IIa-H131 Equilibrium dissociation constant between Fc 
variants and FcγRIIa-H131 
(Table 2.1) This work 
KD_IIa-R131 Equilibrium dissociation constant between Fc 
variants and FcγRIIa-R131 
(Table 2.1) This work 
KD_IIb Equilibrium dissociation constant between Fc 
variants and FcγRIIb 
(Table 2.1) This work 
 
The interaction between Her2-bound IgG on a tumor cell and FcγRs on a 
macrophage occurs in a “contact” region where the two cells are in close proximity, but 
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this interaction is not possible outside of this region because of physical constraints 
imparted by the curvature of the two cells (Fig. 2.5). The contact area was estimated to be 
1/3 of the surface area of the smaller SKOV-3/MDA-MD-453 cells based on geometric 
considerations. A lower bound of 1/10 of the surface area has been calculated for a non-
deforming bead
46
, but the actual contact area is significantly higher because macrophages 
deform and spread around IgG-bound cells
47,48
. 
 
Figure 2.5. Schematic of the mathematical model. (A) Overall schematic of the various species considered 
in the mathematical model. Anti-Her2 IgG molecules with different Fc domains saturably bind the Her2 
receptors on SKOV-3 or MDA-MB-453 cells. The different Fc domains have various binding affinities to 
FcγRIIa-H131, FcγRIIa-R131, and FcγRIIb on macrophages in the contact region. Serum IgG is also 
included in the model and is able to bind to FcγRII receptors both inside and outside of the contact region. 
(B) Schematic of binding interactions and their respective affinity parameters considered in the model. 
 
2.3.2 Interactions between species in the model 
We considered three types of FcγRs on macrophages: FcγRIIa-H131, FcγRIIa-R131, and 
FcγRIIb. The number of FcγRIIa and FcγRIIb were experimentally quantified (Fig. 
2.3B), and the FcγRIIa-H131 and FcγIIa-R131 variants were assumed to exist in 50/50 
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proportions
20. FcγRIIs partitioned between the contact area and the free (non-contact) 
area with equilibrium constant Kdiff: 
 FcγRIIxfree 
Kdiff FcγRIIxcontact 
where Kdiff = [FcγRIIxfree] / [FcγRIIxcontact] = (macrophage surface area – contact _area) / 
(contact_area) and FcγRIIx = FcγRIIa-H131, FcγRIIa-R131 or FcγRIIb. 
All Her2 receptors on SKOV-3 and MDA-MD-453 cells were considered to be 
evenly distributed and receptor numbers were calculated from experimental 
quantification of relative expression levels (Fig. 2.3A) and total absolute values from 
literature
49,50
. The effective concentration of cell-bound IgG ([L0]) was calculated in an 
“effective contact volume”, defined as the product of contact_area and cell_gap. These 
cell-bound IgGs were free to interact with FcγRIIs in the contact area (FcγRIIxcontact) with 
ligand depletion: 
L + FcγRIIxcontact 
KD_x FcγRIIxcell-bound 
where KD_x = KD_IIa-H131, KD_IIa-R131, or KD_IIb from SPR data for different Fc variants 
(Table 2.1).  
To mimic conditions in our in vitro experiments, as well as in normal physiology, 
10 µM serum IgG ([IgG]s) was included in the system to compete with Her2-bound IgG 
for binding with Fc receptors. Serum IgG was assumed to be in excess and could bind 
FcγRIIs anywhere on the macrophage surface without ligand depletion: 
 IgGs + FcγRIIxfree 
KD_x_IgG FcγRIIxfree I bound 
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 IgGs + FcγRIIxcontact 
KD_x_IgG FcγRIIxcontact I bound 
where KD_x_IgG = KD_IIa_IgG or KD_IIb_IgG. 
 Since receptor crosslinking leads to cell activation or inhibition, we assumed that 
dimers represent the minimal signaling unit (and serve as proxies for any higher-order 
receptor clusters). Any IgG-bound FcγRIIs were allowed to dimerize with equilibrium 
dissociation constant Kcross. Kcross was chosen to be 2500 #/µm
2
, which maximizes the 
difference in the number of crosslinked receptors with and without MDA-MB-453 cells 
(chosen for this signal optimization since they express fewer Her2 molecules than 
SKOV-3 cells and therefore have lower signals). All possible combinations of dimers 
were allowed between the three FcγRII subunits with the same crosslinking constant, 
whether occupied by serum IgG of Her2-bound IgG. However, geometric constraints 
limited receptors in the contact area to only crosslink with those in the contact area, while 
receptors outside of the contact area could only crosslink with those outside: 
 FcγRIIxcell-bound + FcγRIIxcell-bound 
Kcross FcγRIIx – FcγRIIx 
 FcγRIIxcontact I bound + FcγRIIxcontact I bound 
Kcross FcγRIIx – FcγRIIx 
 FcγRIIxfree I bound + FcγRIIxfree I bound 
Kcross FcγRIIx – FcγRIIx 
No discrimination was made between crosslinked receptors in and out of the contact area 
because all of them could lead to activating or inhibitory signal. However, local 
concentration effects made the density of dimers (and potentially higher-order clusters) 
much higher in the contact area. 
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The diffusion, binding and crosslinking reactions above yield the following 
system of equations (x = IIa-H131, IIa-R131 or IIb): 
 [FcγRIIx]free = Kdiff [FcγRIIx]contact                (1, 2, 3) 
 [([L0]SK/MD – [FcγRIIx]cell-bound)/(Nav*cell_gap)]*[FcγRIIx]contact 
= KD_x [FcγRIIx]cell-bound                (4, 5, 6) 
[IgG]s [FcγRIIx]free = KD_x_IgG [FcγRIIx]free I bound              (7, 8, 9) 
[IgG]s [FcγRIIx]contact = KD_x_IgG [FcγRIIx]contact I bound       (10, 11, 12) 
[FcγRIIx]cell-bound [FcγRIIx]cell-bound = Kcross [FcγRIIx : FcγRIIx]          (13 to 18) 
[FcγRIIx]contact I bound [FcγRIIx]cell-bound = Kcross [FcγRIIx : FcγRIIx]         (19 to 27) 
[FcγRIIx]free I bound [FcγRIIx]free I bound = Kcross [FcγRIIx : FcγRIIx]         (28 to 33) 
where [FcγRIIx] is in #/μm2. Conservation of mass gives: 
 all [FcγRIIx] in free area * (macrophage total surface area – contact_area)  
  + all [FcγRIIx] in contact area * contact_area = Mac_IIx      (34, 35, 36)  
This system of equations was solved in Matlab using fsolve to obtain the 36 unknowns. 
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2.3.3 Activating and inhibitory receptors signaling to ADCP 
Finally, the resulting distribution of FcγRII dimers was correlated to the experimental 
output of ADCP. The relative contribution of activating/inhibiting homodimers to this 
cellular response is not known and, although there is evidence that heterodimers (FcγRIIa 
crosslinked with FcγRIIb) do form2, it is not known whether they activate or inhibit. 
Therefore, we did not assign any a priori functions or signaling weights to these species, 
but rather allowed their contributions to be determined by the model by assigning an 
“intrinsic signaling potency” to each subunit. The signaling potency for FcγRIIb was 
fixed at -1 (negative for inhibitory) and the signaling potencies for FcγRIIa-H131 and 
FcγRIIa-R131 were allowed to vary freely. We then assumed that the signaling potency 
of each dimeric species (used as a proxy for higher-order receptor clusters and phagocytic 
propensity) as the sum of potencies of the two receptor subunits comprising the dimer. 
The overall response was calculated from:  
Phagocytosis ∝ Σ (FcγRIIx : FcγRIIx * signaling potency of the respective dimer) 
The level of phagocytosis was then compared to ADCP experimental data for only two 
Fc variants to obtain the intrinsic signaling potencies for FcγRIIa-H131 and FcγRIIa-
R131 relative to the signaling potency for FcγRIIb (which was -1; negative for 
inhibition). Fitted potency values are presented in Table 2.3. 
Table 2.3. Intrinsic signaling potencies of FcγRIIa-H131, FcγRIIa-R131, and FcγRIIb. 
ADCP data considered 
Intrinsic signaling potency 
FcγRIIa-H131 FcγRIIa-R131 FcγRIIb a 
Fitting Herceptin and AglycoT-Fc1001 only 2.8 0.4 -1 
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Fitting Herceptin and AglycoT-Fc1004 only 2.0 0.3 -1 
Fitting AglycoT-Fc1001 and AglycoT-Fc1004 only 11.3 0.1 -1 
 
a The signaling potency of FcγRIIb was always held fixed at -1, since the goal of each fit was to determine 
the relative potencies among the three receptor subunits.
 
 
2.4 Results 
2.4.1 Antigen-bound IgG, but not monomeric IgG, can elicit phagocytic response 
To gain insights into the molecular determinants triggering ADCP, especially the 
puzzling lack of phagocytosis of Her2 expressing tumor cells opsonized with the 
AglycoT-Fc1001 antibody, we developed a quantitative model to relate the formation of 
IgG:FcγRIIa and IgG:FcγRIIb ICs to phagocytosis. FcγRs are free to diffuse into and out 
of a “contact” region, where they can interact with Her2-bound IgGs that coat the 
adjacent tumor cell (Fig. 2.5). IgG-bound FcγRs can then crosslink and generate an 
activating or inhibitory signal, with ADCP as the output. Monomeric IgG, which is 
present in serum and interstitial fluid at concentrations sufficient to saturate all FcγRII 
subunits, can compete with antigen-bound IgG for FcγR binding. Our simulations suggest 
that antigen-bound IgG, but not monomeric IgG, can elicit a significant phagocytic 
response. This is because the clustered presentation of antigen-bound IgGs in the contact 
region results in an increased local concentration of Fc domains that leads to the 
displacement of monomeric IgG and promotes a sufficiently high level of FcγR cross-
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links to elicit effector responses. This result is in complete agreement with in vivo 
observations that serum IgG alone, in the absence of ICs, cannot elicit FcγR signaling1. 
  
2.4.2 Mathematical modeling accurately captures ADCP results 
To link biomolecular interactions at the cell surface to ADCP efficacy, we assigned an 
“intrinsic signaling potency” parameter to each receptor subunit and assumed that the 
signaling potency of each dimeric IgG:FcγR (used as a proxy for higher-order IgG:FcγR 
clusters) was equal to the sum of its constituents. The net signal generated by all FcγR 
complexes on the macrophage surface constituted the level of ADCP response
3
. With the 
exception of the intrinsic signaling potencies for FcγRIIa-H131 and FcγRIIa-R131 
(relative to FcγRIIb), all other parameters were obtained from experimental data, 
literature values, or simulations (Table 2.2). To parameterize the two relative signaling 
potencies for FcγRIIa-H131 and FcγRIIa-R131, the model was fit only to ADCP data for 
Herceptin and AglycoT-Fc1001 using SKOV-3 and MDA-MB-453 cells; this model was 
then used to predict the expected ADCP response of AglycoT-Fc1004 in both cell types 
(Fig. 2.6A and B). Similarly, parameterization of the model using the data for any two 
antibodies within the Herceptin, AglycoT-Fc1001, and AglycoT-Fc1004 set accurately 
predicted the ADCP response for the third antibody (Fig. 2.6C−F). Notably, the trend in 
magnitudes of the relative intrinsic signaling potencies was always the same: FcγRIIa-
H131 > FcγRIIb > FcγRIIa-R131 (Table 2.3). 
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Figure 2.6. Validation of the mathematical model with ADCP data. (A, B) ADCP data for Herceptin and 
AglycoT-Fc1001 were used to fit intrinsic signaling potencies of the receptor subunits. This model was 
then directly used to predict ADCP responses for AglycoT-Fc1004 with both SKOV-3 cells (A) and MDA-
MB-453 cells (B). Data from any two of the Fc variants can be selected and the ADCP response for the 
third variant can be accurately predicted. ADCP data for (C, D) Herceptin and AglycoT-Fc1004 or (E, F) 
AglycoT-Fc1001 and AglycoT-Fc1004 were used to obtain intrinsic signaling potency values in the model, 
which was then used to predict ADCP responses for AglycoT-Fc1001 with SKOV-3 cells (C) and MDA-
MB-453 cells (D), or Herceptin with SKOV-3 cells (E) and MDA-MB-453 cells (F). 
 
Using the relative signaling potencies determined by the first fit (using 
experimental data for Herceptin and AglycoT-Fc1001 only), ADCP responses of the 
other Fc variants were predicted for both SKOV-3 and MDA-MB-453 cells (Fig. 2.7). 
Since ADCP data for those Fc variants were not quantified, quantitative comparisons 
between model and experimental results were not possible. Nevertheless, qualitatively, 
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the very low ADCP response exhibited by AglycoT-Fc5-2a has been observed 
experimentally (G. Georgiou, personal communication). The predicted phagocytosis level 
for the two other variants, AglycoT-Fc1002 and AglycoT-Fc1003, did not exceed that for 
wild-type Herceptin, which is in agreement with our initial hypothesis after SPR analysis 
when those variants were not chosen for further characterization. AglycoT-Fc1004 
exhibits the highest predicted ADCP level, also in agreement with experimental results 
(Fig. 2.4).  
 
Figure 2.7. Predicted phagocytic responses of other Fc variants. Based on KD_IIa‐H131, KD_IIa‐R131, and KD_IIb 
values from SPR analysis (Table 2.1), phagocytic response was predicted by the mathematical model for 
both SKOV‐3 cells (dark red bar) and MDA‐MB‐453 cells (light red bar). Intrinsic signaling potencies for 
FcγRIIa‐H131, FcγRIIa‐R131 and FcγRIIb were the same as in Fig. 2.6A, B (2.8, 0.4, and ‐1 respectively). 
 
2.4.3 Activation signaling and ADCP response is dominated by FcγRIIa-H131 
affinity 
The model provides a framework for understanding the molecular basis for enhanced 
ADCP response. From SPR analysis (Table 2.1), the most potent variant, AglycoT-
Fc1004, has the highest affinity for all three FcγRII subunits, but it has a lower AIIa-H131/I 
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ratio than Herceptin. To determine whether absolute affinity or A/I ratio plays a more 
important factor in physiological response, the model was used to plot predicted 
phagocytic response for various KD_IIa‑H131, KD_IIa‑R131, and KD_IIb values (Fig. 2.8). In 
Fig. 2.8A, KD_IIb was held constant at 1 µM, which is the same order of magnitude as all 
experimentally determined KD_IIb values. The IgG variants examined in this work were 
overlaid on this heat map on the basis of their KD_IIa‑H131 and KD_IIa‑R131 values to show 
their approximate expected ADCP responses (see Fig. 2.7 for actual predictions). The 
simulations show that enhanced ADCP most dominantly correlates with increased 
affinity to FcγRIIa-H131, with minimal dependence on FcγRIIa-R131 affinity. This is 
due to the fact that the intrinsic signaling potency of FcγRIIa-H131 is predicted to be 
significantly stronger than that of FcγRIIa-R131, which is, in turn, weaker than FcγRIIb 
(Table 2.3). This prediction is also consistent with clinical observations that FcγRIIa-
R131 homozygous individuals are more susceptible to bacterial infections and 
autoimmune diseases
16–18
, perhaps due to inefficient generation of activation signals in 
the absence of FcyRIIa-H131 subunits.  
 
Figure 2.8. Mathematical modeling provides insights into design rules governing phagocytic potency of Fc 
variants. Predicted fraction of SKOV-3 cells phagocytosed for a range of KD_IIa-H131, KD_IIa-R131, and KD_IIb 
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values. (A) KD_IIb was held constant at 1 µM, and KD_IIa-H131 and KD_IIa-R131 values were varied. Phagocytic 
responses for Herceptin (H), AglycoT-Fc5-2a (F), AglycoT-Fc1001 (1), AglycoT-Fc1002 (2), AglycoT-
Fc1003 (3), and AglycoT-Fc1004 (4) were predicted on the basis of their experimentally determined 
equilibrium binding constants to FcγRIIa-H131 and FcγRIIa-R131 (see Table 2.1). (B) KD_IIa-R131 was held 
constant at 0.01 µM and KD_IIb and KD_IIa-H131 values were varied: fixed AIIa-H131/I (i.e., KD_IIb/KD_IIa-H131) 
ratios of 1 (white dash), 10 (red dash), and 100 (blue dash) are shown. (F) KD_IIa-H131 was held constant at 
0.1 µM, and KD_IIb and KD_IIa-R131 values were valued. The same ratios of AIIa-R131/I affinity as in panel B are 
shown. 
 
2.4.4 Implications for future Fc engineering 
We further used our mathematical model to elucidate design rules for future 
engineering of Fc variants. It has been suggested that effector response can be predicted 
by the A/I ratio, defined as the ratio of IgG Fc affinity for FcγRIIa to that for FcγRIIb6. 
To investigate the utility of A/I ratio in predicting phagocytosis, lines of constant 
AIIa‑H131/I or AIIa‑R131/I were plotted for fixed KD_IIa‑R131 and KD_IIa‑H131, respectively in 
Figure 2.8 (i.e., KD_IIb/KD_IIa‑H131 in Fig. 2.8B and KD_IIb/KD_IIa‑R131 in Fig. 2.8C). Even 
though a higher A/I ratio tends to elicit a higher effector response, phagocytic activity can 
vary significantly even for a fixed A/I ratio, indicating that absolute receptor affinities 
also play a significant, if not dominant, role in shaping cellular response. Interestingly, 
for a fixed A/I ratio, increasing FcγRIIa-H131 affinity generally leads to increased 
phagocytosis (Fig. 2.8B), while increasing FcγRIIa-R131 affinity leads to decreased 
phagocytosis (Fig. 2.8C). This can be explained by the relative intrinsic signaling 
potencies of the receptor subunits (Table 2.3). At a fixed AIIa‑H131/I, increasing the 
affinity for FcγRIIa-H131 (potency > 1) would also increase the affinity for FcγRIIb 
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(potency = −1), but the net effect would be increased activation due to the differential 
potencies. By contrast, at a fixed AIIa‑R131/I, increasing affinities for both subunits would 
reduce ADCP response because FcγRIIb is more potent at signaling than FcγRIIa-R131 
(potency < 1). Our findings agree with recent crystal structure data that suggest the 
FcγRIIa-R131 polymorphism adopts a conformation that maybe less favorable for 
multimerization than FcyRIIa-H131, therefore limiting the proximity of ITAM domains 
required to transduce activation signals
52
. The model suggests that efforts to improve the 
design of IgG Fc variants for enahnaced ADCP should first focus on increasing affinity 
for FcγRIIa-H131 (Fig. 2.8A and B) and, if not possible or insufficient, then on 
decreasing affinity for FcγRIIb (Fig. 2.8B and C). If binding to the low affinity FcγRIIa-
R131 allele is required, then both improved FcγRIIa-R131 affinity and A/I ratio are 
necessary for more potent ADCP (Fig. 2.8C). While FcγRIIa and IIb have been 
established to be by far the most important receptors for phagocytosis by tumor cells
23,53
, 
the inclusion of FcγRI and FcγRIIIa in the model could be used to determine design 
criteria for glycosylated antibodies or future aglycosylated variants with more complex 
FcγR mediated effector function.  
 
2.5 Discussion 
In this work, a bacterial display system has been developed to display full length IgG1 
antibodies tethered to the inner membrane of E. coli. Full length IgG, instead of only the 
human Fc domain and hinge, was displayed because earlier work showed that binding of 
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aglycosylated Fc2a mutant, which had been engineered to bind FcγRIIa/FcγRIIb24, was 
impaired when displayed in the homodimeric Fc display system
26
. Since aglycosylated 
antibodies are displayed, a more complex display system capable of glycan processing is 
not necessary. The selected antibodies can also be more readily transferred to expression 
in large quantities by E. coli following successful selections. This system has the 
additional advantage of utilizing FACS, a high-throughput screening method allowing up 
to 10
8
 clones/round to be screened. This elegant display system was combined with 
random mutagenesis to generate a diversity of sequences. Ultimately, just two point 
mutations were able to engender up to 5.7-fold and 160-fold increases in affinity for the 
FcγRIIa-H131 and -R131 alleles, respectively, as well as a 75% increase in tumor cell 
phagocytosis by macrophages (Fig. 2.2A). This general theme of library construction to 
generate diversity, followed by screening or selection to achieve desired protein 
properties, will be seen frequently in the next few chapters. 
The generation of highly FcγR selective Fc domains might allow for directed 
recruitment of certain immune effector cells, such as macrophages as shown here 
(because AglycoT-Fc1004 does not engage FcγRIIIa and has 50-fold lower affinity for 
FcγRI). So far, aglycosylated antibodies have been used for applications where 
inflammatory engagement of FcγRs or C1q complement proteins is undesirable30. The 
generation of aglycosylated antibodies with unique affinities and selectivities may open 
the possibility for a new class of therapeutics with intriguing biological properties. Fc 
engineered aglycosylated IgGs offer additional advantages by bypassing the need for N-
linked glycosylation; eliminating glycan heterogeneity and broadening the range of 
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expression systems that can be used to produce large quantities of antibody. In several 
recent clinical trials, no evidence of aglycosylated antibody immunogenicity has been 
reported
30
. However, at this point it is unclear whether mutations to an aglycosylated 
structure will induce immunogenicity either through residue change or the generation of 
non-native conformational epitopes. The results from these studies will be reported in the 
future. 
The present work has focused on improving phagocytosis using FcγRIIa-R131, 
instead of FcγRIIa-H131, especially since patients homozygous for FcγRIIa-R131 have 
an increased risk of bacterial infection and autoimmunity
16–19
. The screens were designed 
and set up to only enrich variants displaying improved FcγRIIa-R131/FcγRIIb selectivity 
(or AIIa-R131/I ratio), by using a progressively increasing excess of unlabeled FcγRIIb over 
fluorescent FcγRIIa-R131 conjugate. Interestingly, our mathematical model suggests that 
the increased phagocytic response from the best mutant, AglycoT-Fc1004, is 
predominantly attributed to increased affinity to FcγRIIa-H131. While AglycoT-Fc1004 
exhibited a 5.7-fold enhancement in affinity to FcγRIIa-H131 and slight decrease in AIIa-
H131/I ratio (0.88), leading to a 75% increase in ADCP, these properties only emerged by 
coincidence during enrichment for AIIa-R131/I. By comparison, AglycoT-Fc1004 displayed 
a 163-fold increase in FcγRIIa-R131 affinity, with a 25-fold improvement in AIIa-R131/I 
due to the direct screen. This favorably suggests that a future screen with the same 
display system set up instead to use fluorescent FcγRIIa-H131 conjugate would likely 
achieve a significantly greater improvement in FcγRIIa-H131 affinity and AIIa-H131/I 
selectivity. Since our model predicts that these two effects alone are dominant in 
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modulating ADCP (Fig. 2.8A, B and Table 2.3), this new screening strategy should yield 
variants with ADCP responses greater than that elicited by AglycoT-Fc1004. In addition, 
such Fc variants could be used much more broadly in treatment, since 74% of African 
Americans and 81% of Caucasian Americans are FcγRIIa-H131 homozygous or FcγRIIa-
H131/R131 heterozygous
20
. 
 Here, a mechanistic model has been used after directed evolution experiments to 
successfully link the biochemical properties of a clone to its consequent cellular response. 
Specifically, the model predicts ADCP from binding affinities to multiple FcγRII 
receptors. This mathematical framework can be further generalized to include other 
FcγRs to model additional effector functions. The initial goal in constructing the model 
was to quantitatively capture the diverse, non-intuitive behaviors of the selected mutants, 
but it also provided unexpected biological insights, leading to the identification of a new, 
more potent target for future engineering of Fc domains. 
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CHAPTER 3 
Model-guided ligation strategy for optimal assembly of DNA 
libraries 
Since the success of a directed evolution experiment depends heavily on library 
construction, we begin our discussion on directed evolution by first investigating ways to 
improve DNA library assembly by optimizing the ligation reaction. 
 
3.1 Introduction 
DNA ligation is indispensible in molecular biology research. The ligation reaction, 
usually catalyzed by a DNA ligase, consists of joining DNA molecule ends by creating a 
phosphodiester bond between the 3’ hydroxyl and the 5’ phosphate of adjacent 
nucleotides
1
. Maximizing ligation efficiency is important in systems where the vector or 
insert molecule is scarce or where high fidelity of ligated product is required. A prime 
example in which poor ligation efficiency can jeopardize success is in directed evolution 
experiments, because the quality and size of the protein library greatly depend on the 
extent and accuracy of DNA ligation during initial library construction as well as 
between selection rounds
2
.  
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However, methods for optimizing the ligation reaction are extremely limited and 
typically rely on extensive trial and error through experimentation. The plethora of 
ligation guidelines
a
 and web calculators
b
 do not provide any optimization capabilities or 
information beyond basic recommendations and unit conversions. Most current ligation 
calculators perform calculations for the traditional circular vector-insert ligations, 
allowing input of mass concentrations, vector:insert molar ratios and fragment lengths 
while outputting the volumes of vector and insert stock solution to be used in the ligation 
reaction
3
. There is no precise control over the extent of product formation because 
different experiments utilize ends with different properties (e.g. palindromic vs. non-
palindromic) and sequences of overhang bases, as well as different lengths of insert and 
vector. Also, since ligation and transformation are often coupled, the troubleshooting 
space is exponentially increased. Furthermore, optimization requires extensive work and 
has to be repeated anytime the system is varied. Thus, a more generic but easily altered 
strategy is needed to improve DNA ligation, and mathematical modeling provides a 
promising approach. 
While mathematical models for ligation were developed decades ago
4–7
, these 
models are either too specific to be applied in different experimental systems or too 
general to offer significant improvement over the universal guidelines. In addition, by 
                                                          
a
 https://www.neb.com/tools-and-resources/troubleshooting-guides/troubleshooting-tips-for-ligation-
reactions 
http://www.promega.com/~/media/Files/Resources/Protocols/Product%20Information%20Sheets/G/T4%20
DNA%20Ligase%20Blue%20White%20Cloning%20Qualified%20Protocol.pdf 
 
b
 http://www.insilico.uni-duesseldorf.de/Lig_Input.html 
http://www.molecularstation.com/calculators/laboratory-research/ligation-insert-vector-calculator/ 
http://django.gibthon.org/tools/ligcalc/ 
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assuming irreversibility in the ligation reactions, the models mentioned above can only 
provide distribution of various species with respect to products but not reactants. 
Advances in molecular biology, specifically the extensive use of polymerase chain 
reaction (PCR) and the availability of Type IIS restriction enzymes
8
, necessitates the 
development of new models that accommodate ligation reactions with linear fragments as 
well as non-palindromic ends.  
Most commercially available enzymes for restriction digest belong to the Type 
IIP (palindromic) family, which recognize, and cleave within, symmetric DNA 
sequences
9,10
. Using palindromic ends generated by these enzymes complicates 
downstream intermolecular ligations because palindromic ends in two identical 
molecules can anneal, thus competing with intermolecular ligations that form the product 
of interest. To avoid such byproducts, Type IIS restriction enzymes can be used. Type IIS 
enzymes cleave at asymmetric target sites, some away from their recognition sites
9
, 
allowing custom design of sticky ends. The advantages of rationally designing the 
sequences of the sticky ends include eliminating undesired intramolecular or 
intermolecular ligations that lead to unwanted species, increasing ligation fidelity by 
forcing directional cloning, and optimizing ligation efficiency by matching the free 
energy of annealing at sticky ends, among others
8
. In addition, it is possible to generate 
multiple different sticky ends in a single digestion reaction with one Type IIS enzyme, 
streamlining restriction digest protocols. Several Type IIS enzymes (e.g. BbsI, BsaI, 
BsmBI and SapI) are suitable candidates for routine cloning in replacement of Type IIP 
enzymes because: (1) they do not require two copies of their target sequences before 
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cleavage, (2) they have high fidelity in the number of bases between recognition and 
cutting sites, and (3) they cleave relatively close to the recognition sites
11
. In this study, 
we used BbsI as a model Type IIS restriction enzyme for comparison of ligation events 
with Type IIP enzymes NcoI and HindIII. 
Here, we redesigned the original ribosome display vector
12
 with two BbsI cutting 
sites adjacent to the NcoI or HindIII cutting sites that flank the insert and then used this 
second-generation display vector (pRDV2) to directly compare ligation strategies. We 
tested ligation of the sequence-of-interest, Off7
12
, to either doubly digested pRDV2 
(circular ligation) or PCR-generated and digested fragments of the upstream and 
downstream ends of pRDV2 (linear ligation). We demonstrate that circular and linear 
ligation following digestion with BbsI give up to 15- and 2.6-fold increases, respectively, 
in the yield of desired product compared with digestion with NcoI and HindIII. Based on 
Type IIS sticky ends, an easily parameterized thermodynamic model was developed to 
rationally guide ligation optimization. Our model offers significant advancement over 
previous models because not only does our model provide thermodynamic insight and 
general guidance in ligation optimization, but it also allows custom characterization (e.g., 
different ligase, sticky ends, and ligation temperature) if needed. The only parameters in 
the model are the free energies of ligation, one for each sticky end. To demonstrate the 
utility of our model, we first experimentally determined ΔG1 and ΔG2 for two sticky 
ends, CGAA and GCTT, and then computationally predicted the relative abundance of 
ligation products from three-piece linear ligation reactions and transformation yields from 
circular ligation reactions. All these predictions were successfully validated 
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experimentally. Finally, to demonstrate how our model may be useful in directed 
evolution applications, we performed simulations that provide guidelines for optimizing 
ligations for both in vivo and in vitro display technologies.  
We have further expanded this thermodynamic model for general use in ligation 
by incorporating an estimator of free energy for sticky ends of any sequence and length 
(including mismatches) and by porting the entire model online 
(https://alliance.seas.upenn.edu/~caslab/ligcal) for free and easy access by the scientific 
community. Our web server estimates the free energy of ligation for specific sticky end 
sequences from DNA thermodynamics, while also providing free energies of possible 
mismatches, to rationally guide the design of highly specific sticky end sequences to be 
generated from Type IIS restriction digests. Once specific sequences are identified, the 
estimated free energies can be used directly, or they can be determined from a simple 
two-piece linear ligation experiment, which has the additional advantage of making no 
assumptions about the ligation conditions (e.g., ligase type, ligation temperature, and salt 
concentration). With the sticky end free energies, the distribution of ligation products can 
be predicted in two-piece linear ligation, three-piece linear ligation, or vector-insert 
circular ligation. This information can be used to estimate library diversity, library size, 
or the relative number of colonies after transformation; it can also help in deciding 
between purification schemes or determining if there is enough product for the next step. 
Moreover, our ligation calculator can predict product formation over a range of input 
concentrations and molar ratios of reactants to allow custom optimization of the reaction, 
whether it be to maximize library diversity or to maximize reaction efficiency. Finally, a 
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ligation worksheet is available through the web site to facilitate conversion between mass 
concentrations and molar concentrations, as well as to formulate the ligation reaction. 
Overall, this customizable, model-guided strategy and web-based ligation calculator 
provides a means to rapidly identify the globally optimum conditions for multi-
parametric ligation reactions in order to maximize formation of the desired product and, 
thus, library size. 
 
3.2 Materials and methods 
3.2.1 DNA manipulations 
T4 DNA ligase (#M0202L) was used in all ligation reactions with the supplied 1× T4 
ligase reaction buffer (New England Biolabs; NEB). Ligation reactions were carried out 
with 200 cohesive end units per 10 µl reaction at 25
o
C for 3 h, followed by heat 
inactivation at 65
o
C for 10 min. All restriction and nicking enzymes were purchased from 
NEB. Ten-fold overdigestion was used in all digestion and nicking reactions by adjusting 
time and units of enzymes used. Phusion high-fidelity DNA polymerase (NEB) was used 
in all PCR reactions as recommended by the manufacturer. Qiagen PCR purification or 
gel extraction kit was used to purify or isolate DNA between the above steps following 
the standard procedure. DNA concentrations were determined by absorbance readings at 
260 nm using a spectrophotometer (NanoDrop 1000, Thermo Scientific). 
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3.2.2 Plasmid construction 
Primers used for DNA amplification (Integrated DNA Technologies) are listed in Table 
3.1. The initial template for further plasmid engineering was pRDVstops:Off7
13
, which is 
a modified version of the original ribosome display vector pRDV
12
 that contains the off7 
ankyrin gene. The first BbsI site was introduced by amplifying pRDVstops:Off7 with 
primers 3/4, digesting with BseYI and NcoI, and ligating into similarly cut pRDVstops-
Off7. The ligation mixture was transformed into chemically competent E. coli XL1-Blue 
cells
14
. The resulting plasmid pRDV1b:Off7 was isolated with a Qiagen miniprep kit 
following the standard procedure. The second BbsI site was introduced by amplifying 
pRDVstops:Off7 with primers 5/6 and cloning into pRDV1b:Off7 via the HindIII and 
NotI sites, giving rise to pRDV2:Off7 (Fig. 3.1). To replace off7 with β-lactamase to 
obtain pRDV2:Blac, the insert from NcoI- and HindIII-digested pRDV-Blac was ligated 
into the vector from similarly digested pRDV2:Off7. All clones were confirmed by DNA 
sequencing. 
 
Table 3.1. Primers used in this study. 
Primer 
Number 
Primer Name Nucleotide Sequence (5’  3’) a 
1 T7B_noBsaI ATACGAAATTAATACGACTCACTATAGGGACACCACAACGG  
2 tolAk CCGCACACCAGTAAGGTGTGCGGTTTCAGTTGCCGCTTTCTTTC
T 
3 BbsIsite1_BseYI_f GTTCGTGCACACAGCCCAGC 
4 BbsIsite1_NcoI_r TCCGCCATGGATATATCTCCTTCTTTCGGTGTCTTCAAATTATT
TCTATTG 
5 BbsIsite2_HindIII_f GCAAAAGCTTGGGTCTTCCGGTGGCCAGAAGCAAGC 
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6 BbsIsite2_NotI_r TCATCTGCCTCTGCGGCCGC 
7 pRDV_BbsI_f AATAATTTGAAGACACCGAAAGAAG 
8 pRDV_BbsI_r GGCCACCGGAAGACCCAAGC 
9 pRDV_NcoI_f AGAAGGAGATATATCCATGG 
10 pRDV_HindIII_r GGCCACCAGATCCAAGCTT 
 
a
 Restriction sites are underlined. 
 
 
 
Figure 3.1. Schematic representation of pRDV2 vector design and NcoI, HindIII, and BbsI cutting sites. 
(A) Representative map of pRDV2:Off7 showing T7 promoter, ribosome binding site (RBS), off7 gene, 
tolA spacer, and the various restriction enzyme cutting sites. Primer 1 is a forward primer that anneals at 
the beginning of the T7 promoter and primer 2 is a reverse primer that anneals within tolA. Primers 3–10 
anneal at their respective positions near restriction sites as indicated by the names of the primers (Table 
3.1). (B) Partial DNA sequence of NcoI and BbsI restriction sites upstream of off7. The recognition 
sequences are underlined and the cutting sites are indicated by arrows. (C) Partial DNA sequence of 
HindIII (top) and BbsI (bottom) restriction sites downstream of off7. The two sequences are identical but 
are annotated separately for clarity. Amino acid translations in frame with Off7 are shown below the 
sequence. 
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3.2.3 Linear ligation 
To obtain the three DNA fragments for linear ligation – the T7 region, off7 and the tolA 
region – pRDV2-Off7 was amplified by PCR with primers 1/4, 7/8 and 5/2, respectively. 
The PCR-amplified T7 region was digested with NcoI or BbsI, while off7 was digested 
with NcoI/HindIII or BbsI and tolA region was digested with HindIII or BbsI. Two- or 
three-piece linear ligation reactions were carried out as described above with the molar 
ratio and concentration of each species as specified in the experiment. Ligation products 
were resolved and visualized using gel electrophoresis. Agarose gels (1.5% in 1× TAE 
buffer) were stained with ethidium bromide and imaged using an ultraviolet 
transilluminator and CCD camera. Band intensities were quantified with Kodak 
molecular imaging software v4.5.0 using exACTGene 1 kb plus and 50 bp mini DNA 
ladders (Fisher Scientific) as standards. For each image, the relative intensities of each 
band were obtained by averaging quantification at three different aperture and exposure 
settings. 
 
3.2.4 Circular ligation 
pRDV2:Blac was digested with NcoI/HindIII or BbsI and then gel purified to obtain 
doubly digested linear pRDV2 vector. Circular ligation was carried out by ligating this 
vector to digested off7 insert (prepared as described above) at specific molar ratios and 
concentrations. Gel electrophoresis (1% agarose gels) was used to resolve and visualize 
ligation products. Ligation PCR was carried out by amplifying 75 ng ligation product 
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with primers 1/2 for 10 cycles. Transformations were performed using XL1-Blue cells as 
described above and the resulting colonies were counted manually. 
 
3.2.5 Thermodynamic model: linear ligation 
To guide ligation optimization more rationally, a mathematical model was developed that 
predicts product distributions based on input DNA concentrations and free energies of the 
ligation events. Nomenclature used in the thermodynamic model is provided in Table 3.2.  
Table 3.2. Nomenclature used in the thermodynamic model. 
Symbol Description 
[species] Concentration of DNA species (in nM) 
[speciesn] Concentration of nicked DNA species (in nM) 
KD1 Equilibrium dissociation constant for annealing of sticky end CGAA (in nM) 
KD2 Equilibrium dissociation constant for annealing of sticky end GCTT (in nM) 
Klig1 Equilibrium dissociation constant for the sealing of DNA phosphodiester bonds by T4 
DNA ligase for sticky end CGAA (unitless) 
Klig2 Equilibrium dissociation constant for the sealing of DNA phosphodiester bonds by T4 
DNA ligase for sticky end GCTT (unitless) 
K1 KD1×Klig1. Lumped equilibrium dissociation constant for overall ligation of sticky end 
CGAA (in nM) 
K2 KD2×Klig2. Lumped equilibrium dissociation constant for overall ligation of sticky end 
GCTT (in nM) 
J The Jacobson-Stockmayer factor
15
. Effective concentration of one end of a linear DNA 
molecule with respect to the other (in ends/ml) 
[j] Effective concentration of one end of a linear DNA molecule with respect to the other (in  
nM) 
KDcir1 Equilibrium dissociation constant for the circularization annealing of sticky end CGAA 
(unitless) 
KDcir2 Equilibrium dissociation constant for the circularization annealing of sticky end GCTT 
(unitless) 
Kcir1 Lumped equilibrium dissociation constant for the overall circularization and ligation of 
sticky end CGAA (unitless) 
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Kcir2 Lumped equilibrium dissociation constant for the overall circularization and ligation of 
sticky end GCTT (unitless) 
 
A thermodynamic model of linear ligation was developed by considering ligation 
to be a two-step reaction: annealing of sticky ends and sealing of the phosphodiester 
backbone. The thermodynamic reactions for 3-piece linear ligations are as follow: 
 A + B KD1 ABn 
Klig1 AB 
 B + C KD2 BCn 
Klig2 BC 
 AB + C KD2 ABC2n 
Klig2 ABC2 
 BC + A KD1 ABC1n 
Klig1 ABC1 
where KD1 and KD2 are the dissociation constants for annealing of sticky ends CGAA 
and GCTT, respectively, and Klig1 and Klig2 are equilibrium dissociation constants for the 
sealing of DNA phosphodiester bonds by T4 DNA ligase. We assumed that products 
sealed by ligase at one site could not re-nick at the other site (e.g., ABC1 could not be 
converted into ABC2n). 
KD1 = [A][B]/[ABn] or [BC][A]/[ABC1n] 
 KD2 = [B][C]/[BCn]  or [AB][C]/[ABC2n] 
 Klig1 = [ABn]/[AB] or [ABC1n]/[ABC1] 
 Klig2 = [BCn]/[BC] or [ABC2n]/[ABC2] 
At equilibrium, the first reaction gives: 
 [A][B] – (KD1)(Klig1)[AB] = 0 
and the mass balance of species A gives: 
 [A] + [AB](1+Klig1) + [ABC1](1+Klig1) + [ABC2](1+Klig2) = [A]t 
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To reduce the number of parameters, KD1 and Klig1 are multiplied to give the lumped 
parameter K1 and, similarly, KD2 and Klig2 are lumped into parameter K2. The ligation 
equilibrium constants Klig1 and Klig2 can be estimated by the standard free energy of 
ligation (∆Go) of -6.3 kcal/mol16 and can thus be eliminated in the mass balance since (1 
+ Kligx) ≈ 1 for Kligx << 1 (where x = 1 or 2). The values of K1 and K2 were independently 
determined by two-piece linear ligation (described below). Applying these simplifications 
gives a system of seven equations: 
Thermodynamic equilibrium equations: 
  [A][B] – K1[AB] = 0       (1) 
  [B][C] – K2[BC] = 0       (2) 
  [AB][C] – K2[ABC2] = 0      (3) 
  [BC][A] – K1[ABC1] = 0      (4) 
Mass balance equations: 
  [A] + [AB] + [ABC1] + [ABC2] = [A]t    (5) 
  [B] + [AB] + [BC] + [ABC1] + [ABC2] = [B]t   (6) 
  [C] + [BC] + [ABC1] + [ABC2] = [C]t    (7) 
Based on input DNA concentrations [A]t, [B]t and [C]t, this system of equations was 
solved in Matlab using fsolve with tolerance value of 10
-8
 to obtain the unknowns [A], 
[B], [C], [AB], [BC], and [ABC]. Molar ratios of the species were obtained with 
reference to product [ABC] and mass ratios were calculated using the respective base 
pairs of the species. Percent incorporation (defined as full-length product over total 
amount of insert added) was calculated using [ABC]/[B]t × 100% and percent efficiency 
(defined as full-length product over total amount of reactants added) was calculated using 
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[ABC]/([A]t + [B]t + [C]t) × 100%, where the subscript t represents the total amount of 
that species. For experimental determination, the mass fraction of each species was 
quantified on an agarose gel by densitometry and converted to absolute mass by 
multiplying each value by the total mass of the reactants. The absolute mass of correct 
product was then converted to moles and divided by the corresponding moles of insert or 
reactants for the given experimental conditions. 
 
3.2.6 Thermodynamic model: circular ligation 
The thermodynamic reactions for circular ligations are as follow:  
 V + I KD1 VI1n 
Klig1 VI1 
 V + I KD2 VI2n 
Klig2 VI2 
 VI1 
KDcir2 VIc2n 
Klig2 VIc2 
 VI2 
KDcir1 VIc1n 
Klig1 VIc1 
 VI1 + I 
KD2 IVI2n 
Klig2 IVI2 
 VI2 + I 
KD1 IVI1n 
Klig1 IVI1 
 VI1 + V 
KD2 VIV2n 
Klig2 VIV2 
 VI2 + V 
KD1 VIV1n 
Klig1 VIV1 
 IVI + V KD1 VIVI1an 
Klig1 VIVI1a 
 IVI + V KD2 VIVI2an 
Klig2 VIVI2a 
 VIV + I KD1 VIVI1bn 
Klig1 VIVI1b 
 VIV + I KD2 VIVI2bn 
Klig2 VIVI2b 
 VIVI1 
KDcir2 VIVIc2n 
Klig2 VIVIc2 
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 VIVI2 
KDcir1 VIVIc1n 
Klig1 VIVIc1 
where KD1, KD2, Klig1, and Klig2 are equilibrium constants as defined above. KDcir1 and 
KDcir2 are equilibrium dissociation constants for circularization. 
 KDcir1 = [VI2]/[VIc1n]  or [VIVI2]/[VIVIc1n] 
 KDcir2 = [VI1]/[VIc2n]  or  [VIVI1]/[VIVIc2n] 
Analogous to what was done in the linear ligation model, KDcir1 and Klig1 are multiplied to 
give the lumped parameter Kcir1 and KDcir2 and Klig2 are lumped into parameter Kcir2. To 
obtain Kcir1 and Kcir2, the Jacobson-Stockmayer factor j was first calculated: 
 j = jλ (MWλ / MW)
3/2
 
where jλ = 3.6 x 10
11
 ends/ml and MWλ = 30.8 x 10
6
 g/mol
4
. By treating the annealing of 
V and I at one end followed by circularization at the other end as the binding of a 
bipartite ligand to a bipartite receptor, the circularization constants could be calculated as: 
 Kcir1 = K1/[j]  and  Kcir2 = K2/[j] 
where [j] (mol/volume) is the effective concentration converted from j (ends/ml). 
Applying the same simplifications regarding Klig1 and Klig2, the thermodynamic 
equilibrium equations for circular ligation can be written as follow: 
 [V][I] – K1[VI1] = 0        (8) 
 [V][I] – K2[VI2] = 0        (9) 
 [VI1] – Kcir2_VI[VIc2] = 0       (10) 
 [VI2] – Kcir1_VI[VIc1] = 0       (11) 
 [VI1][I] – K2[IVI2] = 0       (12) 
 [VI2][I] – K1[IVI1] = 0       (13) 
 [VI1][V] – K2[VIV2] = 0       (14) 
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 [VI2][V] – K1[VIV1] = 0       (15) 
 [IVI][V] – K1[VIVI1a] = 0       (16) 
 [IVI][V] – K2[VIVI2a] = 0       (17) 
 [VIV][I] – K1[VIVI1b] = 0       (18) 
 [VIV][I] – K2[VIVI2b] = 0       (19) 
 [VIVI1]  - Kcir2_VIVI[VIVIc2] = 0      (20) 
 [VIVI2] – Kcir1_VIVI[VIVIc1] = 0      (21) 
 [V] + [VI] + [VIc] + [IVI] + 2([VIV] + [VIVI] + [VIVIc]) = [V]t  (22) 
 [I] + [VI] + [VIc] + 2[IVI] + [VIV] + 2([VIVI] + [VIVIc]) = [I]t  (23) 
where [VI] = [VI1] + [VI2], [VIc] = [VIc1] + [VIc2], [IVI] = [IVI1] + [IVI2], [VIV] = 
[VIV1] + [VIV2], [VIVI1] = [VIVI1a] + [VIVI1b], [VIVI2] = [VIVI2a] + [VIVI2b], [VIVI] = 
[VIVI1] + [VIVI2] and [VIVIc] = [VIVIc1] + [VIVIc2].  
This system of equations was solved in Matlab using fsolve with tolerance value of 10
-8
 
to obtain the unknowns [VIc] and [VIVIc]. Molar ratios of the species were obtained with 
reference to product [VIc] at 1:1 I:V molar ratio and mass ratios were calculated using 
the respective base pairs of the species. Percent incorporation (defined as correctly 
ligated circular vector–insert product over total amount of insert added) was calculated 
using [VIc]/[I]t × 100%, percent efficiency (defined as correctly ligated circular product 
over total amount of vector and insert added) was calculated using [VIc]/([V]t + [I]t) × 
100%, and percent accuracy (defined as correctly ligated circular product over total 
circular product formed) was calculated using [VIc]/([VIc] + [VIVIc]) × 100%. 
Experimental values were calculated by dividing colony number by moles of insert or 
reactants at a fixed vector concentration (8 nM or 3 nM); these ratios were then divided 
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by the sum of all such experimental ratios and multiplied by the sum of all corresponding 
simulated values at the same vector concentration. This enabled direct comparison of 
experimental results and model simulations. 
 
3.2.7 Training of thermodynamic model to determine ΔG1 and ΔG2 
Two-piece linear ligation was carried out to experimentally determine ΔG1 and ΔG2 for 
the sticky ends CGAA and GCTT, respectively. To determine ΔG1, BbsI-digested T7 (A) 
and off7 (B) were ligated at molar ratios of 1:1, 2:1, and 1:2 with 21, 32, and 53 nM off7. 
The product mass ratios for the above nine conditions were quantified from agarose gels 
(Table 3.3). Similar to three-piece ligation, the thermodynamic equilibrium equations for 
two-piece ligation can be written as follows: 
  [A][B] – K1[AB] = 0        (24) 
while the mass balance equations are 
 [A] + [AB] = [A]t        (25) 
and [B] + [AB] = [B]t        (26) 
This system of equations was solved with a range of ΔG1 in Matlab using fsolve with 
tolerance value of 10
-8
 and compared to experimentally determined results. Least squares 
regression of ΔG1 was carried out to two decimal places by minimizing the sum of the 
squared residuals. Similarly, to determine ΔG2, BbsI-digested off7 (B) and tolA (C) were 
ligated at molar ratios of 1:1, 1:2, and 2:1 with 21, 32, and 53 nM off7 and the product 
mass ratios were quantified (Table 3.3). The system of equations can be written as 
follows: 
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  [B][C] – K2[BC] = 0        (27) 
 [B] + [BC] = [B]t        (28)  
 [C] + [BC] = [C]t        (29) 
 
Table 3.3. Experimentally determined mass ratios for training two-piece ligations. 
 Concentration of off7 (nM) 
 21 32 53 
Species Mass ratios of species 
(T7:off7 = 1:1)    
T7 0.22 0.21 0.15 
off7 0.49 0.32 0.44 
T7-off7 1.00 1.00 1.00 
(T7:off7 = 2:1)    
T7 0.20 0.33 0.27 
off7 0.22 0.28 0.23 
T7-off7 1.00 1.00 1.00 
(T7:off7 = 1:2)    
T7 0.00 0.18 0.08 
off7 0.97 0.64 0.64 
T7-off7 1.00 1.00 1.00 
    
(off7:tolA = 1:1)    
tolA 0.18 0.31 0.42 
off7 0.16 0.27 0.20 
off7-tolA 1.00 1.00 1.00 
(off7:tolA = 1:2)    
tolA 0.53 0.88 1.16 
off7 0.16 0.31 0.24 
off7-tolA 1.00 1.00 1.00 
(off7:tolA = 2:1)    
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tolA 0.00 0.00 0.10 
off7 0.53 0.32 0.24 
off7-tolA 1.00 1.00 1.00 
 
3.2.8 Correlation test 
Correlation tests were conducted to determine whether model predictions were 
statistically significant in explaining the experimental results. For three-piece linear 
ligation, a correlation test was performed for each molar ratio (10:1:10, 2:1:2, 1:1:1, 
1:2:1, and 1:10:1). The pairwise linear correlation coefficient for the mass ratios of the 
six species in the model and the corresponding mass ratios in three independent 
experiments was obtained by the corr function in Matlab’s statistics toolbox. This value 
was then compared to 1000 correlation coefficients that were determined by randomly 
permuting the mass ratios of species in the model. The p-value was defined as the 
fraction of random correlation coefficients greater than the actual correlation coefficient. 
For vector-insert circular ligation, a correlation test was performed for each vector 
concentration (0.24, 3.02, and 6.04 nM) using the same method but by comparing molar 
ratios for the three different input insert:vector ratios in the model and the corresponding 
colony numbers in three independent experiments. 
 
3.2.9 Ribosome display with pRDVstops-Off7 and pRDV2-Off7 
The two ribosome display vectors, pRDVstops:Off7 and pRDV2:Off7, were PCR 
amplified with primers 1/2 and the products were used directly in in vitro transcription as 
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previously described
17
. Ribosome display selection particles were generated using the 
PURExpress in vitro protein synthesis kit (NEB) using mRNA as a template. For the 
translation reaction, 10 μl solution A, 7.5 μl solution B, 0.5 μl RNasin Plus, 2 μl off7 
mRNA (1.4×10
13
 molecules) and 5 μl H2O were mixed and incubated at 37
o
C for 30 min. 
Translation was stopped with 420 μl ice-cold WBT buffer (50 mM Tris-acetate pH 7.5, 
150 mM NaCl, 50 mM magnesium acetate, 0.05% Tween-20
17
) with 0.5% casein, and 
centrifuged at 20,000g for 5 min at 4
oC. 100 μl supernatant was used in each well for 
binding experiment. Binding was performed using Maxisorp plates (NUNC, Thermo 
Fisher Scientific) prepared as follows: plates were coated with 100 μl 66 nM NeutrAvidin 
(Thermo Fisher Scientific) in Tris-buffered saline (TBS) overnight at 4
o
C and then 
blocked with 0.5% casein (Sigma-Aldrich) in TBS at room temperature for 1 hr with 
shaking. For positive controls, wells were incubated with 1.83 μl 27.4 μM biotinylated 
maltose binding protein (MBP) in 200 μl TBS with 0.5% casein to immobilize the off7 
target. Binding was performed at 4
o
C for 1 hr with shaking. The plate was washed with 
WBT with 0.5% casein (three immediate washes and three 15-minute washes). Reverse 
transcription was performed using AffinityScript reverse transcriptase (Agilent 
Technologies) with reverse primers 10 and 8 for pRDVstops-Off7 and pRDV2-Off7, 
respectively. A modified in situ reverse transcription protocol
18
 was used: 13.5 μl 
solution X (0.25 μl reverse primer, 12.75 μl H2O and 0.5 μl RNasin Plus) was added to 
each well and the reaction was incubated at 65
o
C for 5 min and placed on ice for 1 min. 
Then, 6.5 μl solution Y (2 μl 10x AffinityScript buffer, 2 μl 0.1 M DTT, 2 μl 5mM 
dNTPs and 0.5 μl AffinityScript reverse transcriptase) was added to each well and the 
reaction was incubated at 45
o
C for 1 hr followed by 70
o
C for 15 min and 4
o
C for 7 min. 
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For PCR amplification, 2 μl of each reaction was taken and combined with primers 9/10 
and 7/8 for pRDVstops:Off7 and pRDV2:Off7, respectively, for 25 cycles. Gel 
electrophoresis (1% agarose) was used to visualize the product from the ribosome display 
round. 
 
3.3 Software development 
3.3.1 Web server availability and implementation 
The ligation calculator is freely available at https://alliance.seas.upenn.edu/~caslab/ligcal. 
The user interface is entirely web-based and all entry forms were generated by the 
standard HyperText Markup Language 5 (HTML5) with Cascading Style Sheets 2.1 
(CSS 2.1). All underlying Common Gateway Interface (CGI) scripts were written in 
Python 2.7 (http://www.python.org) with two open-source scientific computing packages 
NumPy (http://www.numpy.org) and SciPy (http://www.scipy.org)
19
, as well as the 
plotting library matplotlib (http://matplotlib.org)
20
. The interface has been tested on 
several web browsers, including Chrome 26, Firefox 16, Internet Explorer 10, and Safari 
5.1.9. 
 
3.3.2 Sticky end free energy calculator 
Estimation of a sticky end free energy from DNA thermodynamics is performed by 
summing 1) the stacking energy arising from the two bases adjacent to the two nick 
81 
 
sites
21,22
, 2) the hydrogen-bonding energy between complementary sticky ends
23
, and 3) 
the energy for formation of the phosphodiester bonds
16
. If desired, the default stacking 
and phosphodiester bond energies in the online calculator can be changed or omitted 
entirely. Hydrogen bonding energies are computed using the parameters and methods for 
nearest-neighbor DNA thermodynamics
23
, with the assumption that temperature and salt 
dependence act in opposite directions to the free energy and would thus negate the effect 
of one another
23
. Free energies for mismatched sticky ends are estimated similarly but 
from tabulated values of nearest-neighbor parameters for one or two mismatches in two 
base pair sequences. For one out of two mismatches, parameter values are obtained from 
literature for G•T24, G•A25, C•A26, C•T27, A•A28, C•C28, G•G28, and T•T28 mismatches. 
Since there are no literature values for the nearest-neighbor free energy change for two 
consecutive mismatches (except GG/TT, GT/TG and TG/GT
24
), we estimated their 
values by summing the free energy contributions from each of the two base pairs (Table 
3.4). This assumes that each base pair contributes independently to the overall free 
energy, which is less accurate than the nearest-neighbor calculation in which neighboring 
bases contribute to the overall free energy, but is nonetheless a good approximation 
(Table 3.6). The sum of the squared residuals between calculated and literature values 
(for complete matches
23
 and single mismatches
24–28
) was then minimized using Solver in 
Microsoft Excel to obtain the energetic contributions of the individual base pairs. The 
resulting parameters are shown in Table 3.5 and the residuals of this global fit are shown 
in Table 3.6. Free energies for mismatched sticky ends with a one nucleotide gap are 
estimated in the same manner except that there are no contributions from DNA base 
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stacking. Free energies for two sticky ends of any length as well as any possible 
mismatch combinations can be estimated by this method. 
 
Table 3.4. Calculated free energy contributions from individual base pairs.  
Base pairs Free energy (kcal/mol)  
AA 1.14  
AT -0.51 (not used) 
AC 1.50  
AG 0.75  
TA -0.35 (not used) 
TT 1.09  
TC 1.38  
TG 0.60  
CA 1.50  
CT 1.38  
CC 1.63  
CG -0.87 (not used) 
GA 0.75  
GT 0.49  
GC -0.93 (not used) 
GG 0.44  
 
 
 
 
 
83 
 
Table 3.5. Nearest-neighbor free energy matrix used in the sticky end free energy calculator. 
a
  
5->3/3->5 AA AT AC AG TA TT TC TG CA CT CC CG GA GT GC GG 
AA 2.28 0.69 2.64 1.89 0.61 -1.00 0.88 0.14 2.64 1.33 3.01 2.26 1.89 0.74 2.26 1.50 
AT 0.61 2.23 2.52 1.63 -0.88 0.69 0.73 0.07 0.77 2.59 2.88 2.00 0.02 1.84 2.13 1.25 
AC 2.64 2.52 2.77 0.17 0.77 0.64 1.33 -1.44 3.01 2.88 3.14 0.47 2.26 2.13 2.38 -0.52 
AG 1.89 1.74 0.43 1.58 0.02 0.71 -1.28 -0.13 2.26 2.10 0.79 1.94 1.51 1.35 0.11 1.19 
TA 0.69 -0.58 0.92 0.42 2.23 0.68 2.59 1.84 2.52 0.97 2.88 2.13 1.74 0.43 2.10 1.35 
TT -1.00 0.68 0.75 0.34 0.69 2.18 2.47 1.58 0.64 2.47 2.76 1.87 0.71 1.69 1.98 0.74 
TC 1.33 0.97 1.05 -1.30 2.59 2.47 2.72 0.45 2.88 2.75 3.01 0.62 2.10 1.97 2.23 0.08 
TG 0.74 0.43 -1.45 0.44 1.84 1.69 -0.12 1.53 2.13 1.97 0.62 1.81 1.35 0.52 -0.47 1.03 
CA 2.64 0.92 3.01 2.26 2.52 0.75 2.88 2.13 2.77 1.05 3.14 2.38 0.43 -1.45 0.75 0.03 
CT 0.88 2.59 2.88 2.00 0.73 2.47 2.76 1.87 1.33 2.72 3.01 2.13 -1.28 -0.12 0.40 -0.32 
CC 3.01 2.88 3.14 0.81 2.88 2.76 3.01 0.98 3.14 3.01 3.26 0.79 0.79 0.62 0.70 -1.84 
CG 2.26 2.10 0.75 1.94 2.13 1.98 0.40 1.82 2.38 2.23 0.70 2.07 0.11 -0.47 -2.17 -0.11 
GA 1.89 0.42 2.26 1.50 1.63 0.34 2.00 1.24 0.17 -1.30 0.81 -0.25 1.58 0.44 1.94 1.19 
GT 0.14 1.84 2.13 1.24 0.07 1.58 1.87 1.15 -1.44 0.45 0.98 -0.59 -0.13 1.53 1.82 0.93 
GC 2.26 2.13 2.38 -0.25 2.00 1.87 2.13 -0.59 0.47 0.62 0.79 -2.24 1.94 1.81 2.07 -1.11 
GG 1.50 1.35 0.03 1.19 1.25 0.74 -0.32 0.93 -0.52 0.08 -1.84 -1.11 1.19 1.03 -0.11 0.87 
 
a
 Values in yellow represent interaction between complementary bases
23, values in dark blue represent G•T 
mismatches
24, values in green represent G•A mismatches25, values in red represent A•C mismatches26, 
values in purple represent C•T mismatches27, values in light blue represent A•A, G•G, C•C or T•T 
mismatches
28
, and values in white represent complete mismatch values calculated using data in Table 3.4. 
 
Table 3.6. Residuals between calculated and literature values after fitting. 
a
 
5->3/3->5 AA AT AC AG TA TT TC TG CA CT CC CG GA GT GC GG 
AA 
 
0.01 
  
0.00 0.02 0.01 0.01 
 
0.03 
   
0.11 
  
AT 0.00 
   
0.02 0.01 0.02 0.01 0.05 
   
0.05 
   
AC 
   
0.00 0.05 0.05 0.04 0.00 
   
0.01 
   
0.12 
AG 
  
0.03 
 
0.05 0.39 0.01 0.00 
  
0.02 
   
0.05 
 
TA 0.01 0.01 0.06 0.00 
 
0.00 
   
0.00 
   
0.03 
  
TT 0.02 0.00 0.08 0.04 0.01 
   
0.05 
   
0.39 
  
0.12 
TC 0.03 0.00 0.05 0.00 
   
0.09 
   
0.03 
   
0.17 
TG 0.11 0.03 0.05 0.12 
  
0.12 
   
0.01 
  
0.45 0.04 
 
CA 
 
0.06 
   
0.08 
   
0.05 
  
0.03 0.05 0.01 0.02 
CT 0.01 
   
0.02 
   
0.04 
   
0.01 0.12 0.01 0.00 
CC 
   
0.06 
   
0.28 
   
0.01 0.02 0.01 0.00 0.00 
CG 
  
0.01 
   
0.01 
   
0.00 
 
0.05 0.04 0.18 0.10 
GA 
 
0.00 
   
0.04 
  
0.00 0.00 0.06 0.00 
 
0.12 
  
GT 0.01 
   
0.01 
  
0.03 0.00 0.09 0.28 0.02 0.00 
   
GC 
   
0.00 
   
0.02 0.01 0.03 0.01 0.14 
   
0.38 
GG 
  
0.02 
  
0.12 0.00 
 
0.12 0.17 0.00 0.38 
  
0.10 
  
a
 Color representations are identical to those in Table 3.5. 
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Alternatively, a sticky end free energy can be estimated from up to ten trials in a 
linear ligation experiment using two DNA fragments containing the sticky end of interest 
as discussed in Section 3.2.7. At equilibrium, the two-piece linear ligation reaction and 
the mass balances yield three equations (24), (25) and (26) which can be analytically 
solved to give: 
 [AB] = 0.5×(KD + [A]t + [B]t – {(KD + [A]t + [B]t)
2
 – 4[A]t[B]t)}
1/2
) 
where [AB] is the concentration of the ligation product at equilibrium and [A]t and [B]t 
are the input concentrations of DNA fragments A and B, respectively. [A] and [B], which 
represent the concentrations of reactants still present at equilibrium, can be easily 
calculated by subtracting [AB] from [A]t and [B]t, respectively. For a range of free 
energies (and, thus, KD values), the computed [A], [B], and [AB] values are compared to 
those in all of the experimental trials to obtain a sum of squared residuals between model 
and experimental results. The free energy that yields the best global fit of species 
concentrations (i.e., the smallest sum of squared residuals) is the experimentally 
determined free energy of the sticky end. The number of base pairs is used to convert 
output mass ratio into molar ratio and the number of overhang bases is used to determine 
the free energy search space. This range of free energies has been estimated from DNA 
thermodynamics for all possible combinations of 2, 3, 4, and 5 base overhangs with 
random flanking bases, with both sources of stacking energy
21,22
. Alternatively, the free 
energy range can be explicitly specified. 
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3.3.3 Linear and circular ligation calculator 
The mathematical models and experimental validations for both linear and circular 
ligations were previously described in Section 3.2.5 and 3.2.6 respectively. For two-piece 
linear ligation, three-piece linear ligation, and circular ligation, systems of 3, 7, and 16 
equations are solved in Python using scipy.optimize.fsolve to obtain the 3, 7, and 16 
unknowns, respectively. Ligation recommendations consist of computed heatmaps for 
incorporation, efficiency, and accuracy (circular ligation only) for molar ratios ranging 
from 1/8 to 8 and library concentrations ranging from 10% to 100% of the concentration 
of the valuable species. Incorporation is defined as the concentration of full-length 
product divided by the input concentration of the valuable species; efficiency is defined 
as the concentration of full-length product divided by the total input DNA concentration; 
and accuracy is defined as the percentage of circular vector-insert product over the sum 
of all circular products. 
 
3.3.4 Ligation worksheet 
To facilitate conversion between mass concentrations and molar concentrations and to 
simplify formulation of the final ligation reaction, a ligation workbook has been 
developed in Microsoft Excel and the file is available for download from the website. 
The first worksheet in the file contains a simple calculator to convert the mass 
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concentration of a sample in stock or in a reaction to a molar concentration
c
. The second 
worksheet contains a calculator for formulating two- or three-piece linear ligation 
reactions, allowing custom input of available mass concentrations, numbers of base pairs, 
targeted molar concentrations for each DNA species, ligase volume, and total reaction 
volume. The last worksheet contains a calculator for circular vector-insert ligations, 
which functions similarly to the linear ligation worksheet except that vector:insert molar 
ratio is specified. 
 
3.4 Results 
3.4.1 Optimal design of Type IIS target sites 
We have designed a new ribosome display vector, pRDV2, which utilizes Type IIS 
restriction sites as an alternative to the predominant Type IIP restriction sites (Fig. 3.1A). 
The ribosome display vector pRDV was chosen as the vector template, and off7, a gene 
evolved from ribosome display to bind maltose-binding protein, was chosen to be the 
model insert
12
. The transcription/translation cassette of pRDV-Off7 consists of the T7 
promoter, ribosome-binding site, off7 gene and tolA spacer (for more details on ribosome 
display, see Chapter 5). The off7 gene is usually flanked by the restriction sites of Type 
IIP restriction enzymes, such as NcoI and HindIII. In a directed evolution experiment, 
these two sites would be used for assembling the initial library into pRDV, reattaching 
the T7 promoter and tolA regions to the library insert between selection rounds, as well 
                                                          
c
 http://www.invitrogen.com/site/us/en/home/References/Ambion-Tech-Support/rna-tools-and-
calculators/dna-and-rna-molecular-weights-and-conversions.html 
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as analyzing selection results by transformation and subsequent sequencing of individual 
clones
29
. Each of the above steps requires high ligation efficiency and fidelity to preserve 
the diversity of the library as the success of any selections depends heavily on the quality 
of the construction, propagation and analysis of the library. We thus picked a directed 
evolution application as the motivation of our study, although our results are generally 
applicable in any context where ligation efficiency is important. 
 NcoI and HindIII cut double-stranded DNA with four-base palindromic 
overhangs CATG and AGCT, respectively (Fig. 3.1B and C). Identical palindromic ends 
in different DNA molecules, usually caused by digestion with the same restriction 
enzyme, can anneal by forming complementary base pairs. However, a molecule can also 
anneal to another copy of itself in reverse orientation as palindromic ends are self-
complementary. This leads to the loss of molecules and unwanted homodimer byproducts 
which is an inherent limitation of any Type IIP restriction enzyme. Fortunately, the two 
ends CATG and AGCT cannot anneal to each other for more than 1 base, which 
generally falls outside of the mismatch tolerance of T4 DNA ligase
30,31
. Thus, NcoI and 
HindIII represent two good palindromic restriction sites for drawing comparisons to Type 
IIS sites. 
Since the Type IIS restriction enzyme BbsI cuts at sites 2 and 6 bp away from the 
recognition sequence, it allows us to custom design the sequence of each cutting site. 
CGAA and GCTT (Fig. 3.1B and C) were chosen for several reasons. First, they are non-
palindromic and eliminate homodimer formation. Second, they cannot recombine with 
each other within mismatch tolerance of T4 DNA ligase. In contrast, the use of sub-
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optimal cutting sequences ACTA and GCTT, which have two out of four correctly 
positioned complementary bases between sense and anti-sense overhangs, gave a very 
high misannealing of the two sites. The selection of CGAA and GCTT overhangs 
provides a simple solution to the above two problems, as the two sites are identical in 
overall base composition (thus providing similar annealing temperatures) but have 
opposite sequence orientations (thus minimizing spurious annealing). Third, the first BbsI 
site was inserted between the T7 promoter and RBS so as not to perturb transcription and 
translation, while the second site was inserted at the beginning of tolA preserving in-
frame glycines and serines to maintain the flexibility of the spacer (Fig. 3.1C, bottom). 
Single-clone ribosome display was carried out using pRDV2:Off7 to demonstrate that 
insertion of the BbsI sites had no adverse effect on selection (Fig. 3.2). Lastly, the BbsI 
sites were positioned next to the original NcoI and HindIII sites to generate similar 
fragment sizes, which facilitated direct comparison of the methods. 
 
Figure 3.2. Results from one round of ribosome display with pRDVstops:Off7 and pRDV2:Off7 as 
templates. A “+” denotes a well with MBP immobilized and a “−“ denotes a well without MBP. Each 
condition was tested in duplicate. 
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3.4.2 Vector-insert ligation of Type IIS digested fragments yields more full-length 
product 
We first performed ligation of off7 and pRDV2 with NcoI/HindIII cuts or with two BbsI 
cuts. A constant amount of vector with different molar ratios of insert:vector were ligated 
and the products were resolved and visualized with agarose gel electrophoresis. Figure 
3.3A shows ligation of off7 and pRDV2 digested by NcoI and HindIII. Even without 
insert, many high molecular weight products were formed through vector–vector 
annealing events. As the amount of insert increased, high molecular weight products 
remained and additional lower molecular weight bands were visible. The presence of 
circular species and the exponential combination of linear and circular products make 
determination of the identity of these bands extremely difficult (the sizes of products 
containing up to four ligated molecules are provided in Table 3.7). pRDV2:Off7 nicked 
at a single BsmI site was included to mimic the circular ligation product of interest since 
both are of identical length and should have similar migration properties in the agarose 
gel, but no ligation products are visible at this distance in the gel. In contrast, ligation of 
off7 and pRDV2 cut by BbsI shows a faint product band at the same distance as the 
nicked pRDV2-Off7, and this band is strongest for a 1:1 insert:vector ratio (Fig. 3.3B). In 
the BbsI ligation, excess insert at 0.5 kb (5:1 and 3:1) or excess doubly digested vector at 
3–4 kb (1:3 and no insert) was clearly present, indicating that neither insert–insert nor 
vector–vector annealing events occurred with our designed non-palindromic sticky ends. 
The sizes of the product bands are provided in Table 3.7. 
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Figure 3.3. Comparison of NcoI/HindIII- and BbsI-digested products in vector-insert ligation (V: digested 
pRDV2 vector; I: digested off7 insert). Ligation of (A) NcoI/HindIII-digested or (B) BbsI-digested 
products resolved in a 1% agarose gel. Amount of vector ligated was fixed at 200 ng (~8 nM) for each lane 
with the corresponding amount of insert based on the molar ratio shown. Nic.V represents Nb.BsmI-nicked 
pRDV2:Off7 which should migrate at approximately the same rate as the ligation product VIc (c denotes 
circular product). Cut V represents NcoI/HindIII- or BbsI-digested pRDV2 backbone (in A and B, 
respectively) used for ligation reactions. (C) Vector (75 ng ≈ 8 nM) ligated with the corresponding amount 
of insert was PCR amplified with primers 1/2 for 10 cycles. Products at 902 bp (full-length product) are 
shown. (D) Vector (8 or 3 nM) ligated with the corresponding amount of insert was transformed into XL1-
Blue cells. Shown here is the number of colonies relative to the number obtained for 1:1 BbsI ligation of 
the same vector concentration. With 8 nM vector, vector-only transformations gave 2–10 colonies with 
NcoI/HindIII digestion and 1–11 colonies with BbsI digestion; with 3 nM vector, vector-only 
transformation gave 0–2 colonies with NcoI/HindIII digestion and 0–2 colonies with BbsI digestion. NH: 
sites from NcoI/HindIII digestion (blue), B: sites from BbsI digestion (red). The data represent the mean ± 
SD of two independent experiments, *P < 0.05 and **P < 0.01. A one-tailed t-test was used to examine 
statistical significance. 
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Table 3.7. Possible identities and sizes of species formed from insert-vector and three-piece linear ligation 
of fragments generated by NcoI/HindIII or BbsI restriction digests. 
Insert-vector circular ligation Three-piece linear ligation 
 Number of based pairs  Number of base pairs 
Species NcoI/HindIII BbsI Species NcoI/HindIII BbsI 
V 3428 3408 A 106 87 
I 500 520 B 500 520 
VI 3928 3928 C 296 295 
VI (circular) 3928 
a
 3928 
 a
 AB 606 607 
VV 6856 −  b BC 796 815 
VV (circular) 6856 
a
 −  b AA 212 −  b 
II 1000 −  b CC 592 −  b 
II (circular) 1000 
 a
 −  b BB 1000 −  b 
IVI 
c
 4428 4448 BB (circular) 1000 
a
 −  b 
VIV 
c
 7356 7336 ABC 902 902 
VVV 10,284 −  b ABB 1106 −  b 
III 1500 −  b BBC 1296 −  b 
VIVI 
c
 7856 7856 BBB 1500 −  b 
VIVI 
c
 (circular) 7856 
 a
 7856 
a
 ABBA 1212 −  b 
VIII 
d
 4928 −  b CBBC 1595 −  b 
VIII 
d
 (circular) 4928 
 a
 −  b ABBB 1606 −  b 
VVVI 
d
 10,784 −  b BBBC 1796 −  b 
VVVI 
d
 (circular) 10,784 
 a
 −  b BBBB 2000 −  b 
VVVV 13,712 −  b BBBB (circular) 2000 a −  b 
VVVV (circular) 13,712 
 a
 −  b 5th order or higher e varies −  b 
IIII 2000 −  b    
IIII (circular) 2000 
 a
 −  b    
5
th
 order or higher 
 e
 varies varies    
 
a
 The migration distance of circular DNA molecules varies depending on the conformation and cannot 
easily be determined on an agarose gel. 
b
 These species should not form due to incompatible ends created by BbsI digestion. 
c
 The orientation shown is only for BbsI digestion; other combinations are possible for NcoI/HindIII 
digestion (i.e. VVI, IVI, IIV, etc.) 
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d
 Other combinations are possible for NcoI/HindIII digestion. 
e
 Products containing up to four ligated molecules are shown. 
 
 For comparison of the relative amount of correctly ligated product, each ligation 
mixture was subjected to 10 cycles of PCR amplification with outer primers that anneal 
to insert-flanking regions of pRDV2 (Fig. 3.3C). This procedure should selectively 
amplify circular vector-insert products and not linear vector-insert products or other 
undesired products (vector-vector, insert-insert, etc.). Across all molar ratios, ligation of 
BbsI-digested fragments gave more amplified product than NcoI/HindIII-digested 
products. Approximate quantification of the gel indicated a 5- to 10-fold increase in BbsI 
products over NcoI/HindIII products. In addition, the ligation mixture was transformed 
and the number of bacterial colonies were counted (Fig. 3.3D). To minimize any 
variability in transformation efficiencies across experiments, colony numbers were 
normalized to the result for the 1:1 insert:vector ligation reaction at the same vector 
concentration. At both vector concentrations, BbsI-digested products gave 4- to 15-fold 
more colonies than NcoI/HindIII-digested products at all molar ratios examined. All these 
results suggest that it is preferable to use Type IIS restriction enzymes in generating 
fragments for ligation to yield more full-length product. 
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3.4.3 Three-piece linear ligation of Type IIS digested fragments yields more full-
length product 
In order to gain more understanding of the ligation reaction, a minimal system consisting 
of the linear ligation of three DNA fragments was developed. This scheme is also 
particularly useful for applications in which transformation is not needed and linear 
ligation products can be directly used (e.g., in vitro directed evolution). A constant 
amount of digested off7 was ligated to digested T7 and tolA at the specified molar ratios, 
and the products were resolved and visualized on an agarose gel (Fig. 3.4A). At all molar 
ratios, more full-length ligated product (at 902 bp) was observed for BbsI-digested 
fragments than NcoI/HindIII-digested fragments. Quantification of the gel confirmed this 
observation, indicating a 1.5- to 2.6-fold increase in full-length species. It should be 
noted that the smallest increase (1.5-fold) was achieved using the suboptimal 1:2:1 A:B:C 
ratio, and more significant improvements can be realized when using ratios in which A 
and C are in excess (discussed below). A closer look at ligation following NcoI and 
HindIII digestion (Fig. 3.4B) shows that the loss of full-length product was due to 
stoichiometry-dependent byproduct formation. With excess T7 and tolA (10:1:10 and 
2:1:2), T7-T7 and tolA-tolA homodimers are the major products, but the desired product 
is also maximized since off7 is less likely to homodimerize when T7 and tolA are in such 
abundance. In contrast, with excess off7 (1:2:1 and 1:10:1), many high molecular weight 
products could be seen, likely due to the undesired formation of off7 multimers, which 
can further circularize or anneal to T7 or tolA fragments to generate further species 
diversity. Indeed, a ligation reaction containing only NcoI/HindIII-digested off7 showed 
many high molecular weight bands. A closer look at ligation following BbsI digestion 
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(Fig. 3.4C) showed minimal byproducts: the only major species other than reactants or 
full- length product were T7-off7 and off7-tolA, both of which were intermediate ligation 
products. More full-length products were observed with higher molar excesses of T7 and 
tolA, as there was no risk of byproduct formation. Again, this minimal ligation system 
clearly shows that BbsI-digested fragments are preferable to NcoI/HindIII-digested 
fragments for maximizing generation of the desired linear product in a ligation reaction. 
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Figure 3.4. Representative 1.5% agarose gels showing NcoI/HindIII- and BbsI- digested products in three-
piece linear ligation (A: T7; B: off7; C: tolA). (A) Comparison of linear ligation band patterns between 
NcoI/HindIII-(N/H) and BbsI-digested reactants at three molar ratios of A: B: C. In all ligation reactions, 
100 ng (~54 nM) of B was used with corresponding amounts of A and C. The arrow shows full-length 
ABC product at 902 bp. Linear ligation products of (B) NcoI/HindIII-digested and (C) BbsI-digested 
product at different molar ratios. In all ligation reactions, 100 ng (~24 nM) of B was used (except for *: 50 
ng of B was used in 10:1:10). Arrows in (B) indicate positions of selected species; locations of higher order 
species can be found in Table 3.7. Arrows in (C) indicate positions of all of the species. No lig.: 1:1:1 
A:B:C reaction without ligase. 
 
3.4.4 Development and training of a computational model for Type IIS ligation 
Viewing ligation as a two-step process, a thermodynamic model was developed for both 
the minimal three-piece ligation and the more complicated vector-insert ligation for 
fragments generated by Type IIS restriction enzymes (Fig. 3.5). The first step is the 
annealing of two sticky ends by hydrogen bonding across complementary bases and/or 
stacking between adjacent bases
22
, and the second step is the sealing of the DNA 
backbone by the formation of phosphodiester bonds
32
. We modeled each ligation reaction 
as a reversible equilibrium process with the free energy defined by the identity of the 
sticky ends involved in that particular reaction. This thermodynamic model was used to 
estimate output from input when ligation had proceeded for a sufficiently long time to 
reach equilibrium. Assuming that both sealing events after an annealing event occur in 
rapid succession and that only ligated products, but not annealed and nicked products, are 
stable enough to proceed to the next ligation reaction, a system of thermodynamic 
equations was written. 
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Figure 3.5. Schematic of the thermodynamic model proposed in this study. Refer to Table 3.2 for 
nomenclature used. (A) Model of three-piece linear ligation based on two lumped free energy parameters: 
annealing and sealing at site 1 (CGAA) and site 2 (GCTT) were represented by ΔG1 and ΔG2, respectively. 
All possible species are shown in the diagram. A: T7, B: off7, C: tolA. (B) Model of vector-insert circular 
ligation based on ΔG1, ΔG2, ΔGcir1 and ΔGcir2, where the latter two were calculated from the three ΔG1, ΔG2 
and j. For clarity, only one orientation is shown for VI, IVI, VIV and IVIV, along with their corresponding 
free energies. Only products containing up to four reactant molecules were included in the model. *: free 
energy parameters used for the alternative orientations (i.e. when V and I anneal in a different configuration 
than that shown). Cir: circular product. 
 
 Although free energies of annealing for specific sequences can be estimated using 
available calculators, experimentally determined free energies are more accurate since the 
specific ligation conditions (e.g., temperature and salt concentration) are intrinsically 
captured in the values. In our model, these free energies of annealing can easily be 
lumped with the free energies of sealing to yield one ΔG parameter per sticky end. Thus, 
we carried out two-piece linear ligation at different molar ratios to experimentally 
determine ΔG1 and ΔG2 for the sticky ends CGAA and GCTT, respectively. ΔG1 was 
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determined to be -12.00 kcal/mol and ΔG2 was determined to be -12.23 kcal/mol. These 
two values were used for all subsequent simulations. 
 Figure 3.5A shows the three-piece linear ligation model for non-palindromic 
sticky ends. All possible species were considered. We assumed no homodimer formation, 
no cross-reactivity between sites 1 and 2, and no blunt-end ligation. Figure 3.5B shows 
the vector-insert ligation model for non-palindromic sticky ends. Species containing up to 
four fragments were explicitly included and any higher order molecules were assumed to 
be insignificant. This assumption is valid in the range of concentrations and molar ratios 
that were most commonly used, and accounting for higher-order species would have a 
minimal effect on the optimizations that were examined in this work. The probability of 
circularization is reflected by the Jacobson–Stockmayer factor j which represents the 
effective concentration of one end of a linear molecule with respect to the other, which is 
dependent on length of the linear molecule but independent of DNA concentration
15
. If 
the competing DNA concentration is above j, linear multimers will be favored; 
conversely, circularization will be favored if the DNA concentration is below j
4
. ΔGcir1 
and ΔGcir2 were calculated by dividing the corresponding K values by this effective 
concentration factor.  
 
3.4.5 Thermodynamic model accurately captures ligation product formation 
To test the validity of the model, we compared its predictions to experimental results. 
First, three-piece linear ligations with five different molar ratios were simulated by 
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solving the system of equations to obtain equilibrium molar concentrations for the 
reactants, intermediates and products in each ligation (Fig. 3.6A–E). For each reactant 
molar ratio, product molar concentrations were converted into product molar ratios by 
normalizing to full-length product and further converted to mass ratio based on the 
number of base pairs. This was done to facilitate direct comparison with experiments in 
which mass ratios were determined by quantifying product bands in agarose gels. Across 
all reactant molar ratios, the model predictions were in good agreement with the 
experimental results. The only major difference between predictions and experiments was 
for 1:10:1, where predictions generated mass ratios much higher than those obtained by 
experiments (Fig. 3.6E). This was likely due to inaccuracy from saturating gel signals and 
further error amplification from the small amount of full-length product compared with 
intermediates and reactants. Correlation tests conducted within each molar ratio gave P < 
0.05 for 10:1:10, 1:1:1 and 1:2:1, and P < 0.01 for 2:1:2 and 1:10:1, showing that 
predictions and experimental results were indeed significantly correlated. 
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Figure 3.6. Validation of thermodynamic model with experimental results. Model predictions and 
experimental results for three-piece linear ligation of BbsI-digested products with A: B: C (molar ratios) of 
(A) 10:1:10, (B) 2:1:2, (C) 1:1:1, (D) 1:2:1 and (E) 1:10:1. Values shown are mass ratios normalized to the 
mass of the desired product, ABC. ΔG1 = -12.00 kcal/mol, ΔG2 = -12.23 kcal/mol, and B = 24 nM were 
used in all ligation simulations (except in (A), in which B = 12 nM was used). In all experiments, 100 ng 
(~24 nM) B was used (except in (A), in which 50 ng (~12 nM) B was used). Data represent the mean ± SD 
of three independent experiments (one of which is shown in Fig. 3.4C). Corresponding comparisons in 
molar ratios are given in Fig. 3.7. Model predictions and experimental results for vector-insert circular 
ligation of BbsI-digested products with vector concentrations of (F) 0.24 nM, (G) 3.02 nM and (H) 6.04 
nM. Values shown are molar ratios of VI circular product (model) or colony numbers (experiment) 
normalized to the corresponding value for insert/vector = 1. ΔG1 = -12.00 kcal/mol and ΔG2 = -12.23 
kcal/mol. In all experiments, 25 ng of vector was ligated to insert using the specified molar ratio. Within 
each vector concentration, relative colony numbers were obtained by subtracting the background (colony 
number for corresponding vector-only ligation) and dividing this specific colony number by the specific 
colony number for I/V = 1. Vector-only transformations gave 0 colonies with 0.24 nM vector, 0–2 colonies 
with 3.02 nM vector, and 0–7 colonies with 6.04 nM vector. 
 
For model validation above, we chose to plot the species using relative mass 
because quantification of the product bands in the agarose gels directly yields this 
quantity. Any error in experimental procedure or DNA quantification would artificially 
magnify errors in molar ratios. This is particularly problematic when considering lower 
molecular weight species, since small absolute errors in mass quantification lead to large 
absolute differences in corresponding moles, which in turn could dramatically, yet 
artificially, alter a molar ratio (e.g., compare relative amounts of species A in Fig. 3.6C 
and Fig. 3.7C). Nevertheless, with this caveat in mind, the use of molar quantities can 
provide additional insight into ligation efficiency under different conditions, so we also 
present the data in molar units in Figure 3.7. 
100 
 
 
Figure 3.7.  Comparison of thermodynamic model and experimental results (same data as in Fig. 3.6A–E 
but presented here in molar quantities). Model predictions and experimental results for three-piece linear 
ligation of BbsI-digested products with A:B:C (molar ratios) of (A) 10:1:10, (B) 2:1:2, (C) 1:1:1, (D) 1:2:1, 
and (E) 1:10:1. Values shown are molar ratios normalized to the number of moles of the desired product, 
ABC. ΔG1 = -12.00 kcal/mol, ΔG2 = -12.23 kcal/mol, and B = 24 nM were used in all ligation simulations 
and experiments (except in (A), in which B = 12 nM was used). Data represent the mean ± SD of three 
independent experiments. 
 
 We then proceeded to test the predictions of the vector-insert ligation model. 
Ligations at three different molar insert:vector ratios were simulated at low, medium and 
high vector concentrations. Within each vector concentration, all correctly ligated circular 
products were normalized to the 1:1 insert:vector yield (Fig. 3.6F–H). At low 
concentration, a 2:1 ratio was predicted to yield more functional product because this 
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ligation is limited by the availability of reactants. At high concentration, a 2:1 ratio was 
predicted to have a slightly adverse effect because free insert would compete with 
circularization reaction by forming more linear insert-vector-insert products. These 
predictions were experimentally tested by bacterial transformation, assuming the number 
of colonies corresponds primarily to circular vector-insert products. The experimental 
trends again match the computational predictions. Correlation tests conducted within 
each vector concentration gave P < 0.05 for 3.02 and 6.04 nM vector and P < 0.01 for 
0.24 nM vector, again statistically confirming that our model predictions are significant.  
 
3.4.6 Optimal conditions to preserve insert in linear ligation 
To further explore a specific application of the linear ligation model, we investigated 
model predictions for applications where the insert is the valuable entity. For example, in 
in vitro directed evolution methods such as ribosome display
33
 and mRNA display
34
, the 
amount of insert ligated would directly influence library quality and diversity. For such 
applications, linear ligation is preferable to vector-insert ligation because no molecules 
would be lost in byproduct formation. The product could also be directly used, without 
the need for PCR amplification or transformation, allowing better quantification of 
reactions. First, we simulated ligations at different insert concentrations and across a 
range of reactant molar ratios based on our two previously characterized cutting sites, 
CGAA and GCTT. Percent incorporation of insert into full-length product (Fig. 3.8A) 
and ligation efficiency defined as product divided by reactants (Fig. 3.8B) were 
determined both by simulations and by experiments. Across all molar ratios, increasing 
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reactant concentrations led to an increase in overall incorporation of insert. At each 
concentration, increasing the molar ratios of the upstream and downstream pieces also 
monotonically increased incorporation of insert, in agreement with experimental results. 
Since there are no byproducts, any increase in reactants (insert or either end) will shift the 
equilibrium in each ligation reactions towards product formation. Ligation efficiency, 
however, shows a clear optimum at different ends/insert ratios in both simulations and 
experiments. At sufficiently high concentrations, 1:1:1 gives optimal ligation efficiency. 
As concentration decreases, an excess of ends is needed to achieve maximum ligation 
efficiency. Since the amount of insert is fixed, increasing the concentration of the ends is 
needed to compensate for the unfavorable equilibrium caused by the lower overall 
reactant concentration, though the compensation is never enough to reach the same 
ligation efficiency.  
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Figure 3.8. Simulations of three-piece linear ligation with experimental comparison. Percent incorporation 
is defined as product/insert ([ABC]/[B]t × 100%) and percent efficiency is defined as product/reactants 
([ABC]/([A]t + [B]t + [C]t) × 100%). (A) Percent incorporation and (B) percent efficiency of linear ligation 
with 100 nM (solid line), 10 nM (long dashed line), 1 nM (short dashed line), 0.1 nM (dotted line), 0.01 nM 
(dashed and dotted line) of B (off7/insert) and specified amounts of A (T7) and C (tolA), all digested by 
BbsI. ΔG1 = -12.00 kcal/mol and ΔG2 = -12.23 kcal/mol. The overlaid experimental results, quantified from 
Fig. 3.4C, show ligation reactions with 24 nM of B in A:B:C reactant stoichiometry of 1:10:1, 1:2:1, 1:1:1 
and 1:2:1 (solid circles) and 12 nM of B in an A:B:C reactant stoichiometry of 10:1:10 (solid triangle). 
Data represent the mean ± SD of three independent experiments. (C) Percent incorporation and (D) percent 
efficiency of linear ligation with 10 nM of B (off7/insert) and specified amounts of A (T7) and C (tolA), all 
digested by BbsI. ΔG1 = -14.00 kcal/mol and ΔG2 = -10.00 kcal/mol. 
 
We also investigated the effect of different ΔG1 and ΔG2 values on optimal 
incorporation and efficiency while allowing concentrations of the two ends to vary (Fig. 
3.8C, D). Since the linear ligation model is symmetric (the lengths of the end fragments 
have no effect on molar concentration or ligation behavior), we perturbed ΔG1 and ΔG2 
only once in separate directions. ΔG1 was set to be more negative (-14.00 kcal/mol; 
equilibrium more favorable towards product) and ΔG2 was set to be less negative (-10.00 
kcal/mol; equilibrium less favorable towards product). An intermediate insert 
concentration was chosen (10 nM: long dash in Fig. 3.8A and B). For a less negative ΔG 
value (ΔG2), a higher molar excess of that end (C) is needed to achieve high insert 
incorporation (Fig. 3.8C) as well as efficiency (Fig. 3.8B). However, even using an 
excess of C cannot compensate for the less favorable equilibrium to achieve the same 
incorporation and efficiency values. If the insert concentration is increased (e.g., 100 nM: 
solid line in Fig. 3.8A and B), the shift in molar excess of C to achieve optimal 
incorporation and efficiency is smaller and the optimal values are also. 
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Based on these simulation results, it is recommended that, for high incorporation 
of insert and maximal ligation efficiency, the two sticky end sites should be designed to 
have ΔG values that are as similar and as negative as possible (i.e. match the number of 
G/C and A/T base-pairs on the two sticky ends with no more than two A/T base-pairs per 
sticky end). In three-piece linear ligation reactions in which the middle piece (insert) 
needs to be maximally incorporated, the upstream and downstream pieces should be used 
in as great excess as possible. 
 
3.4.7 Optimal conditions to preserve insert in vector-insert ligation 
Vector-insert ligation represents the more common type of ligation, so we also 
investigated model predictions for this setup, again where the insert is the valuable entity. 
These insights may be useful for in vivo directed evolution methods that require circular 
display vectors, including phage display
35
, bacterial display
36
 and yeast display
37
. Again, 
we simulated ligations across a range of vector concentrations and insert:vector molar 
ratios based on ΔG1 and ΔG2 values for our previously characterized cutting sites, CGAA 
and GCTT. We examined percent incorporation of insert into circular vector-insert 
molecules (Fig. 3.9A), ligation efficiency defined as product concentration divided by the 
sum of the reactant concentrations (Fig. 3.9B) and accuracy defined as the concentration 
of circular vector-insert molecules divided by the sum of all circular product 
concentrations (Fig. 3.9C). At a fixed vector concentration, increasing the insert:vector 
ratio decreases incorporation and efficiency as insert-vector-insert is preferentially 
formed over circular insert-vector molecules. On the other hand, even though low 
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insert:vector ratio gives minimal byproduct, the insert concentration is too low for 
sufficient product formation to achieve high efficiency. Incorporation in this regime 
remains high because the input, total insert, is also low. At a fixed insert:vector ratio, 
optimal incorporation and efficiency lie at an intermediate concentration (which is around 
the K value, where K = exp(ΔG/RT)) because a low concentration shifts the equilibrium 
to the reactant side and a high concentration promotes the formation of vector-insert-
vector products. Circular product shows high accuracy at medium-to-low vector 
concentrations. At high vector concentrations, the accuracy remains good for very low or 
high insert:vector ratios as those ratio are not preferable in forming circular vector-insert-
vector-insert products. Only at high vector and insert concentrations with approximately 
an equal molar ratio does the accuracy drop. To further highlight the utility of this model 
in experimental design, we overlaid our experimental results from Fig. 3.3D on these heat 
maps. The model not only captures the experimental trends, but it also indicates how to 
rationally change the experimental conditions to further improve a given ligation 
reaction. 
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Figure 3.9. Simulations of vector-insert circular ligation with experimental comparison. Percent 
incorporation is defined as correct product/insert ([VIc]/[I]t × 100%), percent efficiency is defined as 
correct product/reactants ([VIc]/([V]t + [I]t) × 100%), and percent accuracy is defined as correct 
product/total product ([VIc]/([VIc] + [VIVIc]) × 100%). (A) Percent incorporation, (B) percent efficiency 
and (C) percent accuracy of circular ligation of the specified amount of BbsI-digested vector and insert. 
ΔG1 = -12.00 kcal/mol and ΔG2 = -12.23 kcal/mol. Experimental values from Fig. 3.3D are shown on the 
heat maps next to the open circles that correspond to the tested reaction conditions. (D) Percent 
incorporation, (E) percent efficiency and (F) percent accuracy of circular ligation for the specified amount 
of BbsI-digested vector and I:V = 1:2. For reference, K values of 0.1, 1, 10 and 100 nM correspond to ΔG 
values of -13.63, -12.27, -10.91 and -9.54 kcal/mol, respectively. 
 
 Finally, we investigated the effect of different ΔG1 and ΔG2 values in optimal 
insert incorporation, efficiency and accuracy of ligation by fixing the insert:vector ratio at 
1:2 and allowing the total vector concentration to vary. This ratio was chosen because it 
strikes a good balance between incorporation and efficiency, based on the analysis above. 
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Incorporation and efficiency show the same trends (Fig. 3.9D and E, respectively). At 
different K1 and K2 values, the optimal incorporation and efficiency appears to be at a 
vector concentration very close to the K values. At fixed K1 and K2 values of 1 nM 
(corresponding ΔG of -12.27 kcal/mol which is close to our experimental value), the 
trends shown in Fig. 3.9A and B could be seen. As expected, accuracy drops at high 
vector concentration (Fig. 3.9F). This effect is slightly counteracted at unfavorable 
equilibrium (high K value) as the competing reactions to form circular vector-insert-
vector-insert are not as strong. Combining the two simulation results, it is recommended 
that for high insert incorporation, maximal ligation efficiency and best accuracy, the 
insert:vector ratio should be 1 or slightly less and the vector concentration should be kept 
close to the K values. 
 
3.4.8 Ligation calculator: free energy estimation by DNA thermodynamics 
To facilitate more widespread use of our thermodynamic model, we have developed a 
web-based ligation calculator. The only parameter required by the thermodynamic model 
is the lumped equilibrium dissociation constant for ligation, which can be calculated from 
the free energies of annealing and ligation for each sticky end. The first section of the 
web ligation calculator estimates free energy of annealing based on the unique overhang 
and flanking bases of each sticky end. An added advantage is that the free energy of 
sticky end misannealing (to itself or to another sticky end) can also be quantified, 
allowing quick and quantitative evaluation of the performance of each sticky end, which 
can help guide rational design of these sequences. 
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An example of this free energy calculation is shown in Figure 3.10A. There are 
three components to the free energy. First, hydrogen bonding interactions between 
complementary bases drive the annealing of complementary sticky ends. The free energy 
change due to these interactions can be estimated by oligonucleotide nearest-neighbor 
thermodynamics, which assumes that the stability of each base pair depends on the 
identity and orientation of neighboring base pairs
23
. Values for all 16 such interactions 
have been tabulated
23
, and the hydrogen-bonding free energy between two 
complementary 4-base overhang sticky ends can be estimated by the addition of three 
nearest-neighbor free energy values. The second component comes from stacking 
between adjacent bases across the nick sites, and information about the flanking bases 
and the type of overhang (5’ or 3’) are used to compute this free energy. Since the input 
flanking bases are strictly one base upstream and downstream of the sticky ends in the 
upper strand, the type of overhang then dictates the locations of the nick sites and the 
appropriate bases that participate in stacking. The free energies of base stacking for all 16 
combinations have also been determined
21,22
, although there are some discrepancies 
between the two studies. Using tabulated values from Florián et al.
21
 in the overall free 
energy calculation, we estimated the free energy values for sticky ends (with 
parenthetical flanking bases) (C)CGAA(A) and (A)GCTT(G) to be -11.77 and -12.02 
kcal/mol, respectively; these predictions closely match our experimentally determined 
values of -12.00 and -12.23 kcal/mol (Section 3.4.4). We therefore set the base stacking 
interactions from Florián et al.
21
 as the default, but the options to use values from 
Protozanova et al.
22
 or to ignore base stacking contributions are also available. The third 
and final component of the sticky-end free energy comes from repair of the 
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phosphodiester bond at the nick site. Assuming that products sealed by ligase at one site 
cannot re-nick at the other site, this free energy can be lumped into the free energy 
contributions from hydrogen bonds and base stacking to give the overall free energy of 
sticky end. The default value is -6.3 kcal/mol
16
, but any custom value can be specified by 
the user. Using all of the default parameters, the free energies of randomly generated 4-
base overhang sticky ends (both 5’ and 3’ overhangs) with their complementary sticky 
ends were calculated (Fig. 3.10B). The values are approximately normally distributed 
with a mean of -11.63 kcal/mol, a standard deviation of 1.03 kcal/mol, and a range of -
15.15 to -8.74 kcal/mol. The subset of palindromic 4-base overhangs is shown in red. 
 
Figure 3.10. Schematic and distribution of values obtained from the sticky end free energy calculator. (A) 
Two sticky ends – (C)TCCA(A) and (T)GCAA(C) – with 5’ overhangs are shown in both correct and 
mismatch orientations, with complementary bases and stacking interactions indicated by color lines. The 
lumped free energy of sticky end (C)TCCA(A) (ΔGSE1) is calculated as the sum of two stacking energies 
(ΔGstack), complementary base pairing interactions by nearest-neighbor thermodynamics (ΔGnn), and the 
energies for phosphodiester bond formation (ΔGlig). The lumped free energy for mismatches are calculated 
similarly exception that mismatches with a one nucleotide gap do not include stacking energy 
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contributions. Distributions of free energies of 100,000 randomly generated 4 bp overhang sticky ends are 
given for (B) complementary sticky ends, (C) self-misannealing sticky ends, (D) two different sticky ends 
that misanneal, and (E) two different sticky ends that misanneal with a one nucleotide gap. Distributions of 
free energies for the subset of palindromic sticky ends are shown in red in (B) and (C). 
 
Since Type IIS restriction enzymes can, in principle, generate all possible 4-base 
sticky ends, our web calculator also computes free energies for sticky end mismatches to 
quantify the formation of unwanted byproducts. Four types of mismatches are calculated 
(Fig. 3.10A). The first two scenarios – mismatch between sticky end and itself (and 
complementary sticky end and itself) and mismatch between two different sticky ends (all 
4 possible combinations) – form the majority of unwanted byproducts and are the main 
competitors to correct product formation. Mismatch energies are calculated in the same 
way as described above, except with an expanded set of nearest-neighbor parameters 
which include mismatches
24–28
.  Figure 3.10C shows the distribution of free energies for 
self-annealing of 4-base overhang sticky ends, with palindromic sticky ends indicated in 
red. Compared to the free energies for sticky ends annealing to their complementary 
bases (Fig. 3.10B), this distribution is negatively skewed with a median value of -3.07 
kcal/mol and a range from -15.15 to 2.84 kcal/mol. Due to the nature of palindromic 
sticky ends, the free energies for self-annealing and complementary base annealing are 
identical, which explains why palindromic sticky ends generated by Type IIP restriction 
enzymes result in significant ligation byproducts and are therefore not preferred for 
maximizing ligation efficiencies. The distribution of free energies between two randomly 
generated 4-base overhangs (Fig. 3.10D) shows significant spread to the right (with a 
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range of -14.88 to 2.88 kcal/mol) and a slight negative skew compared to Figure 3.10B. 
The last two types of mismatches – self-misannealing sticky ends and misannealing with 
another sticky ends with a one nucleotide gap – were included since there is evidence that 
DNA ligase can seal one-nucleotide gaps
38,39
, although this occurs with lower efficiency 
and should therefore be a secondary consideration in the evaluation of sticky ends. Gap 
mismatches between two random sticky ends results in a distribution of free energies 
similar to that of mismatches without gaps, but with less spread (from -10.71 to 0.22 
kcal/mol) due to the lack of stacking energies and one less nearest-neighbor interaction 
term. Overall, most non-palindromic sticky ends have mismatch free energies 
significantly less negative than their free energies for accurate interactions with their 
complementary ends, thus providing flexibility in rationally customizing sticky end 
sequences with high specificity. 
 
3.4.9 Ligation calculator: sticky end free energy estimation by experiments 
Alternatively, sticky end free energies can be experimentally determined through a series 
of simple ligation reactions containing two DNA fragments with the sticky end sequence 
of interest as described during model development. This method, though more time-
consuming, can be more accurate since it enables fitting of free energies based on the 
specific ligation reaction conditions routinely employed by the user; it is especially 
recommended for applications involving general-use display vectors, since the sticky 
ends are typically constant for all applications involving these vectors. Using user-
specified input molar concentrations of the two DNA fragments (up to ten independent 
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trials can be inputted), the calculator globally fits the free energy for a specific sticky end 
from the output mass ratios of the remaining reactants and full-length product, which can 
be obtained by quantifying band intensities on a DNA agarose gel. We previously 
performed nine trials for the sequences (C)CGAA(A) and (A)GCTT(G) using this 
method and obtained the free energy values of -12.00 and -12.23 kcal/mol (Section 
3.4.4), which closely match the predictions from DNA thermodynamics described above 
(-11.77 and -12.02 kcal/mol). 
 
3.4.10 Linear ligation calculator 
With the free energies of up to two sticky ends in hand, the distribution of linear ligation 
products can be predicted (Fig. 3.11A). A major assumption in the calculation is that the 
chosen sticky ends are non-palindromic and do not form major byproducts. This is 
reasonable since the free energies of complementary base-paring (Fig. 3.10B) are, on 
average, ~8 kcal/mol lower than those for mismatch annealing (Fig. 3.10C, D and E); 
thus, byproducts can typically be safely neglected since each 1 kcal/mol increase in free 
energy corresponds to a 5.41-fold decrease in equilibrium affinity (equivalently, a 
7.38×10
6
-fold decrease in equilibrium affinity for a 8 kcal/mol increase in free energy). 
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Figure 3.11. Schematic and representative output from the linear ligation calculator. (A) Schematics are 
given for two-piece and three-piece ligations as well as for the definitions of product distribution, 
incorporation, and efficiency. The free energy values used in this calculation (ΔGSE1 and ΔGSE2) are 
obtained from the sticky end free energy calculator (Fig. 3.10). (B) Screenshot of linear ligation prediction 
output showing product distributions of a three-piece ligation reaction with 20, 10, and 20 nM of DNA 1, 2, 
and 3, respectively. Representative outputs from the linear ligation recommendation calculator showing (C) 
incorporation and (D) efficiency of ligation across a range of library concentrations and molar ratios for a 
three-piece ligation reaction with 10 nM library construct (DNA 2). ΔGSE1 ((G)CCTA(C)) of -11.10 
kcal/mol and ΔGSE2 ((T)GGAT(A)) of -11.32 kcal/mol were used in all simulations. 
 
The first part of the linear ligation calculator predicts product concentrations, 
incorporation, and efficiency from input DNA concentrations for two or three linear 
DNA fragments with one or two sticky end free energies, respectively (Fig. 3.11A). The 
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user can specify which DNA species is “valuable” (e.g., the fragment containing diversity 
in a DNA library assembly application) for calculation of percent incorporation. Again, 
the molar DNA concentrations can be converted from mass concentrations and volumes 
with the ligation excel worksheet. A representative output for three-piece DNA ligation 
with 10 nM valuable entity (DNA 2), 2:1 molar ratios for the other DNA fragments 
(DNA 1 and DNA 3), and the sticky end sequences (G)CCTA(C) and (T)GGAT(A) is 
shown in Fig. 3.11B. Product distribution reveals that most of DNA 2 (61.9%) is 
incorporated into full-length product, which is driven by the excess of the other two 
reactants (approximately half of DNA 1 and DNA 3 remain unreacted). The overall 
ligation efficiency (37.2%) indicates the percentage of all input reactants (DNA 1, 2 and 
3) that end up in full-length products; the remainder are either reactants or intermediate 
products (DNA 1 + 2 or DNA 2 + 3). 
The linear ligation calculator can also predict how incorporation and efficiency 
vary over a range of input concentrations and molar ratios. This feature is particularly 
useful for determining the optimal ligation setup for a specific application. Representative 
outputs of incorporation and efficiency for a three-piece linear ligation with 10 nM DNA 
2 (valuable entity) and the sticky ends (G)CCTA(C) and (T)GGAT(A) are shown (Fig. 
3.11C and D). For a given molar ratio, increasing reactant concentrations enhances 
incorporation and efficiency because the product is thermodynamically favored. For a 
given concentration, augmenting the molar ratio monotonically increases incorporation of 
the valuable entity, while ligation efficiency shows an optimum at intermediate molar 
ratios. At high molar ratios, incorporation becomes more favorable because any increase 
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in reactants (in the absence of byproducts) will shift the equilibrium towards product 
formation, but the overall efficiency drops after an optimal value since increased product 
formation cannot compensate for the excess reactants used. If Figure 3.11D represented a 
routine ligation reaction where the objective is often to maximize efficiency, the optimal 
reaction conditions would be to use a DNA 2 concentration close to the highest 
concentration available (10 nM) and ~2:1 molar ratios of [DNA 1]:[DNA 2] and [DNA 
3]:[DNA 2]. For more stringent applications such as DNA library assembly in which 
library incorporation needs to be maximized without unnecessarily wasting other DNA 
fragments, the optimal setup based on Figure 3.11D would be to use the maximum 
concentration of the library fragment and ~4:1 molar ratios of the other fragments; using 
still higher molar ratios would only marginally increase incorporation but efficiency 
would markedly decline. The chosen molar concentrations and molar ratios can be 
directly entered into the ligation worksheet to determine the final ligation reaction mix 
based on available concentrations and volumes of DNA fragments. The calculator 
assumes that the valuable species is limiting and that excess amounts of the other 
fragments are available; if this is not the case, then a lower concentration of the valuable 
species should be entered into the calculator such that availability of the other DNA 
fragments is no longer an issue. If needed, the user can iterate between the ligation 
calculator and the worksheet to determine a final reaction scheme that is experimentally 
feasible. 
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3.4.11 Circular ligation calculator 
Analogous to the linear ligation calculator, the circular ligation calculator predicts 
product distributions and offers ligation recommendations for insert-vector assembly. 
Using input molar concentrations of vector and insert, two sticky-end free energy values, 
and the number of base pairs of the full length vector-insert product, concentrations are 
calculated for all products containing up to four ligated molecules (any higher molecular 
weight molecules are assumed to be negligible) (Fig 3.12A). The probability of ligated 
vector-insert molecules (and vector-insert-vector-insert molecules) forming circular 
products depends on the effective concentration of the sticky end in the molecule itself 
compared to the concentrations of free vector and insert; this effective concentration is a 
function of the length of the ligated molecule, which is why the number of base pairs in 
the product is a necessary input
4,15
. Since circular ligation and transformation are 
typically performed in series, transformation efficiency (via colony counting) can serve 
as an experimental proxy for ligation efficiency. For DNA library applications, percent 
incorporation can be useful in estimating final library size and diversity. Accuracy gives 
the amount of correct vector-insert product formation compared to that of vector-insert-
vector-insert circular product, although this value is likely a conservative estimate since 
the transformation efficiency of vector-insert-vector-insert circular products will typically 
be less than that for the desired product since transformation efficiency decreases with 
increasing plasmid size
40
. 
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Figure 3.12. Schematic and representative output from the circular ligation calculator. (A) Schematics are 
given for a circular vector-insert ligation as well as for the definitions of incorporation, efficiency, and 
accuracy. Representative outputs from the circular ligation recommendation calculator showing (B) 
incorporation, (C) efficiency, and (D) accuracy of ligation across a range of insert concentrations and 
vector:insert molar ratios for a circular ligation with 5 nM library construct (insert). In all simulations, the 
total number of base pairs of vector and insert was 3500, ΔGSE1 was -11.10 kcal/mol, and ΔGSE2 was -11.32 
kcal/mol. 
 
The circular ligation calculator can also predict how incorporation (Fig. 3.12B), 
efficiency (Fig. 3.12C), and accuracy (Fig. 3.12D) vary over a range of insert 
concentrations and vector:insert molar ratios. At low vector:insert ratios, incorporation 
and efficiency are low because insert-vector-insert is preferentially formed over circular 
insert-vector products, but accuracy remains high since unbalanced molar ratios do not 
favor circular insert-vector-insert-vector molecules. Conversely, high vector:insert ratios 
result in low efficiency because vector-insert-vector products are preferentially formed 
and the effect on incorporation is mixed as the benefit of having excess vector to drive 
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product formation can be offset by an increase in vector-insert-vector byproduct. 
Maximum incorporation occurs when the vector concentration is around the value of the 
average equilibrium dissociation constant. In Fig. 3.12B, in which the equilibrium 
dissociation constants for the two sticky ends are 7.21 nM and 4.98 nM, maximal 
incorporation occurs in a region of concentration space that includes 3.5 nM insert with a 
2:1 molar ratio (7 nM vector), 1.5 nM insert with a 4:1 ratio (6 nM vector), and 0.75 nM 
with an 8:1 ratio (6 nM vector). Maximum efficiency, on the other hand, is achieved at 
~1:1 molar vector:insert ratio and when the insert concentration is approximately the 
value of the average equilibrium dissociation constant, which is around 5 nM in Fig. 
3.12C. Accuracy only drops at high insert concentrations and approximately equimolar 
amounts of vector, although the absolute accuracy remains very high in all of 
concentration space and should therefore not be a major factor in optimizing circular 
ligation reactions. As an example optimization exercise, for normal cloning application 
where efficiency should be maximized, 5 nM insert with 1:1 vector:insert would be 
optimal; for library assembly where the balance between high incorporation and 
efficiency is important, 3.5 nM insert with 2:1 ratio would be preferable (Fig. 3.12B, C). 
Finally, the selected insert concentration and molar ratio can again be directly entered 
into the ligation worksheet to determine the final ligation reaction mix based on the 
availability of the amount of vector and insert. 
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3.5 Discussion 
We have investigated the optimal ligation strategy for applications in both in vitro and in 
vivo directed evolution. We have reported up to 15- and 2.6-fold increases in desired 
products for circular and linear ligation reactions, respectively, when Type IIS restriction 
enzymes were used instead of Type IIP enzymes to generate DNA fragments, indicating 
that even order-of-magnitude improvements in library size can be achieved by this 
strategy. Furthermore, our simulation results can help to more narrowly focus 
optimization efforts and our web-based ligation calculator can enable easy determination 
of maximum ligation yields and library size using Type IIS restriction enzymes without 
extensive experimental testing. 
 To maximize ligation efficiency, next-generation display vectors should contain 
recognition sites of Type IIS restriction enzymes and cutting sites that are non-
palindromic and have a matching number of G/C and A/T base-pairs. As demonstrated in 
this work, a convenient pair of non-palindromic cutting sites would have the same base 
compositions but would not exhibit any complementary to one another, thus eliminating 
undesired annealing. For linear ligations, the maximum concentration of digested 
reactants should be used, with an excess of upstream and downstream pieces to drive the 
equilibrium towards ligated products. For circular ligations, a concentration comparable 
to the K values of the sticky ends should be used with an insert:vector ratio between 1:2 
and 1:1. These recommendations are different from the common ligation guidelines 
suggesting that insert:vector molar ratios greater than one be used and that the 
concentration of both should be kept within a certain range
6
, which are not applicable to 
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fragments generated by Type IIS restriction enzymes or in directed evolution applications 
where the insert library is scarce. Our recommendations and even our cutting sites should 
be generally applicable to any ligation with T4 DNA ligase where the incorporation of 
insert is essential. Other custom cutting sites with four-base overhangs are not expected 
to deviate greatly from our results because our two sites CGAA and GCTT both contain 
50% GC content and represent moderate ΔG values. 
 We presented two methods for estimating the free energy of ligation: 1) using 
DNA thermodynamics, and 2) by experimental measurement. The two methods gave 
similar results for the set of experimental conditions that we examined. If a specific 
application requires conditions sufficiently different from those examined in this work 
(e.g. different temperature, salt concentration or ligase), our model could still be used to 
capture ligation behavior as long as the ΔG values are properly parameterized (e.g. using 
the simple experimental procedure outlined herein). Importantly, once this 
characterization has been performed for a given pair of overhangs, the model could be 
applied for any system that uses these annealing sequences. Again, in directed evolution 
experiments, a common display vector is typically used for many applications, so the 
trained model could be repeatedly applied to all experimental systems using a redesigned 
display vector with Type IIS restriction sites. 
 Our model is not only practically useful for ligation applications, but also 
provides thermodynamic insight into the annealing of sticky ends. The ligation reaction is 
rarely analyzed quantitatively as there is no thermodynamic information readily available 
in the literature. We have estimated the free energy of ligation by obtaining free energy 
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values of DNA annealing from the nearest-neighbor method
23,41
. However, most 
tabulated values are optimized at 37
o
C and 1 M NaCl, and salt and temperature 
corrections are only accurate to a certain extent and have not been systematically 
investigated for ligation. Empirical observations are available for specific ligation 
reactions but are not easily generalizable
42
. In contrast, considerable work has been done 
to characterize the free energy of sealing by ligase
16,43. From the ΔG values obtained 
from model training, we could calculate the free energy of sticky-end annealing since we 
know the free energy contributed by ligase sealing. In principle, if a variety of sticky ends 
were investigated at different temperatures, free energy values for annealing could be 
obtained, providing insight into DNA thermodynamics. 
 In summary, for applications where ligation efficiency is crucial for experimental 
success, we propose that vectors be redesigned to exploit the desirable properties of 
commercially available Type IIS restriction enzymes. We have developed and validated a 
thermodynamic model of ligation to provide specific experimental strategies for in vitro 
and in vivo directed evolution applications, and our web-based calculator can readily be 
adapted to other ligation conditions. Last but not least, our model can be used to parse the 
complex thermodynamics of sticky-end annealing, further contributing to our 
understanding of this common molecular biology technique. 
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CHAPTER 4 
Streamlined protocol for mRNA display and the display of 
monomeric IgG Fc 
4.1 Introduction 
In vitro directed evolution techniques, such as ribosome display
1
 and mRNA display
2
, are 
powerful tools for protein engineering, capable of handling libraries containing up to 
~10
14
 members. The high library diversity is possible because these in vitro display 
technologies eliminated the need for transformation to generate libraries
3
. Moreover, 
PCR-based mutagenesis is extremely convenient as they are inherent to the display 
procedure
3
. Ribosome display involves in vitro translation of mRNA sequences lacking 
stop codons to generate ternary complexes in which each mRNA and its corresponding 
protein are noncovalently associated via a stalled ribosome. This requires that any 
selections carried out with these ternary complexes be performed under conditions that 
maintain the integrity of the ribosome
4
. By contrast, mRNA display uses an mRNA-
DNA-puromycin fusion as its template for in vitro translation, which results in a covalent 
puromycin linkage between the mRNA and the corresponding nascent peptide
5
. This 
creates a highly stable selection particle, which is particularly useful for performing in 
vitro selections in harsh environments that are not compatible with ribosome display. 
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Since its introduction in 1997, mRNA display has been used in a wide variety of 
applications, such as the investigation of protein-protein interactions
6
 and the 
development of peptides
7
, enzymes
8
, scFvs
9
, and novel binders based on alternative 
scaffolds
10
. Despite the potential utility of mRNA display in a plethora of protein 
engineering applications, the technically demanding nature of this method has precluded 
its widespread use. Currently established protocols for mRNA display take ~4–7 days per 
round, which includes several lengthy purification steps. We therefore sought to simplify 
and streamline the mRNA display procedure to make it more broadly accessible to the 
scientific community. The time required for 1 round is reduced to 2 days with our 
protocol, thus simplifying and accelerating mRNA display experiments. 
 We then displayed a human monomeric IgG1 Fc (mFc) using this streamlined 
protocol to investigate its binding to the neonatal Fc receptor (FcRn). The display of mFc 
was chosen as a proof of principle to illustrate possible variations and special features of 
mRNA display, since this is an ideally suited platform for future engineering of mFc 
properties, which we explain below. mFc also represents a very important fusion partner 
to therapeutic proteins, so engineered versions, tailored for specific applications, should 
have great potential in the clinic. 
 As its name suggests, the neonatal Fc receptor is involved in the transport of IgG 
antibodies from a mother to her child, across the placenta and the intestine
11
. In both 
cases, FcRn binds the Fc portion of IgG with high affinity at acidic pH (< 6.5) but not at a 
physiological pH (7.4)
12,13
. In adult humans, FcRn is expressed in several cell types, 
including the vascular endothelium, antigen-presenting cells (APCs), and the intestine
11
. 
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It has been shown that FcRn present on the vascular endothelium mediates IgG 
homeostasis by rescuing IgGs that have been passively internalized by pinocytosis and 
recycling them back to the cell surface, thus prolonging the serum half-life of IgGs
14
. On 
the other hand, FcRn expressed on intestinal epithelial cells
15
 can transport IgG across the 
lumen by receptor-mediated transcytosis
16
. The unique pH-dependent binding of Fc and 
FcRn, which in turn modulates in vivo IgG levels or mediates transcytosis, has made this 
interaction the subject of many engineering efforts
17–22
. 
 Recently, Ying et al.
23
 developed three human monomeric IgG1 Fcs – mFc.1, 
mFc.23, and mFc.67 – that are highly soluble and retain pH-dependent binding to human 
FcRn. Eliminating the need for the dimeric form of Fc for receptor binding opens up 
many possibilities for developing much smaller therapeutic antibodies and for fusing the 
Fc domain to other active proteins to prolong half-life or facilitate transcytosis. In our 
proof-of-principle studies, we chose mFc.67 as the starting template due to its high 
thermal stability and high affinity to FcRn at pH 6.0
23
. Based on previous mutational 
studies on the IgG1 Fc fragment, we also included two sets of mutations that could 
potentially improve mFc.67 binding to FcRn: M252L/T256F (LF) double mutations
18
 and 
M252Y/S254T/T256E (YTE) triple mutations
24
. 
 The mRNA display platform is ideally suited for displaying monomeric Fcs 
against FcRn. We previously discussed evolving the Fc domain for selective FcRII 
binding by displaying full length IgG in a bacterial display system (Chapter 2). However, 
mRNA display can be used for the smaller and simpler monomeric Fc domain since this 
moiety is sufficient for FcRn binding. Our streamlined mRNA display method uses a 
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bacterial in vitro translation system, which is potentially problematic for studying 
glycosylated proteins or domains, but notably, glycosylation state does not affect the 
interactions between Fc and FcRn
25
. mRNA display also tolerates a wider range of pH 
values compared to ribosome display, due to the covalent nature of the mRNA-
puromycin-protein complexes; thus, pH stability selections and/or pH-dependent binding 
selections (e.g., binding at pH 6.0 and elution at pH 7.4 for Fc/FcRn) can be carried out 
more easily and robustly. Moreover, if future engineering of trafficking processes such as 
transcytosis are to be performed on mammalian cells, the minimal, covalently linked 
selection particles offer the greatest chance of being internalized and trafficked intact. In 
this chapter, we have successfully demonstrated binding of mFc.67, mFc.67(LF), and 
mFc.67(YTE) against FcRn using our streamlined mRNA display protocol. 
 
4.2 Materials and methods 
4.2.1 Materials 
Oligonucleotides were purchased from Integrated DNA Technologies (IDT; Coralville, 
IA) unless otherwise specified (Table 4.1). DNA purification was performed using 
agarose gel electrophoresis with SYBR Safe (Invitrogen, Carlsbad, CA) and the 
QIAquick gel extraction kit (Qiagen, Valencia, CA). Restriction enzymes, T4 
polynucleotide kinase, T4 DNA ligase (used for all ligations), and Phusion DNA 
polymerase (used for all PCRs) were purchased from New England Biolabs (Ipswich, 
MA) and used as recommended by the manufacturer. DNA and RNA concentrations 
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were determined by absorbance readings at 260 nm using a NanoDrop 1000 
spectrophotometer (Thermo Scientific, Waltham, MA). 
Table 4.1. Plasmids used in this study.  
Plasmid Description Source 
pRDV2:Off7 pRDV2 containing the FLAG-tagged Off7 gene; Amp
r
 Chapter 3 
pRDV2:H10-2-G3 pRDV2 containing the H10-2-G3 gene; Amp
r
 This work 
pRDV2:Off7m pRDV2 containing the FLAG-tagged Off7 gene 
modified with silent mutations to eliminate repeating 
nucleotides; Amp
r
 
This work 
PIGG-P14 Eukaryotic expression vector with the hinge region, 
CH2 and CH3 domain of IgG Fc  
Courtesy of 
Dr. Don Siegel 
pRDV2:Hinge-mFc_E pRDV2 containing monomeric Fc with the hinge 
region; Amp
r
 
This work 
pRDV2:mFc.67 pRDV2 containing the mFc.67 gene; Amp
r
 This work 
pRDV2:mFc.67_intB pRDV2 containing the mFc.67 gene (with internal BsaI 
silent mutation); Amp
r
 
This work 
pRDV2:mFc.67_intB_LF pRDV2 containing the mFc.67 gene with 
M252L/T256F double mutations (and with internal 
BsaI silent mutation); Amp
r
 
This work 
pRDV2:mFc.67_intB_YTE pRDV2 containing the mFc.67 gene with 
M252Y/S254T/T256E triple mutations (and with 
internal BsaI silent mutation); Amp
r
 
This work 
 
4.2.2 Plasmid construction 
Plasmids used in this work are listed in Table 4.2. To create DNA constructs suitable for 
in vitro transcription, the genes encoding H10-2-G3 and Off7 were first cloned into 
pRDV2 (from Chapter 3). The cDNA encoding H10-2-G3
26
 was synthesized by IDT and 
PCR amplified with primers 1/2. The resulting product was digested with BamHI and 
HindIII, and ligated into similarly digested pRDV2:Off7. The ligation mixture was 
transformed into chemically competent E. coli XL1-Blue
27
. Individual colonies were 
selected for standard liquid culturing and plasmid extraction procedures using a Qiagen 
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miniprep kit. The purified plasmid, pRDV2:H10-2-G3, was sequence verified. The 
cDNA encoding Off7
28
 was modified with silent mutations to eliminate repeating 
nucleotides in order to minimize nonspecific amplification products in PCR. This gene 
was synthesized by IDT and PCR amplified with primers 3/4. The resulting product was 
BamHI/HindIII digested and ligated into pRDV2 as described above to obtain 
pRDV2:Off7m, which was also purified by miniprep and sequence verified. 
Table 4.2. Oligonucleotides used in this study. 
Number Name Nucleotide Sequence (5’  3’) a 
1 H10_BamHI_f GACAAAGGATCCGACCTGGGTAAAAAACTGCTG 
2 H10_HindIII_r AGACCCAAGCTTTTGCAGGATTTCAGCCAG 
3 pRDVFLAG_BamHI_f GATGACGATGACAAAGGATCC 
4 pRDV_BbsI_r GGCCACCGGAAGACCCAAGC 
5 T7_no_BsaI ATACGAAATTAATACGACTCACTATAGGGACACCACAACGG 
6 DNA-puromycin linker AAAAAAAAAAAAAAAAAAAAAAAAAAACC-puromycin 
7 GS_splint TTTTTTTTTTGGCCACCGGAA 
8 mFc.67_f AGACACCGAAAGAAGGAGATATATCCATGGCACCTGAACTCCTG 
9 mFc.67GGG_f ACCAGGTCAGCCTGAGCTGCCTGG 
10 mFc.67GGG_r CCAGGCAGCTCAGGCTGACCTGGT 
11 pRDV_BbsI_f AATAATTTGAAGACACCGAAAGAAG 
12 mFc.67BsaImut_f GTGCAAGGTGTCCAACAAAG 
13 mFc.67BsaImut_r CTTTGTTGGACACCTTGCAC 
14 LF_f GACACCCTCCTGATCTCCCGGTTTCCTGAGGTC 
15 LF_r GACCTCAGGAAACCGGGAGATCAGGAGGGTGTC 
16 YTE_f GACACCCTCTATATCACCCGGGAACCTGAGGTC 
17 YTE_r GACCTCAGGTTCCCGGGTGATATAGAGGGTGTC 
18 pRDV_Off7stops_r TTGCAGGATTTCAGCCAGG 
 
a
 Restriction sites are underlined. Mutation sites are double underlined. 
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 To construct mFc.67 and its variants, pRDV2:Hinge-mFc_E was first constructed 
from PIGG-P14 (courtesy of Dr. Don Siegel, University of Pennsylvania). The hinge 
region, CH2, and CH3 domains were each PCR amplified and assembled to eliminate 
introns from the original construct in PIGG-P14; this product was cloned into pRDV2 to 
give pRDV2:Hinge-mFc_E. pRDV2:mFc.67 was then constructed by overlap extension 
PCR with 1) a PCR amplicon of pRDV2:Hinge-mFc_E using primers 8/10, and 2) a gene 
fragment of mFc.67 (from residue 60 onwards
23
), synthesized by IDT, and PCR 
amplified with primers 9/4. The assembled product was amplified with primers 11/4, 
digested with BbsI, and ligated into similarly digested pRDV2:Off7. To remove the 
internal BsaI site in mFc.67 to facilitate cloning in future selection experiments, 
pRDV2:mFc.67 was PCR amplified with two separate primer sets (11/13 and 12/4) to 
create the two fragments assembled in overlap extension PCR using primers 11/4. The 
final product was digested with BbsI and ligated into pRDV2 to obtain 
pRDV2:mFc.67_intB. For incorporation of the M252L/T256F (LF) mutations
18
 or the 
M252Y/S254T/T256E (YTE) mutations
24
, pRDV2:mFc.67_intB was PCR amplified with 
primers 11/15 (LF_piece1) and 14/4 (LF_piece2) or 11/17 (YTE_piece1) and 16/4 
(YTE_piece2), respectively. LF_piece1 and LF_piece2 were assembled in overlap 
extension PCR with primers 11/4, and YTE_piece1 and YTE_piece2 were assembled 
with the same primers. The PCR products were digested with BbsI and ligated into 
pRDV2 to give pRDV2:mFc.67_intB_LF and pRDV2:mFc.67_intB_YTE, respectively. 
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4.2.3 In vitro transcription 
Primers 5 and 4 were used to amplify plasmids pRDV2:H10-2-G3, pRDV2:Off7m, 
pRDV2:Off7, pRDV2:mFc.67_intB, pRDV2:mFc.67_intB_LF and 
pRDV2:mFc.67_intB_YTE. The H10-2-G3 and Off7 products were gel purified and 
eluted with 50 μl EB (Qiagen), while the products of mFc.67 and its variants were used 
directly for in vitro transcription. Gel-purified products (46 μl) or PCR products (22.5 μl) 
were used directly for transcription as described previously
29
. Lithium chloride (LiCl) 
precipitation was used to purify the newly transcribed mRNA as described
29
 and the 
product was reconstituted in 20 μl RNase-free water. 
 
4.2.4 Ligation of mRNA to DNA-puromycin linker 
A DNA-puromycin linker
5
 (oligonucleotide 6 in Table 4.2) was purchased from 
Biosearch Technologies (Novato, CA) and an oligonucleotide splint (oligonucleotide 7 in 
Table 4.2) was also used. The DNA-puromycin linker was phosphorylated according to 
Keefe et al.
5
 and desalted using illustra ProbeQuant G-50 Micro Columns (GE 
Healthcare, Piscataway, NJ). The ligation was adapted from Keefe et al.
5
 to include: 1 
nmol mRNA, 1 nmol 5′ phosphate DNA linker, 1 nmol GS_splint, water up to 86 μl, and 
2 μl RNasin Plus RNase inhibitor (Promega, Madison, WI). These components were 
heated at 95°C for 2 min. Then, 10 μl 10× T4 DNA ligase buffer was added. The reaction 
was vortexed and then cooled on ice for 10 min. The tubes were removed from ice for 5 
min, at which time 4 µl high-concentration T4 DNA ligase (2000 U/µl) was added. The 
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reaction was incubated at room temperature for 50 min, and then 400 µl 7 M urea was 
added and the tube was lightly vortexed. 
 
4.2.5 Purification of mRNA-DNA-puromycin 
Each ligation reaction was loaded onto a 100 kDa cutoff Amicon Ultra-0.5 ml centrifugal 
filter unit (Millipore, Billerica, MA) and ultrafiltration was performed at 2000g for 15 
min. After addition of 7 M urea (200 µl), the device was centrifuged again. RNase-free 
water (500 µl) was then added, followed by an additional spin. This washing step with 
water was repeated twice more to remove essentially all of the urea. 
 
4.2.6 PURExpress reaction 
The PURExpress in vitro protein synthesis kit (New England Biolabs; NEB) was used for 
translation reactions. For Her2 selection experiments, the master mix included 10 µl 
Solution A, 7.5 µl Solution B, 0.5 µl RNasin Plus, and 5 µl RNase-free water. The master 
mix was then split into 4 reaction tubes with 5.5 µl each, and 60 pmol total mRNA was 
added to each reaction (ribosome content of PURExpress is 15 pmol per reaction). In the 
first round, the input in the 4 reactions contained the mRNAs encoding H10-2-G3 and 
Off7m in molar ratios of 1:10, 1:100, 1:1,000, and 1:10,000, with the mRNA encoding 
Off7m in molar excess in all cases. In each subsequent round, the input DNA from the 
previous round was transcribed and ~60 pmol total mRNA was added to each translation 
reaction. Translation was performed for 30 min at 37
o
C and then the reaction was kept at 
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room temperature for another 10 min. In the first round, 1 µl of this translation reaction 
was saved and kept on ice for direct RT-PCR. Then, 100 µl ice-cold TBS-cas [TBS (50 
mM Tris-HCl pH 7.4, 150 mM NaCl)
4
 with 0.5% casein  (Sigma-Aldrich, St. Louis, 
MO)] was added to the remaining translation reaction and the solution was kept on ice. 
 For FcRn selection experiments, PURExpress master mix included 10 µl Solution 
A, 7.5 µl Solution B, 1 μl Disulfide bond enhancer 1 (NEB), 1 μl Disulfide bond 
enhancer 2 (NEB), 0.5 µl RNasin Plus, and 3 µl RNase-free water.  mRNA encoding 
mFc.67 (or the LF or YTE variants) was added to the master mix to achieve a 1:1 molar 
ratio of mRNA:ribosomes. Translation was performed as described above and then each 
reaction (one per well) was stopped by adding 100 μl of one of four ice-cold panning 
buffers: TBST-cas-6 [TBS-6 (50 mM Tris-HCl pH 6.0, 150 mM NaCl) with 0.5% casein 
and 0.05% Tween 20 (Bio-Rad, Hercules, CA)], TBST-bsa-6 [TBS-6 with 0.5% bovine 
serum albumin (BSA; Roche, Indianapolis, IN) with 0.05% Tween 20], TBST-cas (TBS-
cas with 0.05% Tween 20), or TBST-bsa. 
 
4.2.7 Affinity selection 
Affinity selection for Her2 was performed on NUNC Maxisorp plates (Thermo Fisher 
Scientific, Rochester, NY). Each well was coated with 1.4×10
13
 Her2 receptors (Sino 
Biological, Beijing, China) in 100 μl TBS for at least 16 h at 4°C, washed 3 times with 
300 μl TBS, blocked with casein (300 μl TBSC added) at room temperature for 1 h with 
shaking, and then washed 3 times with TBS and once with TBS-cas. The translation 
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reaction in TBS-cas was added to each well and panned for 1 h at 4°C with shaking to 
allow binding. The wells were subjected to 3 quick washes with TBS-cas and 3 additional 
5-min washes prior to reverse transcription.  
 For FcRn selection, target immobilization was carried out as described above for 
Her2, except that 1.2×10
13
 mouse FcRn receptors (R&D Systems #6775-FC, 
Minneapolis, MN) were present in each well. For negative controls, 100 μl TBS without 
FcRn was added to each well at 4
oC for 16 h. Wells were washed 3 times with 300 μl 
TBS, blocked with casein or BSA (300 μl TBS-cas or TBS-bsa) at room temperature for 
1 h, and washed 3 times with TBS and once with the appropriate panning buffer. The 
translation reaction (100 μl) was added to each well and panned at 4oC for various times, 
as specified in the experiment. The wells were washed 6 times with TBST-cas-6, TBST-
bsa-6, TBST-cas, or TBST-bsa at 4
o
C or 37
o
C, with washing times as specified. 
 
4.2.8 Reverse transcription 
For Her2 selection, reverse transcription was performed in situ using AffinityScript 
reverse transcriptase (Agilent Technologies, Santa Clara, CA) and reverse primer 4. A 
reverse transcription protocol adapted from He and Taussig
30
 was followed. Briefly, 
Solution 1 (12.75 μl water, 0.25 μl 100 μM primer 4, and 0.5 μl RNasin Plus) was 
pipetted into the wells (or into 1 μl saved translation reaction in the first round), 
incubated at 70°C for 5 min, and allowed to cool at room temperature for 10 min. 
Solution 2 [2 μl 10× AffinityScript buffer, 2 μl 0.1 M dithiothreitol, 2 μl dNTPs (5 mM 
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each), and 0.5 μl AffinityScript reverse transcriptase] was then added and the reaction 
was incubated at 25°C for 10 min, 50°C for 1 h, and then heat-inactivated at 70°C for 15 
min. Although not necessary for highly oversampled libraries such as the ones used in 
this study, this reaction could be scaled up to recover rare sequences that may be 
immobilized higher on the well walls after selection. 
 For FcRn selection, pH-based elution was performed before reverse transcription. 
To elute the mRNA-puromycin-mFc complexes, 200 μl ice-cold TBS (pH 7.4) containing 
50 μg/ml S. cerevisiae RNA (Sigma-Aldrich) was added and incubated for 1 min with 
shaking. The eluate was then added to 400 μl lysis buffer and purified with the High Pure 
RNA isolation kit (Roche) according to the manufacturer’s instructions. The purified 
mRNA was eluted in 30 μl RNase-free water, denatured at 70oC for 10 min, and reverse 
transcribed as described
29
, except that AffinityScript reverse transcriptase and reverse 
primer 4 were used. 
 
4.2.9 PCR to verify enrichment 
After each round of Her2 selection, the products of reverse transcription (2 μl) were 
amplified by PCR with primers 5/4 for 35 cycles in a 50 μl reaction (30 cycles for saved 
translation reaction without selection in the first round). Each PCR product was subjected 
to gel purification by excising a rectangle encompassing both full-length DARPin 
product bands and this purified DNA was then reamplified with T7_no_BsaI and 
pRDV_BbsI_r to obtain enough product for transcription for the next round. For 
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analytical gel electrophoresis, PCR products were visualized in agarose gels with 
ethidium bromide staining and imaged using an ultraviolet transilluminator and CCD 
camera. After FcRn selection, the products of reverse transcription (2 μl) were PCR 
amplified with primers 5/4 for 23 or 25 cycles in a 20 μl reaction and visualized similarly. 
 
4.2.10 Determining the effect of Tween 20 
PURExpress was used to translate the mRNA encoding Off7 (from pRDV2:Off7), with 5 
pmol mRNA and ribosomes for each reaction condition. The reaction was translated at 
37
oC for 30 min, and allowed to incubate at room temperature for 10 min. Then, 500 μl 
ice-cold TBST-cas or TBS was added to the master translation reaction and loaded onto a 
100 kDa cutoff Amicon Ultra-0.5 ml centrifugal filter unit. Ultrafiltration was performed 
at 2000g for 15 min. After addition of 500 μl TBST-cas or TBS, the device was 
centrifuged again. This washing step was repeated twice more. In situ reverse 
transcription was carried out as described above with primers 7 or 4, and 2 μl product was 
PCR amplified for 30 cycles with primers 11/7 or 11/4, respectively. 
 
4.3 Results 
4.3.1 Streamlined mRNA display protocol 
A traditional mRNA display schematic is given in Figure 4.1
2,5,31
, with our modifications 
highlighted in red. First, we redesigned the DNA construct with a different 5′ end (Fig. 
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4.1a). The 5′ untranslated region (5′ UTR), taken from the modified ribosome display 
vector pRDV2 (Chapter 3), contains a T7 promoter and a Shine-Dalgarno ribosome 
binding site (RBS). This 5′ UTR drives strong transcription by T7 RNA polymerase, as 
well as efficient translation by Escherichia coli ribosomes, and has been shown to work 
in both crude extract
1
 and a cell-free reconstituted system
32
. Since the minimal translation 
system used in this work (discussed below) contains reconstituted components from the 
E. coli translational machinery, it is necessary to replace the tobacco mosaic virus 
translational enhancer commonly used with the eukaryotic rabbit reticulocyte lysate in 
mRNA display with the Shin-Dalgarno RBS to allow efficient translation with the 
prokaryotic E. coli components
33,34
. 
 
Figure 4.1. Changes in the streamlined mRNA display protocol. A traditional mRNA display protocol is 
shown
2,5,31, with our modifications highlighted in red: (a) 5’ UTR with T7 promoter and Shine-Dalgarno 
RBS; (b) mRNA purification with LiCl precipitation instead of lengthy PAGE purification; (c) mRNA-
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DNA-puromycin purification with ultrafiltration instead of lengthy PAGE purification; (d) in vitro 
translation with minimal, reconstituted translation system (PURExpress) instead of crude lysate to achieve 
higher library diversity with less nuclease and protease activity, which, in turn, can (e) eliminate need for 
purification of selection particles; (f) postpone reverse transcription, thus eliminating an additional 
purification step as well as avoiding a high-temperature incubation step of the displayed polypeptide prior 
to selection.  
 
 After in vitro transcription, mRNA is traditionally purified using denaturing 
PAGE (Fig. 4.1b)
2,5
. While effective at separating full-length RNA transcripts from 
truncated RNA and PCR primers, this method requires lengthy steps and manual excision 
from the gel. Instead, we use lithium chloride (LiCl) precipitation to isolate transcribed 
mRNA, a technique that has been used to purify mRNA prior to in vitro translation
4
. LiCl 
selectively precipitates RNA from unwanted DNA
35
, smaller RNA, unincorporated 
NTPs, and proteins
36
, thus enabling rapid purification while minimizing the number of 
processing steps during which detrimental nucleases and proteases could be introduced. 
 We have also replaced another PAGE purification step after ligating mRNA to the 
DNA-puromycin linker (Fig. 4.1c). Instead, we utilize the repertoire of commercially 
available ultrafiltration devices to quickly purify the mRNA-DNA-puromycin molecules 
from the DNA splint and unligated DNA-puromycin linkers, which can interfere with the 
subsequent translation reaction if not removed
5
. Although ultrafiltration cannot separate 
mRNA-DNA-puromycin molecules from unligated mRNA molecules, this limitation is 
also encountered in PAGE purification with templates longer than 500 nucleotides
5
. 
Furthermore, any mRNA molecules lacking puromycin will not be able to covalently 
attach to their corresponding polypeptide sequences and therefore will not be erroneously 
141 
 
enriched during the selection step. We have successfully purified the desired product 
using Amicon Ultra-0.5 ml (Millipore) or Vivaspin 500 (Sartorius) ultrafiltration 
columns, which are available in a range of molecular weight cutoffs (30−300 kDa) that 
enable their use across a broad range of construct sizes. In the current proof-of-principle 
studies, a 100 kDa ultrafiltation device can effectively remove the splint and unligated 
linkers (9.5 kDa), while retaining the mRNA-DNA-puromycin molecules (170−210 kDa) 
with a yield of 85−90%. 
In vitro translation reactions for mRNA display and ribosome display have 
typically relied on crude cell lysates for the necessary translational machinery. However, 
cell lysates are not ideal for reproducibly achieving high-complexity libraries because 
they contain endogenous RNases and proteases and time-intensive optimization 
procedures must be applied to correct for the inherent batch-to-batch variability. These 
limitations can be overcome by using a minimal E. coli-based translation system 
reconstituted from purified components (PURExpress, New England Biolabs) (Fig 4.1d). 
The fully defined PURExpress system offers better reproducibility, lack of nucleases and 
proteases, and a high concentration of ribosomes. These characteristics maximize the 
number of intact selection particles, increasing the likelihood of a successful selection. 
The resulting mRNA display particles can be used directly in selection experiments 
without additional purification steps (Fig. 4.1e).  
Selection is carried out after translation and followed by reverse transcription 
(RT). We delay RT until after selection because the displayed proteins may be adversely 
affected by the elevated temperatures required during the RT process, including initial 
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thermal denaturation of the RNA template and high-temperature incubation with the 
reverse transcriptase (Fig. 4.1f). Postponing RT also eliminates an additional purification 
step, as RT products can be used directly in subsequent PCR amplification but require a 
gel filtration step if RT is done prior to selection, further streamlining the procedure. 
However, since it is possible that delaying the RT step may allow for enrichment of RNA 
aptamers in addition to polypeptide binders in some affinity selections, an additional 
selection round can be performed with RT prior to selection to specifically isolate the 
polypeptide binders. Since the polypeptide binders should be substantially enriched at 
this point, the adverse effects of RT can be better tolerated than in initial rounds in which 
binders are scarce. Alternatively, DNA primers that are complementary to conserved 
regions of the mRNA can be added prior to selection to destabilize any RNA aptamers in 
the pool.  
 
4.3.2 Affinity selection against Her2 using binary libraries 
We performed a proof-of-principle selection to test our new streamlined mRNA display 
procedure. Two designed ankyrin repeat proteins (DARPins), Off7m
28
, a maltose-binding 
protein (MBP) binder, and H10-2-G3
26
, a Her2 binder, were assembled in mRNA display 
format and their mRNAs were combined at 4 different molar ratios (1:10 to 1:10,000 
H10-2-G3:Off7). These binary libraries were subjected to selection against immobilized 
Her2. After 2−3 rounds of our streamlined mRNA display protocol, the Her2-binding 
DARPin was selectively enriched, as evidenced by agarose gel electrophoresis 
visualization of the RT-PCR products (Fig. 4.2). Since RT-PCR of the original 1:100 
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mRNA mixture shows no discernible signal for H10-2-G3 but the original 1:10 mixture 
shows a faint yet clear lower band, we infer that the enrichment factor in these selection 
experiments is as high as 2 orders of magnitude. On the basis of the gel, we estimate an 
average enrichment of approximately 50- to 100-fold per selection cycle. 
 
Figure 4.2. Model DARPin selections using our streamlined mRNA display protocol. Four binary libraries 
containing mRNAs encoding H10-2-G3 (H = a Her2 binder) and Off7m (O = an MBP binder) at different 
molar ratios (1:10, 1:100, 1:1,000, and 1:10,000) were subjected to 2−3 rounds of selections against 
immobilized Her2. The original library (Ori.) and selective enrichment of H10-2-G3 in the RT-PCR 
product after each round of mRNA display (R1, R2, and R3) is visualized by agarose gel electrophoresis. 
Each selection round took 2 days in the laboratory. 
 
4.3.3 Variations of the mRNA display protocol 
Several variations of the mRNA display protocol were investigated. The presence of 
Tween 20 in the reaction during the panning and washing steps (added with the TBS and 
blocking agent) has a pronounced effect on the resulting DNA products. Tween 20 is 
routinely included in ELISA and display technologies because this detergent can help 
saturate vacant sites and minimize nonspecific background binding
37
, and this has been 
seen in mRNA display as well
9,38
. However, our preliminary studies using mRNA display 
to present Off7 to immobilized MBP showed that RT-PCR products contain almost no 
full-length DNA product, but many non-specific, low molecular weight bands, although 
there were indications of target-specific enrichment since these product bands were 
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stronger in the positive wells than in the negative ones (Fig. 4.3A). To more directly see 
this effect, RT-PCR was performed directly on the translation reaction, diluted in TBS 
with or without Tween 20, without an actual selection step (no panning, washing, or 
elution). As shown in Figure 4.3B, the addition of Tween 20 after translation adversely 
affected the yield of the correct RT-PCR product, instead resulting in amplification of 
lower molecular weight bands. Denaturing the mRNA at 70
o
C before RT, as part of the 
standard procedure, seemed to exacerbate this effect. In the absence of Tween 20, product 
bands of the correct size can be clearly seen (Fig. 4.3C). The appearance of 2 lower 
molecular weight species below the correct product band in Figure 4.3C have been 
identified by DNA sequencing as Off7 DARPin with only two of the three internal 
repeats and one of the three internal repeats, respectively. These byproducts may have 
arisen during the RT step if secondary structure in the mRNA allowed mispriming at the 
repeat junctions since the nucleotide sequences of the repeats are similar. Thus for our 
selection experiment against Her2 in the previous section, we constructed an Off7m, an 
Off7 variant with rationally introduced silent mutations to remove these repeating 
nucleotide motifs, which successfully eliminated the lower molecular weight byproducts. 
As we will discuss later, the effect of Tween 20 in a given selection strategy is likely to 
be protein specific; therefore, its inclusion in mRNA display protocols should be tested in 
pilot studies before starting selection experiments with new libraries and/or targets. 
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Figure 4.3. The effect of Tween 20 on Off7 RT-PCR products. (A) One mRNA display selection round 
with mRNA encoding Off7 (from pRDV-Off7) against immobilized MBP. TBST-cas was used as both the 
panning and washing buffers. RT and PCR were performed with reverse primer 18. The arrow indicates the 
size of the full-length product band (534 bp). (B, C) mRNA encoding Off7 (from pRDV2-Off7) was 
translated, diluted in TBS (B) with or (C) without 0.05% Tween 20, and purified. The products were 
reverse transcribed with GS_splint (splint; primer 7) or pRDV_BbsI_r (BbsI_r; primer 4). Products were 
either denatured at 70
o
C for 5 min, followed by a slow cool down at room temperature for 10 min, and then 
reverse transcribed as normal or they were incubated at room temperature for 15 min where the 
denaturation step was eliminated. exACTGene 1 kb plus DNA ladder (Fisher) was used. The arrow on each 
panel indicates the size of the full-length product band (556 bp). 
 
Another variable in the protocol is the choice of blocking agent. Casein has been 
shown to be more effective than other commonly used blocking agents such as BSA and 
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gelatin
39
, so it was chosen for the Her2 selection experiments described above. We have 
specifically observed that casein is able to prevent non-specific binding of smaller 
proteins better than BSA, likely due to the size heterogeneity of its component proteins, 
resulting in more effective blocking of wells on the microtiter plate (P. Barendt, personal 
communication). However, BSA blocking seemed to show a more uniform background 
signal in the display of mFc.67 (Fig. 4.4A), which might be due to secondary BSA 
recruitment from FcRn-BSA interactions
40
. These observations indicate that the choice of 
an optimal blocking agent will benefit from some experimental work as well. 
mRNA recovery from in situ RT-PCR, as demonstrated in our streamlined 
protocol, can be altered to reflect selection needs. The in situ method simplifies the 
recovery process and avoids losses by bypassing the need for elution and purification of 
mRNA, since RT is performed directly on the display complexes
30
. However, in situ RT-
PCR amplifies all mRNA present after selection, which can result in a higher signal-to-
background ratio in some cases. Additionally, some selection experiments may 
incorporate specific elution protocols to recover only functional complexes (e.g., specific 
proteolysis, chemical cleavage, chelating agents, or pH change), which would prevent in 
situ RT-PCR. For example, the display of mFc.67 benefited from pH-based elution since 
the binding of Fc to FcRn is pH dependent. In the following section, we show that such a 
specific elution step is compatible with our streamlined mRNA display protocol. 
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4.3.4 Selection against FcRn with mFc.67 and its variants 
mFc.67, mFc.67(LF) and mFc.67(YTE) was displayed in mRNA display format and 
selected against immobilized FcRn. All three proteins exhibited specific, pH-dependent 
binding to FcRn (Fig. 4.4A). The mRNA-puromycin-protein selection particles were 
panned against immobilized FcRn at pH 6.0, and subsequent washing at pH 6.0 was 
performed to remove unbound selection particles. Elution was performed by incubating 
the bound complexes for 1 minute in a buffer at pH 7.4, which should dramatically 
decrease the affinity of mFc to FcRn and thereby allow selective recovery of specifically 
bound selection particles. Strong specific signals can be seen at pH 6.0 when comparing 
all three mFc variants panned with or without immobilized FcRn (Fig. 4.4A), indicating 
that binding is indeed mediated by FcRn. When panning was done at pH 7.4, no specific 
signals were observed, further confirming that mFc binding to FcRn is pH dependent. 
Casein seems to lower the background signal to a greater extent than BSA, with the 
exception of mFc.67 incubated at pH 6.0 without FcRn and mFc.67 variants incubated at 
pH 7.4 without FcRn. Overall, mFc.67(LF) seemed to perform slightly better in the pH-
dependent binding to FcRn, though a selection experiment with a ternary library of all 
three complexes could confirm this hypothesis. 
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Figure 4.4. mRNA display with selection of mFc.67, mFc.67(LF), and mFc.67(YTE) against immobilized 
FcRn receptors. (A) Wells with (+) or without (-) immobilized FcRn were first blocked with 0.5% BSA or 
0.5% casein, as specified. Monomeric Fc variants were panned against FcRn in TBS with 0.5% BSA/casein 
and 0.05% Tween 20 at pH 6.0 or pH 7.4 for 1 h at 4
o
C with shaking. Each well was subjected to three 
immediate washes and three 30-sec washes at 4
o
C, and then eluted in pH 7.4 TBS for 1 min. RT and 23 
cycles of PCR were used to amplify the selected products. (B) mFc.67 was panned against FcRn in TBST-
bsa-6 for 0.5, 1, 2, or 5 min at 4
o
C, as indicated. Each well was then subjected to three 2-min washes and 
three 10-min washes at 37
o
C. Products after RT and 25 cycles of PCR are shown.  
 
 We further altered the procedures to examine the impact of on-rate and off-rate 
conditions for mFc.67 selection, by using progressively shorter panning times at low 
temperature and longer washing times at high temperature, respectively. Several 
iterations were carried out, and the most stringent conditions are shown in Figure 4.4B. 
mFc.67 complexes were panned against FcRn at 4
o
C for 30 sec, 1 min, 2 min, and 5 min 
(from 1 hr previously), while the complexes were washed for 10 min at 37
o
C (from 30 
sec at 4
o
C previously). These substantially more stringent selection conditions did not 
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seem to affect the signal-to-background ratio, suggesting that the affinity of mFc.67 at pH 
6.0 might be higher than previously reported (KD ~100 nM)
23
. 
 
4.4 Discussion 
We have developed a simplified, streamlined protocol for mRNA display that reduces the 
time for a single selection round from ∼4−7 days to 2 days (Table 4.3). In addition to a 
number of simplifications in purification steps, the procedure postpones the RT step until 
after selection, which has the extra benefit of protecting displayed polypeptides from 
thermal denaturation. Wherever possible, complex or poorly regulated steps in the 
procedure have been replaced with simple, robust alternatives. Importantly, in applying 
these procedural simplifications, we have not compromised the achievable library size 
(∼1014) or the enrichment capability of mRNA display. Furthermore, any of our 
streamlined steps can be readily reverted to the older procedures if there are additional 
constraints specific to a given experiment. Whether the entire protocol or only selected 
individual steps are adopted, this new protocol should enable faster and easier in vitro 
directed evolution experiments. 
Table 4.3. Step-by-step comparison of two traditional mRNA display procedures and our proposed 
streamlined method. 
Keefe procedure
5
 Cotten el al. procedure
31
 Proposed procedure 
In vitro transcription  
(3 h) 
 
In vitro transcription  
(7 h to overnight) 
 
In vitro transcription  
(3 h) 
 
Denaturing PAGE purification of 
mRNA 
(overnight + 3 h) 
DNase digestion to remove 
cDNA from mRNA  
(3.5 h) 
LiCl-based purification of 
mRNA 
a ,b
  
(2.5 h) 
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Phosphorylation of DNA-
puromycin linker 
(2.5 h) 
 
Conjugation of mRNA with 
DNA-puromycin linker 
(1 h) 
Phosphorylation of DNA-
puromycin linker 
(2.5 h) 
Splinted ligation of DNA-
puromycin linker and mRNA 
(1 h) 
 
 Splinted ligation of DNA-
puromycin linker and mRNA 
(1 h) 
Denaturaing PAGE purification 
of ligated mRNA 
(overnight + 3 h) 
 
LiCl-based purification of ligated 
mRNA 
(4 h) 
Ultrafiltration of ligated mRNA 
c
 
 
(1.5 h) 
In vitro translation with rabbit 
reticulocyte lysate 
(1.5 h) 
In vitro translation with rabbit 
reticulocyte lysate 
(1 day) 
In vitro translation with 
PURExpress system 
(1 h) 
 
Oligo(dT) purification 
(1.5 h) 
 
Oligo(dT) purification 
(3 h) 
 
Ni-NTA purification 
(3 h) 
 
Reverse transcription (RT) 
(1 h) 
 
Reverse transcription (RT) 
(1 h) 
Buffer exchange after RT 
(0.5 h) 
 
 
Buffer exchange after RT 
(0.5 h) 
 
Anti-FLAG purification 
(4.5 h) 
 
Selection 
(varies) 
 
Selection 
(varies) 
Selection 
(varies) 
 
PCR amplification 
(3 h) 
PCR amplification 
(3 h) 
PCR amplification 
d
 
(3 h) 
 
~ 4 days 
 
~ 7 days ~ 2 days 
 
a 
An RNA purification kit could be used to further shorten the time required for this step, but the LiCl 
precipitation procedure is significantly cheaper and also lends greater flexibility to the protocol by 
providing an additional potential stopping point that does not unnecessarily introduce an extra freeze-thaw 
cycle for the mRNA. 
b 
Potential stopping point: storage of mRNA at -20
o
C at an intermediate step during LiCl-based 
purification. 
c 
Potential stopping point: storage at -80
o
C after ultrafiltration of ligated mRNA. 
d 
Potential stopping point: storage of PCR product at 4
o
C or -20
o
C after PCR amplification. 
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The dramatic, adverse effect of Tween 20 on RT-PCR of Off7 selected using 
mRNA display is surprising, since the experiment was carried out after purification of 
translation complexes and only trace amounts of Tween 20 must have been present. 
Tween 20 has been routinely used in RT-PCR in our lab and in many ribosome display 
protocols without showing any adverse effects, and this detergent has even been used in 
an RT buffer
41
. However, this effect is protein specific because mRNA display of mFc.67 
yields no non-specific bands in the presence of Tween 20; in fact, the detergent actually 
enhanced the signal-to-background ratio for the display of mFc.67. Off7, due to its repeat 
nature, is prone to secondary structure artifacts during RT and, based on our findings, the 
presence of Tween 20 appears to promote or stabilize these artifacts, although it is still 
unknown how heat denaturation further exacerbates this effect. Interestingly, ribosome 
display of Off7 against MBP with Tween 20 as an additive shows no such artifacts, likely 
because the bound ribosomes prevent formation of extensive mRNA secondary structure, 
although the true molecular mechanisms cannot be established without further 
experiments. 
 With some alterations to the standard streamlined mRNA display protocol, 
including addition of Tween 20, usage of a different blocking agent, and specific elution, 
monomeric Fc variants were successfully displayed and exhibited specific, pH-dependent 
binding to FcRn receptors. It remains to be tested whether these mFcs bind to other Fc 
receptors, for example the FcγRs examined in Chapter 2. Though glycosylation is not 
necessary for Fc-FcRn interactions
25
, the aglycosylated mFc form will likely need to 
acquire additional mutations before it will bind to FcγRs (Chapter 2). It will be 
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interesting to see if the point mutations introduced from stabilization of the monomeric 
and aglycosylated forms will have additive effects in enabling monomeric, aglycosylated 
mFc to bind to both FcRn and FcγRs. If so, the functions of mFc fragments can be 
extended beyond serum persistence and transcytosis to include antibody-dependent 
cellular phagocytosis and possibly other effector responses. 
 For this particular mFc variant (mFc.67), mRNA display may not be capable of 
improving binding properties without using unrealistically short panning times or long 
washing times. However, this new streamlined mRNA display strategy opens up many 
other potential selection schemes; for example, cell-based mRNA display can be used to 
select for mFc mutants with better transcytosis properties across cultured monolayers of 
intestinal epithelial cells. Nevertheless, the newly constructed LF and YTE mutants may 
already have therapeutic utility. 
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CHAPTER 5 
Ribosome display of scaffold proteins and agonists 
5.1 Introduction 
Ribosome display is another powerful in vitro directed evolution technique
1
. It shares 
many characteristics with mRNA display
2
, which we described in detail in the previous 
chapter. Like mRNA display, ribosome display is performed entirely in vitro, which 
enables the display of large libraries (up to 10
14
 members) and allows for easy additional 
mutagenesis
3
. Unlike mRNA display, ribosome display does not covalently link the 
mRNA and displayed protein; instead, the mRNA and its corresponding in vitro 
translated protein are noncovalently associated via a stalled ribosome
4
. A side-by-side 
graphical comparison of the two display methods is shown in Figure 5.1. First, the 
transcription/translation cassette is constructed by attaching the T7 promoter and 
ribosome binding site to the 5’ end of the DNA library and an unstructured spacer to the 
3’ end. After PCR amplification, in vitro transcription yields mRNAs which contain 5’ 
and 3’ stem loops to confer additional stability4. The mRNA library, which lacks stop 
codons, is then translated, resulting in nascent polypeptides that are not released from the 
ribosomes. The last amino acid of each translated protein is thus connected to peptidyl-
tRNA within the ribosome, the unstructured spacer fills the ribosomal tunnel, and the 
protein of interest folds outside of the ribosome
4
. Without release of the polypeptide 
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chain and dissociation of the ribosome, the mRNA also remains attached. This ternary 
mRNA-ribosome-protein complex is then used for selection
3
. The mRNAs encoding the 
selected proteins are recovered by reverse transcription (RT) and amplified by PCR
4
. The 
DNA can then be used in the next round of selection or it can be sequenced and analyzed. 
 
 
Figure 5.1. Comparison of ribosome display and mRNA display. (A) The mRNA display protocol, as 
described in Chapter 4. The selection particle is an mRNA-protein complex that is covalently connected by 
a puromycin linker. (B) In ribosome display, a DNA library is transcribed into an mRNA library by in vitro 
transcription. The mRNA library, which lacks stop codons, is translated and the nascent polypeptides 
remain attached since the ribosomes stall. The ternary mRNA-ribosome-protein complexes are used for 
selection. After washing to remove unwanted complexes, the mRNAs encoding the selected complexes are 
reversed transcribed into cDNAs and further amplified by PCR. This DNA can be used in the next round of 
selection or it can be sequenced and analyzed. 
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The ribosome display method is slightly simpler to perform than even our 
streamlined mRNA display protocol (Chapter 4) because no ligation to the DNA-
puromycin linker is needed before translation. However, a notable drawback is that the 
mRNA-ribosome-protein ternary complex is inherently less stable, even though 
stabilization strategies (e.g., the addition of Mg
2+
) have enabled complexes to be 
maintained intact for more than 10 days
5
. Ribosome display has been used in many 
protein engineering applications, including the development of peptides
6
, enzymes
7
, 
single chain variable fragments (scFvs)
8
, and novel binders based on alternative 
scaffolds
9
. In this work, we examined some of the challenges of ribosome display and 
developed a robust display protocol for a variety of interesting scaffolds and therapeutic 
proteins. 
We first investigated a new display strategy involving an emerging alternative 
protein scaffold, the designed ankyrin repeat protein (DARPin)
10
. Ankyrin repeat proteins 
comprise a prominent repeat protein family that occur in many species and naturally 
mediate protein-protein interactions in the cytoplasm, nucleus, membrane and 
extracellular space
11
. They usually consist of 4–6 stacks of 33 amino acids repeats, 
forming an elongated protein domain with a continuous hydrophobic core
12
. The diversity 
of functions exhibited by these repeat proteins have led to the hypothesis that such 
proteins can be engineered to generate novel binding specificities
13
. Using sequence and 
structural consensus analysis, libraries of ankyrin repeat proteins have been generated by 
fixing consensus residues and randomizing the protruding β-turn and the following α-
helix within each internal repeat, and this hydrophobic core is sealed with N- and C-
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terminal capping repeats (N-cap and C-cap)
13
. These scaffolds exhibit favorable 
biophysical properties, since they are soluble, very stable, and well-expressed
14
. DARPin 
libraries  designated N2C and N3C (consisting of an N-cap, two or three internal repeats, 
respectively, and a C-cap) have been generated and used in ribosome display selections to 
enrich for binders against maltose binding protein (MBP). Through these selections, a 
high-affinity binder, Off7 (KD of 4.4 nM)
9
, was recovered. We used this high-affinity 
interaction between MBP and Off7 to test and develop a robust ribosome display protocol 
that incorporates advances from our own work and various other groups
15,16
 into the 
standard procedure
17
. Furthermore, to examine the minimal binding module as well as the 
interaction between the internal repeats and the N- and C-caps, we progressively 
truncated Off7 and then assessed MBP binding using ribosome display. This reverse 
engineering approach can help elucidate the molecular determinants of stable folding and 
high affinity binding in DARPins. 
We then used the same ribosome display strategy to display two important 
agonists: insulin, which, for decades, has been indispensible in the treatment of diabetes, 
and leptin, which has shown promise in treating obesity
18
, lipodystrophy
19
, hypothalamic 
amenorrhea
20
, and diabetes
21
. Human insulin normally consists of separate A and B 
chains connected by three disulfide bonds, two inter-chain and one intra-chain
22
. 
However, since genotype and phenotype must be coupled for applications involving 
ribosome display, a single-chain insulin analog was used for these studies. Of the 
characterized single-chain analogs
23
, SCI-57
24
 was chosen because it retains the folding 
properties and the biological activity of wild-type human insulin, with additional 
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advantages of enhanced thermodynamic stability and reduced aggregation
24
. On the other 
hand, human leptin, which is naturally a single-chain protein, could be expressed in 
ribosome display without modifications. Since both proteins contain disulfide bonds, in 
vitro translation of these proteins using a reconstituted translation system from E. coli 
(PURExpress) could be problematic in achieving correct folding. Since previous studies 
have shown that the addition of chaperones or disulfide isomerases can help alleviate this 
problem
1,15,25
, we examined the specific binding of SCI-57 and leptin to their cognate 
receptors using our ribosome display protocol with or without such supplements. We 
further investigated the effect of removing disulfide bonds in leptin, since this could 
increase production yield in lower organisms and simplify downstream purification. Our 
results provide insights into the stabilities of SCI-57 and leptin. These two therapeutic 
proteins will be discussed in more detail in the next chapter, which focuses on their 
secretion from Lactococcus lactis. 
Next, we use a forward engineering approach to increase the stability of an scFv. 
Many scFvs have been expressed and evolved using ribosome display
1,8,26
; however, the 
success of such experiments can depend strongly on the stability of the protein displayed. 
Here, we studied two scFvs of interest: R6.5
27,28
 and YN1 (Colin Greineder, unpublished 
results), which bind to human and mouse intercellular adhesion molecule-1 (ICAM-1), 
respectively. ICAM-1 is a transmembrane glycoprotein that is constitutively present on 
endothelial cells. It is upregulated by proinflammatory cytokines and participates in the 
firm arrest and transmigration of leukocytes from blood vessels to tissues
29
. Anti-ICAM-
1 antibodies have great potential in various anti-inflammatory treatments; however, 
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clinical trials of the R6.5 antibody for treatment of refractory rheumatoid arthritis
30
, renal 
transplant
31
, and acute ischemic stroke
32
 showed side effects and limited efficacy. The 
fusion of an anti-ICAM-1 scFv with the extracellular domain of thrombomodulin, an 
endothelial protective membrane protein, may allow for endothelial targeting and show 
better clinical outcomes. In fact, using this strategy, promising results have been seen in 
the treatment of acute thrombosis, inflammation, and lung injury (C. Greineder, personal 
communication). In collaboration with Dr. Vladimir Muzykantov and Dr. Colin 
Greineder (University of Pennsylvania), we thus sought to engineer a more stable anti-
ICAM-1 scFv which would maintain binding to ICAM-1. Inspired by the established 
method of complementarity determining region (CDR) grafting onto closely related 
human antibody frameworks to reduce immunogenicity, we grafted the CDRs of R6.5 
and YN1 onto more stable human frameworks in order to improve antibody stability and 
folding efficiency
33,34
. The human combinatorial antibody library (HuCAL) consensus 
frameworks
35
 were used since scFvs with HuCAL frameworks have been shown to be 
solubly expressed in E. coli
35
 and have been successfully used to select for novel binders 
with ribosome display
8
, which is the platform of choice for further evolution of these 
stability-engineered scFvs. In addition, by improving stability through humanization, 
these antibodies and their progeny may proceed clinically with less additional 
modifications. 
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5.2 Materials and methods 
5.2.1 Plasmid construction 
For all DNA manipulation techniques and materials, please refer to Sections 4.2.1 and 
4.2.2. Plasmids used in this work are listed in Table 5.1 and primers are listed in Table 
5.2. To clone the off7 gene and subsets of its repeats into pRDV, various fragments from 
the off7 gene were PCR amplified from pRDV:Off7
9
 (courtesy of Dr. Andreas Plückthun, 
University of Zurich). pRDV:Off7 was PCR amplified with primers 1/6, 1/5, 1/4, 3/6, 
2/6, and 2/5 to obtain full off7 without the FLAG tag or spacer, off7 fragment comprising 
the N-cap and the 3 internal repeats, off7 fragment comprising the N-cap and 2 internal 
repeats, off7 fragment comprising 2 internal repeats and the C-cap, off7 fragment 
comprising the 3 internal repeats and the C-cap, and off7 fragment with only the 3 
internal repeats, respectively. These PCR products were gel purified, digested with NcoI 
and EcoRI, and ligated into similarly digested pRDV, yielding pRDV:Off7-FS, 
pRDV:Off7NI3, pRDV:Off7NI2, pRDV:Off7I2C, pRDV:Off7I3C, and pRDV:Off7I3, 
respectively. 
Table 5.1. Plasmids used in this study.  
Plasmids Characteristics Sources 
pRDV:Off7 pRDV containing the FLAG-tagged off7 gene; Amp
r
 Binz et al.
9
 
pRDV:Off7-FS pRDV containing the off7 gene without FLAG tag or 
extra spacer; Amp
r
 
This work 
pRDV:Off7NI3 pRDV containing the N-cap and all 3 internal repeats 
of the off7 gene; Amp
r
 
This work 
pRDV:Off7NI2 pRDV containing the N-cap and first 2 internal repeats 
of the off7 gene; Amp
r
  
This work 
pRDV:Off7I2C pRDV containing the last 2 internal repeats and the C-
cap of the off7 gene; Amp
r
 
This work 
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pRDV:Off7I3C pRDV containing all 3 internal repeats and the C-cap 
of the off7 gene; Amp
r
 
This work 
pRDV:Off7I3 pRDV containing all 3 internal repeats of the off7 
gene; Amp
r
 
This work 
pRDV:SCI-57 pRDV containing the SCI-57 gene; Amp
r
 This work 
pRDV:hLep pRDV containing the human leptin gene; Amp
r
 This work 
pRDV:hLepC96SC146S pRDV containing the human leptin gene with C96S 
and C146S double mutations; Amp
r
 
This work 
pCR4:R6.5 pCR4 containing the R6.5 gene; Amp
r
 Courtesy of 
Dr. Vladimir 
Muzykantov 
and Dr. Colin 
Greineder 
pCR4:YN1 pCR4 containing the YN1 gene; Amp
r
 Courtesy of 
Dr. Vladimir 
Muzykantov 
and Dr. Colin 
Greineder 
pRDV2:R6.5 pRDV2 containing the R6.5 gene; Amp
r
 This work 
pRDV2:YN1 pRDV2 containing the YN1 gene; Amp
r
 This work 
pRDV2:hR6.5 pRDV2 containing the R6.5 gene grafted onto a human 
VH3/Vκ2 framework; Amp
r
 
This work 
pRDV2:hYN1 pRDV2 containing the YN1 gene grafted onto a human 
VH3/Vκ4 framework; Amp
r
 
This work 
 
Table 5.2. Primers used in this study. 
Number Name Nucleotide Sequence (5’  3’) a 
1 pRDV_Off7N_NcoI_f GTCGATCCCCATGGGATCCGACCTGGGTAG 
2 pRDV_Off7I1_NcoI_f GGTCATGACCATGGCTGACGTTAATGCTGCTGACAATACT 
3 pRDV_Off7I2_NcoI_f ATTGACGCCCATGGCTGACGTTGACGCTTCTGACGTTTTT 
4 pRDV_Off7I2_EcoRI_r TACTGGATGAATTCACCGTTCTTCAGCAGAACTTCAACGATTTC
CAGGTGACCCC 
5 pRDV_Off7I3_EcoRI_r ACGTACCTGAATTCACCGTGCTTCAGCAGAACTTCAACGATTTC
CAGGTA 
6 pRDV_Off7C_EcoRI_r TCGGATATGAATTCATTAAGCTTTTGCAGGATTTC 
7 SCI-57gene_f ATATATCCATGGGCTTCGTTAACCAGCACCTGTGCGGTTCTGAC
CTGGTTGAAGCTCTGTACCTGGTTTGCGGTGAACGTGGTTTCTT
CTACACCGACCCGACCGGTGGTGGTCCGCGTCGTGGTATCGTTG
AACAGTGCTGCCACTCTATCTGCTCTCTGTACCAGCTGGAAAAC
TACTGCAACGAATTCGGATCTGGT 
164 
 
8 pRDV_NcoI_f AGAAGGAGATATATCCATGG  
9 pRDV_EcoRI_r TGGCCACCAGATCCGAATTC 
10 hLep_NcoI_f TTGTCGACCCATGGTGCCCATCCAAAAAGTC 
11 hLep_EcoRI_r ATTTCGTTGAATTCGCACCCAGGGCTGAG 
12 hLep_C96S_f TCTAAGAGCAGCCACTTGC 
13 hLep_C96S_r GCAAGTGGCTGCTCTTAGA 
14 hLep_C146S_r ATTTCGTTGAATTCGCTCCCAGGGCTGAGGTC 
15 pRDV_BbsI_f AATAATTTGAAGACACCGAAAGAAG 
16 pRDV_BbsI_r GGCCACCGGAAGACCCAAGC 
17 T7B_noBsaI ATACGAAATTAATACGACTCACTATAGGGACACCACAACGG 
18 tolAk CCGCACACCAGTAAGGTGTGCGGTTTCAGTTGCCGCTTTCTTTC
T 
 
a
 Restriction sites are underlined. Mutation sites are double-underlined. 
 
The gene encoding the single-chain insulin analog SCI-57 was constructed from 
primers 7/9 by extension PCR. Primers 8/9 were then used to amplify this SCI-57 
template and the resulting product was cut with NcoI and EcoRI for ligation into the 
similarly cut pRDV, giving rise to pRDV:SCI-57. To construct pRDV:hLep, human 
leptin cDNA (GenBank accession no. BC069452; Open Biosystems, Waltham, MA) was 
PCR amplified using primers 10/11, digested with NcoI and EcoRI, and ligated into 
similarly cut pRDV. pRDV:hLepC96SC146S was constructed by overlap extension PCR 
of two pieces: the fragment from amplifying pRDV:hLep with primers 10/13 and the 
fragment from amplifying pRDV:hLep with primers 12/14. The resulting product was 
digested with NcoI and EcoRI and ligated into similarly cut pRDV. 
pCR4:R6.5 and pCR4:YN1, which contained the original anti-ICAM-1 scFvs, 
were provided by Dr. Vladimir Muzykantov and Dr. Colin Greineder (University of 
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Pennsylvania). R6.5 and YN1 constructs were digested from the two pCR4 plasmids with 
BbsI and ligated into BbsI-digested pRDV2 (Chapter 3). For pRDV2:hR6.5 and 
pRDV2:hYN1, the grafted hR6.5 and hYN1 genes were synthesized in two mini-gene 
fragments for each construct (Integrated DNA Technologies, Coralville, IA). Overlap 
extension PCR was used to assemble the full-length constructs and amplification was 
performed with primers 15/16. The resulting products were digested with BbsI and 
ligated into similarly digested pRDV2.  
 
5.2.2 CDR grafting onto stable frameworks 
The background and approach for grafting CDRs onto stable antibody frameworks has 
been described
33
. The VH and VL sequences of R6.5 and YN1 were aligned with the 
consensus VH and VL domains derived from the Human Combinatorial Antibody Library 
(HuCAL
®
)
33,35,36
. Based on stability and similarity in framework residues, both R6.5 and 
YN1 VH CDRs were grafted onto the human consensus VH3 domain; R6.5 and YN1 VL 
CDRs were grafted onto the human consensus Vκ2 and Vκ4 domains, respectively. 
Based on Ewert et al.
33
, color coding in Figure 5.2 highlights positions important for 
antigen contacts, VL/VH heterodimer contacts (yellow to red indicates less important to 
more important), and upper core residues (purple) with conserved central core residues 
(blue) that affect CDR conformation
33
. All colored positions contain residues from the 
original R6.5 and YN1 sequences, and all uncolored positions contain residues from the 
human consensus frameworks. For easy visualization, the actual amino acids are also 
color-coded based on residue type. The original HuCAL frameworks, unmodified R6.5 
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and YN1, and the grafted hR6.5 and hYN1 are shown in separate lines in Figure 5.2. 
 
Figure 5.2. CDR grafting information for hR6.5 and hYN1. The color scheme, residue numbering system, 
and worksheet were adopted from Ewert et al.
33
 Antigen contacts and VL/VH hetermodimer interfaces were 
color-coded from yellow to red to reflect the average contribution of residue positions to the contact 
interface (white: 0%, yellow: 0–20%, light orange: 20–40%, orange: 40–60%, orange red: 60–80%, red: > 
80%). Upper core residue positions are purple and central core residues are blue. R6.5 and YN1 residues 
before and after grafting are shown together with the human framework onto which they are grafted. The 
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actual amino acid residues are also color coded: orange: F, Y, W; yellow: I, L, V, P, A, M, C; light green: 
G; Green: S, T, N, Q; light blue: H; dark blue: R, K, red: D, E. 
 
5.2.3 Reagents for ribosome display  
For materials common to both ribosome and mRNA display, please refer to Section 4.2 
for manufacturer’s information. Insulin receptors were manufactured by R&D Systems 
(Minneapolis, MN) and leptin receptors (binding domain) were manufactured by Prospec 
(#CYT-508; Rehovot, Israel). Human insulin solution and leptin were from Sigma-
Aldrich (#I9278; St. Louise, MO) and Peprotech (#300-27; Rocky Hill, NJ), respectively. 
Biotinylated human and mouse ICAM-1 were provided by our collaborator, Dr. Colin 
Greineder. 
Non-biotinylated and biotinylated MBP were produced in E. coli using expression 
plasmids pAT224
9
 (AY327139) and pAT224/pBirA
37
, respectively. To make non-
biotinylated MBP, XL1-Blue cells were transformed with pAT224, inoculated into 5 ml 
Luria Broth (LB) with 100 µg/ml ampicillin (Amp), and grown overnight at 37
o
C with 
shaking. Overnight cultures were diluted 1:25 into 100 ml pre-warmed LB with Amp and 
grown to an OD600 of 0.6. Expression was induced with 1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) and the culture was grown for an additional 4–5 h at 37oC 
with shaking. Cells were harvested by centrifugation at 4000g for 20 min and frozen at -
20
o
C overnight. Non-biotinylated MBP was then purified via its His6 tag with the 
QIAexpress Ni-NTA Fast Start Kit (Qiagen) and analyzed by SDS-PAGE. Biotinylated 
MBP was produced as described but with modifications
37
. XL1-Blue cells were 
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transformed with both pAT224 and pBirA, inoculated into 5 ml TYH media (20 g 
tryptone, 10 g yeast extract,  11 g HEPES, 5 g NaCl, 1 g MgSO4, adjusted to pH 7.2–7.4 
with KOH) with 75 μg/ml Amp and 10 μg/ml chloramphenicol (Cm), and grown 
overnight at 37
o
C with shaking. Overnight cultures were diluted 1:100 into 250 ml of 
prewarmed TYH media with 75 µg/ml Amp and 0.5% glucose and grown at 37
o
C with 
shaking to an OD600 of 0.6–0.7. Expression of biotinylated MBP was induced by addition 
of both 0.2 mM biotin solution (prepared by the addition of 6.1 mg d-biotin to warm 10 
mM bicine buffer at pH 8.3 and sterile filtered through a 0.22-µm filter) and 1.5 mM 
IPTG, and the culture was grown for an additional 3 h. Cells were harvested by 
centrifugation at 5000g for 20 min and frozen at -80
o
C overnight. Purification and 
analysis of biotinylated MBP was performed as described above.  
 
5.2.4 Ribosome display  
Primers 17 and 18 were first used to amplify the gene constructs within the pRDV and 
pRDV2 plasmids, and the resulting products were used directly for in vitro transcription 
as described previously
17
. The mRNA was purified as described
17
 and reconstituted in 30 
µl RNase-free water. In vitro translation was carried out with the PURExpress protein 
synthesis kit (New England Biolabs; NEB) in 25 µl according to manufacturer’s 
instructions. The PURExpress master mix was supplemented with 0.5 µl RNasin Plus, 
and when appropriate, 0.5 µM protein disulfide isomerase (PDI) or 1 µl disulfide bond 
enhancer 1 and 1 µl disulfide bond enhancer 2 (NEB). The mRNA was added to the 
master mix in a 1:1 ratio with ribosomes. Translation was performed at 37
o
C for 30–40 
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min, and immediately put on ice. Ice-cold washing buffer (100 µl) with Tween 20 and 
either casein or bovine serum albumin (BSA) [50 mM Tris-HCl (pH 7.5 at 4
o
C), 150 mM 
NaCl, 50 mM MgAc, 0.05% Tween 20 with either 0.5% casein or 0.5% BSA; WBT-
cas/WBT-bsa, respectively] was added to the stopped translation for each well and kept 
on ice.  
To prepare for selection, wells on a NUNC MaxiSorp plate (Thermo Fisher 
Scientific, Rochester, NY) were coated either with neutravidin (for biotinylated targets) 
or with the non-biotinylated targets directly at 4
o
C for at least 16 h without shaking. For 
Off7-MBP and anti-ICAM-1 experiments, 100 µl of 66 nM neutravidin (Pierce, 
Rockford, IL) was allowed to adsorb overnight;  the neutravidin-coated wells were then 
washed three times with 300 µl TBS [50 mM Tris-HCl (pH 7.4) at 4
o
C, 150 mM NaCl], 
blocked with 300 µl TBS-cas or TBS-bsa [TBS with 0.5% casein or 0.5% BSA] at room 
temperature for 1 h with shaking, and washed again three times with 300 µl TBS. For 
positive wells, 2×10
13
 to 3×10
13
 molecules of biotinylated MBP or ICAM-1 in 200 µl 
TBS-cas or TBS-bsa were added to neutravidin-coated and casein/BSA-blocked wells; 
for negative wells, only buffer (200 µl TBS-cas or TBS-bsa) was added. Wells were 
incubated at 4
o
C for 1 hr with shaking. For insulin and leptin experiments, each well was 
directly coated with 2×10
12
 insulin receptors or 6×10
12
 leptin receptors at 4
o
C for at least 
16 h without shaking. The wells were washed 3 times with 300 µl TBS and blocked with 
300 µl TBS-cas at room temperature for 1 h with shaking. 
All antigen-coated and casein/BSA-blocked wells were then washed 3 times with 
TBS and once with WBT-cas or WBT-bsa. The translation reaction in WBT-cas or WBT-
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bsa was added to each well and panned for 1 h at 4
o
C with shaking. The wells were then 
subjected to various washes with WBT-cas or WBT-bsa (or WBT-cas with 0.25 M KCl 
for leptin binding experiments with KCl) prior to reverse transcription: 10 immediate 
washes for Off7-MBP; 3 immediate and 6 15-min washes for SCI-57-insulin receptor; 3 
immediate and 5 5-min washes for leptin-leptin receptor; 8 immediate washes for leptin 
(C96SC146S)-leptin receptor; 3 immediate washes and 3 2-min washes for R6.5-human 
ICAM-1; and 7 immediate washes for hYN1-mouse ICAM-1. 
Reverse transcription (RT) was performed in situ as described in Section 4.2.8 for 
all experiments except for SCI-57-insulin receptor. For SCI-57-insulin receptor selection, 
elution was performed by adding 200 µl elution buffer (TBS with 50 mM EDTA) with 50 
µg/ml S. cerevisiae RNA and incubated at 4
o
C for 10 min with shaking. The eluted 
mRNA was then purified using the Roche High Pure RNA isolation kit and reverse 
transcribed as described in Section 4.2.8. Reverse primer 9 was used for all experiments 
with pRDV and reverse primer 16 was used for all experiments with pRDV2 (except for 
hYN1 experiments, in which reverse primer 18 was used). 
The products from RT were amplified by PCR with inner primers 8/9 for 
experiments with pRDV and primers 15/16 for experiments with pRDV2. The PCR 
products were subjected to analytical gel electrophoresis with ethidium bromide and 
visualized using an ultraviolet transilluminator and CCD camera. 
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5.3 Results 
5.3.1 The ribosome display protocol 
Through the display of various molecules, many of which are illustrated in this chapter, 
we have improved the ribosome display protocol. Chronologically, the display of SCI-57 
was examined first, followed by the Off7 fragments, human leptin, leptin variants, and 
finally R6.5 and YN1 scFvs. Changes were made to the standard protocol over time, most 
noticeably the switches from pRDV to pRDV2 and from mRNA elution to in situ reverse 
transcription. Selection targets were immobilized directly to the plastic surfaces of the 
wells when biotinylated targets were not available. Insulin and leptin receptors were 
adsorbed directly on the Maxisorp plate overnight at 4
o
C, and successfully exhibited 
specific binding to SCI-57 and leptin with ribosome display, respectively. However, 
ribosome display experiments with directly adsorbed nonbiotinylated MBP and ICAM-1 
showed a worse signal-to-background ratio than with biotinylated MBP and ICAM-1 
immobilized onto neutravidin-coated wells, suggesting that this latter method is 
preferred, if feasible
4,17
. The advantages of immobilizing biotinylated targets include 
robustness to stringent washing and ability to maintain the structure of the target
4
. Our 
current ribosome display protocol now incorporates modifications based on our own 
findings as well as advances from other laboratories, and therefore differs from the 
protocol established by the Plückthun laboratory
4,17
 in a few main areas. 
First, our display vector is pRDV2, which is pRDV
9
 redesigned with restriction 
sites for the Type IIS enzyme BbsI (Chapter 3). Using pRDV2, desired ligation products 
can be increased up to 15- and 2.6-fold following circular and linear ligations, 
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respectively
38
. Maximizing the amount of desired ligation product is essential in 
optimizing DNA library construction since library diversity is directly affected by 
ligation efficiency. The pair of inner primers used during a round of ribosome display is 
now replaced by pRDV_BbsI_f (primer 15) and pRDV_BbsI_r (primer 16), which 
contain the BbsI recognition sites for use with pRDV2. 
For in vitro translation of mRNA, crude extract from E. coli has been replaced 
with the PURExpress protein translation system (NEB), which is a minimal E. coli-based 
translation system reconstituted from purified components
15,25
 (PURExpress was also 
used in our streamlined mRNA display procedure in Chapter 4). This cell-free protein 
synthesis system contains minimal nucleases and other inhibitory factors and allows for 
greater control of the translation reaction. A variation of the PURExpress system without 
release factors is also commercially available (NEB) and this can aid stalling of the 
ribosomes at the last codon and further stabilize the mRNA-ribosome-protein ternary 
complexes
15
. Molecular chaperones or isomerases can also be included in defined 
quantities to facilitate protein folding, and reaction conditions can be adjusted to allow 
for oxidative folding
25
. Some of these variations were tested and the results will be 
presented below. 
An alternative to EDTA elution and purification of mRNA in the original protocol 
is in situ reverse transcription. As discussed in Section 4.3.3, this method involves 
performing RT directly on the display complexes in the wells, thus simplifying the 
recovery process and avoiding losses during elution and purification
16
. All experiments 
except the SCI-57-insulin receptor selection were carried out with in situ RT. 
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5.3.2 Binding of Off7 fragments to MBP 
Wild-type Off7 has an N3C structure, with 3 internal repeats sandwiched between an N-
cap and a C-cap. It has previously been evolved to low nanomolar affinity to MBP by 
ribosome display
9
; in the same work, a high-affinity binder with N2C structure was also 
obtained
9
. While both N3C and N2C ankyrin repeat proteins are extremely stable
14
, we 
investigated the effect that removing repeats from Off7 would have on its ability to be 
displayed and bind MBP. It was hypothesized that the capping repeats, which seal the 
hydrophobic core
13
, would be necessary to form a stable and well-folded ankyrin repeat 
protein capable of binding MBP. 
Various fragments of Off7 were created: Off7-FS (a simplified form of Off7 with 
its FLAG tag and spacer removed), Off7NI3 (off7-FS with the C-cap removed), Off7NI2 
(Off7-FS with the C-cap and the last internal repeat removed), Off7I2C (Off7-FS with the 
N-cap and the first internal repeat removed), Off7I3C (Off7-FS with N-cap removed), 
and Off7I3 (Off7-FS with N-cap and C-cap removed). Ribosome display of these Off7 
fragments against biotinylated MBP revealed specific binding of Off7, Off7-FS, 
Off7NI3, and Off7I3C to immobilized MBP, but not to neutravidin-coated, MBP-free 
wells (Fig. 5.3). To further demonstrate specific binding, samples in which excess non-
biotinylated MBP was added to during the panning step to compete for Off7 binding 
showed markedly lower levels of recovered complexes. By contrast, Off7NI2, Off7I2C, 
and Off7I3 showed increased signals in MBP wells compared to neutravidin-coated 
wells, but the signal intensities remained unchanged when excess MBP was added as a 
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competitor (Fig. 5.3). Our results indicate that at least 4 contiguous repeats of Off7 are 
required for binding MBP in ribosome display format. The lack of specific binding for 
Off7NI2, Off7I2C, and Off7I3 is likely due to disruptions to the binding interface or 
instability of the truncated protein structures. 
 
Figure 5.3. Ribosome display of Off7 and Off7 fragments against MBP. Biotinylated MBP was 
immobilized on neutravidin-coated wells prior to selection. To compete for specific Off7 binding to 
immobilized MBP, 3 µM non-biotinylated MBP was included during the panning step. Products after RT 
and 30 cycles of PCR are shown. The different sizes of the bands for each Off7 variant (as indicated above 
the gel) reflect different truncations of the wild-type Off7. 
   
5.3.3 Ribosome display of SCI-57, human leptin, and leptin variants 
The binding of SCI-57 and leptin to their cognate receptors was also investigated with 
ribosome display. SCI-57, like native insulin, requires three disulfide bonds for correct 
folding and biological activity
39
. Therefore, protein disulfide isomerase (PDI) was added 
to the translation reaction to enhance folding and the formation of disulfide bonds, which 
has previously been shown to have a strong beneficial effect in ribosome display
1
. With 
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PDI, ribosome display of SCI-57 suggested weak, but specific, binding to immobilized 
insulin receptors compared to background controls (Fig. 5.4A). 
 
Figure 5.4. Ribosome display of SCI-57 and leptin against insulin and leptin receptors, respectively. (A) 
Insulin receptors were directly adsorbed onto wells and blocked with casein. To compete for SCI-57 
binding, 30 µM excess insulin was included during the panning step. TBS-EDTA elution was used to 
isolate the mRNA. Products after RT and 19 cycles of PCR are shown. (B, C, D) Leptin receptors were 
directly adsorbed onto wells and blocked with casein. (B) To compete for leptin binding, 0.5 µM excess 
leptin was included during the panning step. Products after RT and 27 cycles of PCR are shown. (C) 
Various concentrations of DTT were included in the translation reaction with PURExpress. Translation was 
carried out as usual. Products after RT and 27 cycles of PCR are shown. (D) Various concentrations of KCl 
were included in WBT-cas during the panning step to assess hydrophobicity of the displayed protein. Both 
human leptin (hLep) and human leptin with C96S and C146S mutations (hLepC96SC146S) were tested. 
Products after RT and 25 cycles of PCR are shown. 
 
Similarly, ribosome display of human leptin showed specific binding to 
immobilized leptin receptors and the level of recovered complexes diminished when free 
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leptin was added during the panning step (Fig. 5.4B). However, no isomerases or 
chaperones were used in this experiment. Native human leptin contains one intrachain 
disulfide bond between C96 and C146 (numbering starts after the signal peptide), but 
there are conflicting reports concerning the importance of this disulfide bond for 
biological activity
40–43
. To further investigate if the disulfide bond is required for binding 
to the leptin receptor, various concentrations of DTT were added to the translation 
reaction to disrupt disulfide bond formation. Only at the highest DTT concentration (100 
mM) was a reduction in leptin-leptin receptor binding observed (Fig. 5.4C). We more 
stringently tested the importance of this disulfide bond by constructing a double mutant 
of leptin (C96S and C146S), which eliminated the disulfide bond completely. Ribosome 
display of leptin and leptin(C96S/C146S) showed no significant difference in leptin 
receptor binding under normal conditions (Fig. 5.4D). However, in high salt conditions (2 
M KCl), the disulfide bond-free leptin variant is “stickier” than wild type, as assessed by 
the signals in the selection wells without leptin receptors. Since non-specific hydrophobic 
interactions are amplified under high salt concentration
44
, our results suggest that the 
disulfide bond-free leptin variant is inherently less stable than wild-type leptin. Based on 
these results, the disulfide bond in leptin does not appear to be necessary for specific 
binding under normal conditions, but its presence enhances the stability of the molecule, 
which may be important both physiologically and biotechnologically. 
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5.3.4 CDR grafting of YN1 engenders specific binding of scFv to mouse ICAM-1 
Full-length R6.5 and YN1 IgG antibodies show specific binding to human ICAM-1 or 
mouse ICAM-1, respectively, in ELISA experiments (C. Greineder, personal 
communication), demonstrating that the parental antibodies are capable of ICAM-1 
binding and that the biotinylated human ICAM-1 and mouse ICAM-1 are functional. 
R6.5 and YN1 scFvs are in a VH-linker-VL orientation, where the linker consists of the 16 
amino acids AGGGGSGGGGSGGGGS. These scFvs have been successfully expressed 
in insect cells (C. Greineder, personal communication). Surprisingly, when tested in 
ribosome display, no specific binding to human or mouse ICAM-1 can be observed with 
either scFv (Fig. 5.5A, B). Different variations to the display protocol were tested, 
including the addition of disulfide bond enhancers, different blocking agents, varying 
concentration of receptors and ternary complexes, and different elution methods, but all 
without success. Since full-length R6.5 and YN1 produced in insect cells are clearly 
functional, we hypothesized that the apparent lack of binding in ribosome display stems 
from the poor stability or folding of R6.5 and YN1 scFvs during in vitro synthesis. We 
therefore decided to graft the CDRs of these antibodies onto more stable scFv 
frameworks. 
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Figure 5.5. Ribosome display of anti-ICAM-1 scFvs against ICAM-1. Biotinylated human or mouse 
ICAM-1 was immobilized on neutravidin-coated wells and blocked with (A, B) BSA or (C, D) BSA or 
casein. The binding of (A) R6.5, (B) YN1, and (C) hR6.5 scFv with ICAM-1 was shown by ribosome 
display after 23 cycles of PCR. (D) The binding of the stabilized and humanized hYN1 with ICAM-1 was 
shown by ribosome display. Reverse primer 18 was used for RT and products after 25 cycles of PCR are 
shown. 
 
Consensus human heavy- and light-chain frameworks from the HuCal library
35
 
were chosen. VH3 was chosen as the new heavy-chain framework for both R6.5 and YN1 
because it is most commonly seen in nature
35
, has exceptional stability
33,45
, and was also 
the most frequently selected heavy-chain framework in previous ribosome display 
experiments
8
. Vκ2 and Vκ4 were chosen as the light-chain frameworks for R6.5 and YN1, 
respectively, since they most closely resemble their original light-chain frameworks, and 
because Vκ domains are more stable than Vλ
33
. The heavy and light chains were 
connected in the same VH-linker-VL orientation, but this time with the 20-amino-acid 
linker AGGGSGGGGSGGGGSGGGGS since this linker has previously been used to 
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connect scFvs for selection in ribosome display
8
. Since the new frameworks were chosen 
from human consensus sequences, the stability-enhanced scFvs hR6.5 and hYN1 were 
also simultaneously humanized. Although ribosome display of hR6.5 showed no specific 
binding to human ICAM-1 (Fig. 5.5C), ribosome display of hYN1 showed strong and 
specific binding to mouse ICAM-1 (Fig. 5.5D). Moreover, the choice of blocking agent 
did not affect binding, although casein blocking showed a lower background than BSA 
blocking. For RT, tolAk (primer 18) was used as the reverse primer instead of the usual 
inner reverse primer pRDV_BbsI_r (primer 16) since preliminary RT experiments 
showed the strongest specific bands when tolAk was used. Our CDR grafting strategy has 
enabled successful display of hYN1 scFv in ribosome display format, as assessed by 
specific mouse ICAM-1 binding. 
 
5.4 Discussion 
The Off7 truncation study revealed the importance of shielding the hydrophobic core of 
ankyrin repeats with the capping repeats. The removal of both N- and C-terminal capping 
repeats (Off7I3) showed no specific MBP binding (Fig. 5.3). Based on the co-crystal 
structure
9
, the Off7-MBP interaction interface involves residues from the three internal 
repeats, but not the capping repeats (the single amino acid mutation in the N-cap is not 
responsible for binding)
9
. Therefore, the lack of Off7I3-MBP binding cannot be 
attributed to disruptions of the binding interface, but instead can be explained by the 
instability of the ankyrin repeat protein without the two capping repeats. With the 
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removal of either the N- or C-cap (Off7I3C or Off7NI3), no noticeable effect in binding 
to MBP was observed. However, our experimental conditions might not be stringent 
enough to explore any destabilization effect of a missing N- or C-cap, particularly since 
the tethered ribosome enhances the solubility of the displayed protein
44
. Nonetheless, our 
results underscore the important stabilizing effect of the hydrophilic caps in sealing the 
hydrophobic core of ankyrin repeat proteins
13
. 
On the other hand, the lack of specific binding by Off7NI2 and Off7I2C can be 
explained by disruptions to the Off7-MBP binding interface. Eight of the 12 potential 
interaction residues are located within the first and second internal repeats, while 10 of 
the 12 potential interaction residues are located within the second and third internal 
repeats
9
. It would be interesting to parse the energetic contributions of residues in each 
internal repeat by comparing MBP binding of Off7 with alanine substitutions for the 
interaction residues in the different internal repeats with ribosome display. Moreover, 
additional randomized repeats could be added to these fragments and selected for MBP 
binding to investigate if this step-wise approach could provide more stable and higher-
affinity binders than wild-type Off7. 
Ribosome display of SCI-57 showed specific binding to the insulin receptor (Fig. 
5.4A), although the signal-to-background ratio could be further improved. One 
improvement could be replacing PDI with other chaperones or isomerases to achieve a 
translation reaction condition for optimal disulfide bonds formation. In particular, the 
disulfide bond enhancers from NEB could be tested, since they were specifically 
designed to supplement the PURExpress translation system to enhance proper folding of 
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disulfide-bonded proteins. Another improvement would be to optimize the buffer pH for 
better insulin folding. Previous work indicates that a basic pH (between 9.5 and 11) 
facilitates proper folding of insulin
46,47
, and our work in engineering Lactococcus lactis to 
secrete SCI-57 (Chapter 6) also suggests that environmental pH plays an important role 
in obtaining bioactive molecules. 
The role of the intrachain disulfide bond on the biological activity of leptin 
remains unclear. While Imagawa et al.
43
 reported that eliminating the disulfide bond has 
no effect on human leptin signaling in mice, Müller et al.
40
 and Giese et al.
41
 
demonstrated the opposite is true in rat adipocytes in vitro and in mice with mouse leptin, 
respectively. Our results suggest the disulfide bond is dispensable for specific binding of 
human leptin to leptin receptors, but the stability of the leptin double mutant 
(C96S/C146S) is likely to be lower. It would be interesting to investigate if the 
importance of the disulfide bond is species-specific. Future work could include 
engineering leptin(C96S/C146S) to increase its stability. A ribosome display screen could 
be set up under high salt conditions, where ternary complexes would first be incubated 
with agarose beads displaying different hydrophobic ligands to remove poorly folded 
proteins
44
. The remaining unbound complexes could then be selected for binding against 
leptin, achieving the dual engineering objective of increasing stability while maintaining 
(or enhancing) affinity. 
The apparent lack of binding of hR6.5 to human ICAM-1 may be due to several 
reasons. It is possible that the VH3-Vκ2 framework is less stable than the VH3-Vκ4 
framework used for hYN1; however, the ribosome display experiment carried out by 
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Hanes et al.
8
 selected 12 useful binders with the VH3-Vκ2 framework, but only 1 with the 
VH3-Vκ4 framework. VH3-Vκ2 is thus clearly able to produce scFvs that are functional and 
stable enough for ribosome display. Since full-length R6.5 IgG exhibited specific binding 
to human ICAM-1, one possibility is that the VH3-Vκ2 framework cannot position the 
R6.5 CDRs in a conformation necessary for human ICAM-1 binding. Although the 
consensus human Vκ2 most closely resembles the wild-type R6.5 murine Vκ framework, 
other Vκ frameworks could be tested. Point mutations could be introduced into the 
framework of hR6.5 and screened for human ICAM-1 binding using ribosome display. 
In summary, we have refined the ribosome display protocol, and we have 
demonstrated that Off7 fragments, SCI-57, leptin, and hYN1 can be successfully 
displayed in this format to achieve specific binding to their respective targets. Using 
ribosome display, we have elucidated some of the stability determinants of these 
molecules, including the importance of capping repeats in DARPins, the role of disulfide 
bonds in agonist folding, and the choice of antibody framework for functional display in 
vitro. Furthermore, these proteins are ready to be further engineered by constructing 
DNA libraries from these starting templates and employing in vitro evolution to quickly 
identify mutants with new and improved properties. 
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CHAPTER 6 
A novel cell-based platform for oral delivery of insulin and 
leptin analogs 
Although the advances in biomolecular engineering described in previous chapters are 
critical to improving the potencies of therapeutic proteins, effective delivery systems are 
also essential to maximize the therapeutic benefit of these proteins in a clinical setting. 
 
6.1 Introduction 
Oral administration is one of the most convenient ways of delivering drugs, but 
therapeutic proteins often must be administered by an invasive method such as 
intravenous or subcutaneous injection
1
. Oral delivery of protein drugs is not generally 
feasible due to poor stability during passage through the gastrointestinal tract and low 
permeability across the intestinal wall, resulting in insufficient bioavailability. To 
increase oral bioavailability of proteins, various encapsulation strategies have been 
developed to protect the polypeptides from enzymatic digestion
2
, but most have 
encountered roadblocks that prevent them from advancing to a clinical setting
3
. Thus, 
better oral delivery systems are needed and one promising option is the microorganism 
Lactococcus lactis. 
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L. lactis is a Gram-positive bacterium widely used in the food industry for 
production of fermented products such as buttermilk and cheese and is therefore routinely 
consumed in these foods. L. lactis has a safe association with humans and has been 
proposed for use as a probiotic
4
. There has been increasing interest in the use of L. lactis 
as a mucosal delivery vehicle because it can survive passage through the stomach acid 
and contact with bile
5
 and it can be engineered to express and secrete targeting molecules 
and adjuvants
6
. In this host, antigens and DNA have been introduced for mucosal vaccine 
delivery, single-chain variable fragments (scFvs) for anti-infectives, and allergens for 
allergy prevention
7
. To address potential safety concerns of using live L. lactis in 
humans, the thymidylate synthase gene can be removed from the host genome, rendering 
the auxotrophic bacteria dependent on thymidine or thymine for survival and thus 
biologically contained
8
. In addition, since the recombinant protein is still locally 
produced when the bacteria reach the intestine, proteolytic degradation is attenuated. 
Recently, a study involving the use of interleukin-10-secreting L. lactis to treat Crohn’s 
disease has passed phase I clinical trials, supporting the notion that this live 
microorganism is a viable platform for oral protein delivery
9,10
. Here, we evaluated 
whether Lactococcus lactis would be capable of producing a bioactive insulin analog, 
human leptin, and insulin-leptin fusion proteins in vitro, and we further examined the in 
vivo performance of insulin-secreting L. lactis. Our work would open the door for using 
this host as a vehicle for oral delivery of protein therapeutics. 
In addition to clear benefits in the ease of administration and improved patient 
compliance, oral delivery of insulin also most accurately recapitulates normal 
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physiological delivery. After absorption in the intestine, orally delivered insulin reaches 
the portal system, more closely approximating what occurs in a non-diabetic individual
11
. 
Insulin is normally secreted by pancreatic β-cells in the form of a single-chain precursor, 
proinsulin, which is subsequently cleaved into separate A (21 residues) and B (30 
residues) chains
12
. However, this heterodimeric protein with three disulfide bonds (two 
interchain and one intrachain) would be challenging to synthesize using L. lactis. We 
therefore chose to heterologously express a single-chain insulin analog, SCI-57,which 
contains four substitutions in the A and B chains (one of which is present in Novalog® 
and another in Humalog®, rapid-acting insulin analogs already in clinical use by 
injection) and a 6-residue linker (GGGPRR) connecting these two chains, resulting in a 
single polypeptide 57 amino acids in length
13
. SCI-57 not only resembles the folding and 
biological activity of wild-type insulin, but it also has enhanced thermodynamic stability 
and reduced aggregation, and allows for simpler single-chain synthesis, making it an 
attractive insulin analog for oral delivery
13,14
. 
To further demonstrate the feasibility of using L. lactis as a general platform for 
oral delivery of protein drugs, we expressed another promising therapeutic protein, leptin, 
using the same system. Largely produced in white adipose tissue in healthy individuals, 
leptin acts mainly in the brain to control food intake and energy metabolism
15
. Leptin 
also targets non-hypothalamic tissues such as hematopoietic cells, T cells, adipocytes, 
skeletal muscles and hepatocytes
16
. Since its discovery two decades ago, leptin therapy 
has shown promises in treating a variety of diseases, including obesity
17
, lipodystrophy
18
, 
hypothalamic amenorrhea
19
, and diabetes
20
. In fact, leptin/insulin co-therapy in the 
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treatment of diabetes has recently been shown to have advantages over insulin 
monotherapy by providing equivalent glycemic control without the increase in body fat 
and up-regulation of cholesterologenic and lipogenic transcription factors and enzymes
21
. 
We further investigated if fusions of SCI-57 and leptin could be expressed with both 
proteins retaining their biological functions. Using leptin as a fusion partner has the 
additional advantage of facilitating intestinal absorption of secreted SCI-57, since 
receptor-bound leptin is absorbed by duodenal enterocytes and released on the basolateral 
side towards the bloodstream through clathrin-mediated endocytosis and subsequent 
intracellular transit and exocytosis
22,23
. Since fusion proteins have long been shown to be 
able to cross the intestinal endothelial layer through receptor-mediated transcytosis
24
, 
leptin represents a potential transcytosis enhancer as well as a diabetic therapeutic when 
delivered together with SCI-57. 
We inducibly expressed SCI-57, leptin, and SCI-57-leptin fusions in L. lactis 
strain NZ9000 using the NICE system, which is based on a two-component signaling 
system involved in the biosynthesis of the bacteriocin nisin
25
. Briefly, upon nisin-binding, 
NisK, a histidine kinase, autophosphorylates and transfers its phosphate group to NisR, 
which when activated induces transcription of a gene of interest under the control of 
promoter PnisA
26,27
. Previous studies of this system using a reporter gene show a linear 
dose–response curve for increasing amounts of nisin28. For in vivo delivery of L. lactis 
secreting SCI-57, the cultures were pre-induced with nisin before oral administration in 
order to achieve immediate therapeutic effect and also to eliminate the need for ingestion 
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of nisin. Protein expression has been shown to proceed for 10 hours after an one-hour 
nisin pulse-induction
29
. 
We demonstrate that, upon nisin induction, L. lactis can secrete SCI-57, leptin, 
and SCI-57-leptin fusions if the genes are fused to the usp45 signal peptide
30
, although 
bacterial growth rate depends on the timing of nisin induction. We further demonstrate 
that secreted SCI-57 and leptin are biologically active by assaying for insulin receptor 
signaling in an adipocyte cell line and leptin signaling in leptin receptor transfected cells, 
respectively. Interestingly, total expression does not correlate with bioactivity on cells, 
suggesting that proper folding of the polypeptide is a bottleneck in maximizing functional 
yield. We identify culture pH as an important regulator of bioactivity of SCI-57 and show 
that a neutral to slightly alkaline pH can significantly enhance the fraction of functional 
secreted SCI-57. Finally, we demonstrate reduction in blood glucose levels in a diabetic 
mouse model after oral administration of L. lactis secreting SCI-57, highlighting the 
potential of this novel cell-based platform for oral delivery of therapeutic proteins. 
 
6.2 Materials and methods 
6.2.1 Bacterial strains, plasmids, and growth conditions 
Bacterial strains and plasmids used in this work are listed in Table 6.1. Escherichia coli 
was grown in TY medium (8 g tryptone, 5 g yeast extract, and 5 g sodium chloride per 
liter) at 37
o
C with shaking and L. lactis was grown in M17 medium (Oxoid, Hamshire, 
UK) containing 0.5% glucose (GM17) at 30
o
C statically (i.e., without shaking). For in 
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vivo testing, L. lactis was resuspended in M9 medium (Amresco, Solon, OH) containing 
0.5% glucose buffered with 50 mM CO3
2-
/HCO3
-
 (BGM9). For buffering BGM9, 1M 
Na2CO3 and 1M NaHCO3 were mixed at a molar ratio of 1:19 and added at a final 
concentration of 50 mM. Solid media were prepared by adding agar (15 g/l) to the 
corresponding broth. Chloramphenicol (Cm) was used at a final concentration of 10 
μg/ml when culturing E. coli EC1000 or L. lactis NZ9000. 
Table 6.1. Bacterial strains and plasmids used. 
 Characteristics Sources 
Strains   
E. coli EC1000 RepA
+
 MC1000, KM
r
, carrying a single copy of the 
pWV01 repA gene in glgB 
Leenhouts, et 
al.
31
 
L. lactis NZ9000 L. lactis MG1363 (nisRK genes on the chromosome) Kuipers et 
al.
27
 
Plasmids   
pRDV:SCI-57 pRDV containing the SCI-57 gene; Amp
r
 Chapter 5 
pNZPnisA:CYTO-LLO Modified pNZ8048 containing PnisA promoter with 
His-tagged hly gene; Cm
r
 
Bahey-El-Din 
et al.
32
 
pNZPnisA:SCI-His Modified pNZ8048 containing PnisA promoter with 
RGS-His-tagged SCI-57 gene; Cm
r
 
This work 
pNZPnisA:usp-SCI-His Modified pNZ8048 containing PnisA promoter with 
RGS-His-tagged SCI-57 gene; fusion with usp45 signal 
peptide; Cm
r
 
This work 
pNZPnisA:usp-SCI Modified pNZ8048 containing PnisA promoter with 
SCI-57 gene without tag; fusion with usp45 signal 
peptide; Cm
r
 
This work 
pNZPnisA:usp-His-Lep Modified pNZ8048 containing PnisA promoter with 
RGS-His-tagged Leptin gene; fusion with usp45 signal 
peptide; Cm
r
 
This work 
pNZPnisA:usp-Lep Modified pNZ8048 containing PnisA promoter with 
Leptin gene without tag; fusion with usp45 signal 
peptide Cm
r
 
This work 
pNZPnisA:usp-His-SCI-
(linker)-Lep 
Modified pNZ8048 containing PnisA promoter with 
RGS-His-tagged SCI-57 and Leptin gene connected by a 
linker (one of the six); fusion with usp45 signal peptide 
Cm
r
 
This work 
pNZPnisA:usp-SCI-(linker)- Modified pNZ8048 containing PnisA promoter with This work 
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Lep SCI-57 and Leptin gene connected by a linker (one of 
the six) without tag; fusion with usp45 signal peptide 
Cm
r
 
pNZPthyA:usp-SCI Modified pNZ8048 containing PthyA promoter with 
SCI-57 gene without tag; fusion with usp45 signal 
peptide; Cm
r
 
This work 
pNZP23:usp-SCI Modified pNZ8048 containing P23 promoter with SCI-
57 gene without tag; fusion with usp45 signal peptide; 
Cm
r
 
This work 
pNZP1:usp-SCI Modified pNZ8048 containing P1 promoter with SCI-57 
gene without tag; fusion with usp45 signal peptide; Cm
r
 
This work 
 
6.2.2 DNA manipulations and transformations 
Plasmid DNA from E. coli was isolated with a Qiagen miniprep kit (Qiagen, Valencia, 
CA) following the standard procedure; plasmid DNA from L. lactis was isolated with the 
same protocol except for an additional incubation of the cells with 4 mg/ml lysozyme 
(USB Affymetrix, Cleveland, OH) in P1 buffer at 37
o
C for 30 min. Phusion high-fidelity 
DNA polymerase (NEB, Ipswich, MA) was used in all PCR reactions as recommended 
by the manufacturer. Restriction enzymes and T4 DNA ligase were purchased from NEB. 
DNA was transformed into E. coli as described previously
33
. DNA was transformed into 
L. lactis by electroporation as described in the manufacturer’s manual (MoBiTec, 
Göttingen, Germany).  
Primers used for DNA amplification are listed in Table 6.2. SCI-57 was PCR 
amplified from pRDV:SCI-57 using primers 1/3 and 2/3 in a preliminary step for 
building full constructs with and without usp45 signal peptide, respectively. The resulting 
PCR products were further amplified with primers 4/9 and 2/9, respectively, to add the 
usp45 signal peptide and RGS-His tag or only the RGS-His tag. The PnisA promoter 
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region was PCR amplified using primers 7/8, with 8 introducing an EcoRI site at the end 
of PnisA. The resulting product was fused to the SCI-57-RGS-His gene product with or 
without usp45 signal peptide by assembly PCR. The assembled products were gel-
purified and sequentially digested with KpnI and BglII. The digested products were then 
ligated into the similarly digested pNZPnisA:CYTO-LLO (plasmid courtesy of Dr. 
Cormac Gahan, University College Cork) using T4 DNA ligase to give pNZPnisA:usp-
SCI-His (Fig. 6.1A) and pNZPnisA:SCI-His. To remove the RGS-His tag from 
pNZPnisA:usp-SCI-His to obtain pNZPnisA:usp-SCI, primers 5/6 were used to PCR 
amplify from pRDV:SCI-57. The resulting SCI-57 gene product without the RGS-His tag 
was sequentially digested using KpnI and BspEI and the product was ligated into the 
similarly digested pNZPnisA:usp-SCI-His vector, giving rise to pNZPnisA:usp-SCI. 
Table 6.2. Primers used in this study. 
Primer 
Number 
Primer Name Nucleotide Sequence (5’  3’) a 
1 SCI57_usp_f TCCGGAGTTTACGCTTTCGTTAACCAGCAC 
2 SCI57_nousp_f CACTCAAAGAATTCATGTTCGTTAACCAGCAC 
3 SCI57_rgshis_r TGGTGGTGATGGTGGGATCCTCTGTTGCAGTAGTTTTCCA 
4 usp45_f GCACTCAAAGAATTCATGAAAAAAAAGATTATCTCAGCTATTTTAAT
GTCTACAGTGATACTTTCTGCTGCAGCCCCGTTGTCCGGAGTTTACG
CT 
5 uspSCI57_f CCCCGTTGTCCGGAGTTTACGCTTTCGTTAACCAGCAC 
6 stopSCI57_KpnI_r GAACTAGTGGTACCTCATTAGTTGCAGTAGTTTTCC 
7 PnisA_BglII_f TACAGCTCCAAGATCTAGTC 
8 PnisA_EcoRI_r CATGAATTCTTTGAGTGCCTCCTTATA 
9 rgshis_KpnI_r GAACTAGTGGTACCTCATTAATGATGGTGGTGATGGTGG 
10 rgshis_lep_BspEI_f ACTCCGGAGTTTACGCTAGAGGATCCCACCATCACCACCATCATGTG
CCCATCCAAAAAG 
11 lep_BspEI_f CCCCGTTGTCCGGAGTTTACGCTGTGCCCATCCAAAAAG 
12 lep_KpnI_r GAACTAGTGGTACCTTATCAGCACCCAGGGCTG 
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13 GSshort_f ACGGTGGCAGTGGTGTGCCCATCCAAAAAGTCCA 
14 GSshort_r ACACCACTGCCACCGTTGCAGTAGTTTTCCAGCT 
15 GSmedium_f CAGGCGGTAGTGGTGGCAGTGTGCCCATCCAAAAAGTCCA 
16 GSmedium_r CCACCACTACCGCCTGCACCGTTGCAGTAGTTTTCCAGCT 
17 GSlong_f GCGGCGGTGCAGGAGGCGGTAGTGGTGTGCCCATCCAAAAAGTCCA 
18 GSlong_r CCTCCTGCACCGCCGCTTCCGCCACCGTTGCAGTAGTTTTCCAGCT 
19 helical_f GCAGCTAAAGAAGCAGCCGCTAAAGCTGTGCCCATCCAAAAAGTCCA 
20 helical_r GGCTGCTTCTTTAGCTGCAGCTTCTGCGTTGCAGTAGTTTTCCAGCT 
21 TCres_f CCAGATGGTGACATTGATGGAAGTGTGCCCATCCAAAAAGTCCA 
22 TCres_r ATCAATGTCACCATCTGGACTACCGTTGCAGTAGTTTTCCAGCT 
23 TCresThrom_f CTTGTTCCACGTGGTTCTGGAAGTGTGCCCATCCAAAAAGTCCA 
24 TCresThrom_r AGAACCACGTGGAACAAGACTACCGTTGCAGTAGTTTTCCAGCT 
25 PthyA_BglII_f AGCTCCAGATCTAGAAAAAGCAGCTGTTGAATTAG 
26 PthyA_EcoRI_r TTTCATGAATTCGAAATTTTCCTATCTTTTTTAATTCCCTTC 
27 P23_BglII_f AGCTCCAGATCTGATGGGGATAAAAGTGACCCG 
28 P23_EcoRI_r TTTCATGAATTCATATTTGGCCTCCCTTTTTAATTTAATTC 
29 P1_BglII_f AGCTCCAGATCTGATTAAAGTCATCTTACCTCTTTTATTAG 
30 P1_asse_r ATTTCTAGTGGGAAACCGTTGTGGTCTCCCGATACTTGTATTATAAC
ATATCTACAAAGG 
31 P1_asse_end_EcoRI
_r 
TTCATGAATTCGTATATCTCCTTTCTAAAGTTAAACAAAATTATTTC
TAGTGGGAAACCG 
 
a
 Restriction sites are underlined. 
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Figure 6.1. Schematic representation of the various constructs used in this study. Representative maps of 
(A) pNZPnisA:usp-SCI-His, (B) pNZPnisA:usp-His-Lep and (C) pNZPnisA:usp-SCI-GSshort-Lep 
showing promoter PnisA, usp45 signal peptide, SCI-57 gene, human leptin gene (Lep), GS short (GGSG) 
linker and RGS-His tag in the modified pNZ8048 backbone. All plasmids were maintained in E. coli 
EC1000 and subsequently transformed into electrocompetent L. lactis NZ9000.  
 
To construct pNZPnisA:usp-His-Lep (Fig. 6.1B) and pNZPnisA:usp-Lep, human 
leptin cDNA (GenBank accession no. BC069452; Open Biosystems, Waltham, MA) was 
PCR amplified using primers 10/12 and 11/12 respectively. The resulting products were 
digested with KpnI and BspEI and the products were ligated into similarly digested 
pNZPnisA:usp-SCI. For SCI-57-leptin fusion plasmids, six different linkers were 
constructed: GGSG (GS short), GAGGSGGS (GS medium), GGGSGGAGGGSG (GS 
long), AEAAAKEAAAKA (helical), GSPDGDIDGS (trypsin/chymotrypsin resistant), 
and GSLVPRGSGS (trypsin/chymotrypsin resistant and thrombin cleavable). 
pNZPnisA:usp-SCI-(linker)-Lep (Fig. 6.1C) was constructed by first PCR amplifying the 
two pieces for assembly PCR, 1) pNZPnisA:SCI amplified with primers 5/14, 5/16, 5/18, 
5/20, 5/22 and 5/24 for linker-fused SCI-57, and 2) leptin cDNA amplified with primers 
13/12, 15/12, 17/12, 19/12, 21/12 and 23/12 for linker-fused leptin. The two pieces for 
each unique linker were then assembled in assembly PCR reactions, digested with KpnI 
and BspEI, and ligated into similarly digested pNZPnisA:usp-SCI. 
To construct pNZPthyA:usp-SCI and pNZP23:usp-SCI, the promoter from the L. 
lactis thyA gene PthyA, and promoter P23, were isolated from NZ9000 by colony PCR 
with primers 25/26 and 27/28, respectively. To construct pNZP1:usp-SCI, the promoter 
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P1 was amplified from NZ9000 by colony PCR with primers 29/30, followed by a second 
PCR with primers 29/31. The resulting products were digested by EcoRI and BglII and 
ligated into similarly digested pNZPnisA:usp-SCI. All ligation mixtures were 
transformed into chemically competent E. coli EC1000 (strain courtesy of Dr. Jan Kok, 
University of Groningen). After confirming the constructs by DNA sequencing, the 
plasmids were transformed into electrocompetent L. lactis NZ9000. 
 
6.2.3 Growth curve determination 
Overnight cultures of L. lactis NZ9000(pNZPnisA:usp-SCI-His or pNZPnisA:usp-His-
Lep) were diluted 1:25 into fresh GM17Cm medium. Nisin (Sigma, St. Louis, MO) at 
various concentrations was added at indicated times. Cultures were grown statically at 
30
o
C up to 4 h after the latest induction point. Growth curves were determined by taking 
measurements of the optical density at 600 nm (OD600) on a plate reader (Infinite M200, 
Tecan, Männedorf, Switzerland). The growth curves were fitted in Matlab (MathWorks, 
Natick, MA) using a logistic equation, K/(1 + e
-r(t-l)
), where r is the growth rate, and the 
doubling times were calculated using ln(2)/r. 
 
6.2.4 Nisin induction and detection of secreted SCI-57 and leptin 
Overnight cultures of L. lactis NZ9000(pNZPnisA:usp-SCI-His, pNZPnisA:SCI-His, 
pNZPnisA:usp-His-Lep, pNZPnisA:usp-SCI, or pNZPthyA:usp-SCI) were diluted 1:25 
into fresh GM17Cm medium. For buffering with sodium phosphates, 1 M NaH2PO4 and 
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1 M Na2HPO4 were mixed at a molar ratio of 1:19 and added at a final concentration of 
50 mM to achieve the desired pH. Cultures were grown to mid-log phase (OD600 ≈ 0.4–
0.5) for 1.5 to 3.5 h and induced with 1 or 10 ng/ml nisin. Cultures were grown for a total 
of 7.5 h. When investigating the effect of pH modulation, 2% or 10% culture volume of 5 
N NaOH was added. At specified time points, aliquots were taken and OD600 and pH 
were measured. Cells were removed from the supernatant by a 10-min centrifugation at 
4
o
C and 5,000g. The supernatant was then passed through a 0.22-μm filter (Millipore, 
Billerica, MA) to remove any cells, and concentrated 20-fold in a 3-kDa cutoff filter 
(Millipore). 15.6 μl of concentrated or unconcentrated supernatant was mixed with 
reducing agent and lithium dodecyl sulfate (LDS) sample buffer for analysis by SDS-
PAGE in a 12% NuPAGE
®
 Bis-Tris gel as described by the manufacturer (Invitrogen, 
Carlsbad, CA). Proteins were then transferred to a nitrocellulose membrane (Invitrogen). 
RGS-His-tagged proteins were analyzed by Western blotting with the RGS-His antibody 
(Qiagen, #34610) or insulin antibody (Santa Cruz Biotechnology, Dallas, TX, sc-9168) 
and then IRDye800-conjugated goat-anti-mouse immunoglobulin G secondary antibody 
(Rockland, Gilbertsville, PA, #610-131-121) or goat-anti-rabbit immunoglobulin G 
secondary antibody (Rockland, #611–132–122). The blot was then scanned on an 
Odyssey infrared imager (LI-COR Biosciences, Lincoln, NE).  
 
6.2.5 Bioactivity of secreted SCI-57 on 3T3-L1 cells 
The murine 3T3-L1 preadipocyte cell line (courtesy of Dr. Christopher Chen, University 
of Pennsylvania) was maintained in Dulbecco’s modified Eagle’s medium (DMEM; 
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Invitrogen) supplemented with 10% calf serum (HyClone, Logan, UT), penicillin (100 
U/ml), and streptomycin (100 μg/ml), with a change of medium every 3 days. The cells 
were differentiated using a slight modification of a published method
34
. Briefly, 3T3-L1 
preadipocytes were allowed to grow for 2 days post-confluency and were then 
differentiated by addition of the same medium containing isobutylmethylxanthine (500 
μM), dexamethasone (1 μM), and insulin (1 μg/ml) for 2 days and then medium 
containing only insulin additive for 3 additional days. The medium was then changed 
every 3 days until the cells contained large oil locules characteristic of fully differentiated 
adipocytes, typically around 9–12 days. 
 3T3-L1 preadipocytes were seeded on a six-well plate and differentiated as 
described above. Fully differentiated 3T3-L1 adipocytes were serum starved overnight 
with 0.5% calf serum in DMEM. Supernatant of L. lactis NZ9000(pNZPnisA:usp-SCI-
His, pNZPnisA:usp-SCI or pNZPnisA:usp-SCI-(linker)-Lep) was prepared as described 
above. 100 μl of concentrated supernatant was added along with 2 ml DMEM to the 
serum-starved 3T3-L1 cells. Dilution into DMEM also ensured that all signaling assays 
were performed at near-neutral pH. After a 15-min incubation at 37
o
C, cells were washed 
once in PBS and lysed in cell extraction buffer (Invitrogen) supplemented with a protease 
inhibitor cocktail (Sigma, #P8340), phosphatase inhibitor cocktails (Sigma, #P0044 and 
#P5726), and phenylmethanesulfonylfluoride (Amresco, Solon, OH). Cell debris was 
removed by centrifugation at 14,000g and 4
o
C for 15 min. Cell lysate (20–50 μg, but 
constant for a given experiment) was mixed with reducing agent and LDS sample buffer 
for analysis by SDS-PAGE in a 4–12% Bis-Tris gel (Invitrogen). Proteins were then 
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transferred to a nitrocellulose membrane. Phosphorylated Akt (p-Akt) was quantified by 
Western blotting, as described above, using p-Akt(Ser473) or total Akt primary 
antibodies (Cell Signaling Technology, Danvers, MA, #4051 and #9272, respectively) 
and then IRDye800-conjugated goat-anti-mouse or goat-anti-rabbit immunoglobulin G 
secondary antibody (same as above). The proteins were quantified by their relative 
intensities from the IR800 channel on the infrared imager. 
 
6.2.6 Bioactivity of secreted leptin on transfected HEK293 cells 
Human embryonic kidney (HEK293) cells (Clontech #630931, Mountain View, CA) 
were maintained in DMEM supplemented with 10% fetal bovine serum (HyClone), 
penicillin (100 U/ml), and streptomycin (100 μg/ml). Transient transfection was carried 
out as described
35
 but with modifications. Cells were seeded on a six-well plate at a 
density of 10
4
 cells/ml with 2 ml per well. When the cells were around 50–80% 
confluent, they were transfected by adding FuGENE
®
 6 (Roche, Indianapolis, IN) and 
700 ng leptin receptor (pcDNA3:hOBRb; courtesy of Dr. Christian Bjorbaek, Harvard 
Medical School), 300 ng signal transducer and activator of transcription-3 (STAT3)-
activated firefly luciferase reporter (4xM67 pTATA TK-Luc; Addgene #8688, 
Cambridge, MA), and 0.01 ng renilla luciferase reporter (pcDNA-RLuc8; courtesy of Dr. 
Andrew Tsourkas, University of Pennsylvania) at a 3:1 FuGENE (µl):total DNA (µg) 
ratio. After 24 h, the media was changed into DMEM with 1% FBS containing either 
commercial leptin (Peprotech, Rocky Hill, NJ) or 50 μl of unconcentrated supernatant 
from L. lactis NZ9000(pNZPnisA:usp-Lep-His, pNZPnisA:usp-Lep, pNZPnisA:usp-His-
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SCI-(linker)-Lep, or pNZPnisA:usp-SCI-(linker)-Lep) culture, prepared as described 
above. After a 24-h incubation at 37
o
C, cells were washed once in PBS and lysed in 500 
μl passive lysis buffer (Promega, Madison, WI) for 15 min at room temperature. After 
centrifugation at 20,000g for 2 min, the supernatants were assayed with a dual-luciferase 
reporter assay (Promega) as described by the manufacturer using the luciferase feature on 
the Tecan plate reader (no attenuation; 0 ms settle time; 5000 ms integration time). 
 
6.2.7 In vivo administration of L. lactis to diabetic mice 
 Streptozotocin was injected intraperitoneally into 5 C57BL/6 mice (male, 10–12 
weeks old; The Jackson Laboratory; courtesy of Dr. Ali Naji, University of Pennsylvania) 
to induce diabetes one week before the inoculation experiments. Food and fluid were 
supplied ad libitum and tail blood glucose level was monitored daily with a glucometer 
(One Touch Ultra II). All animal procedures were carried out in accordance with 
Institutional Animal Care and Use Committee guidelines (IACUC protocol #803168). 
Overnight cultures of L. lactis NZ9000(pNZPnisA:usp-SCI or pNZPthyA:usp-
SCI) were diluted 1:25 into fresh GM17Cm medium and grown at 30
o
C until mid-log 
phase. The nisin-inducible culture was induced with 10 ng/ml nisin for 1 h. Both cultures 
were harvested by centrifugation at 5000g for 10 min at room temperature, and then 
resuspended in BGM9 media to a final concentration of 2×10
10
 to 2×10
11
 CFU/ml. 
Intragastric inoculation was performed by administering 500 μl L. lactis by oral gavage, 
using two mice for each culture. Tail blood glucose was measured before L. lactis 
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administration, 1 h, 2 h, 3 h, and 24 h after inoculation. A control mouse received oral 
gavage of 1 U insulin solution or no treatment. 
 
6.3 Results 
6.3.1 Effect of nisin addition on L. lactis growth rate 
The growth rate of L. lactis NZ9000(pNZPnisA:usp-SCI-His) as a function of inducer 
concentration and time of induction was monitored by taking OD600 measurements every 
30 min for 7 h. When added at 1 h, nisin affected cell growth in a dose-dependent 
manner, with the largest inhibitory effect occurring at the highest inducer concentration 
(10 ng/ml, Fig. 6.2A). Lower OD600 readings were observed as early as the first time 
point after nisin addition (within 30 min) and this attenuated signal persisted until the last 
time point (7 h), indicating that nisin acted immediately and continuously on the culture 
until saturation. However, when the culture was induced at 2.5 h, the extent to which 
nisin adversely affected growth rate and saturated culture density was noticeably 
mitigated (Fig. 6.2B). We therefore tested a wider range of inducer concentrations (0.001, 
0.01, 0.1, 0.5, 1, 5, or 10 ng/ml nisin) and induction start times (0.5, 1, 1.5, 2, 2.5, or 3 h) 
and we quantified the doubling time for each combination of these two variables (Fig. 
6.2C). Low nisin concentrations (≤ 0.1 ng/ml) had a minimal effect on cell growth at all 
induction times. High nisin concentrations (≥ 0.5 ng/ml) resulted in significantly longer 
doubling times at early induction start times, but there was a clear inverse correlation 
between induction start time and culture doubling time. The effect of nisin addition on 
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the growth rate of L. lactis NZ9000(pNZPnisA:usp-His-Lep) followed a similar trend, 
but the effect of nisin inhibition at each induction start time was greater for nisin 
concentrations ≥ 0.1 ng/ml, resulting in lower final culture densities (Fig. 6.2D, E) . 
 
Figure 6.2. Effect of nisin concentration and induction time on growth rate. Various nisin concentrations 
(♦: no nisin; ■: 0.001 ng/ml; ▲: 0.01 ng/ml; ●: 0.1 ng/ml; ◊: 0.5 ng/ml; □: 1 ng/ml; ∆: 5 ng/ml; ○: 10 
ng/ml) were added at (A) 1 h and (B) 2.5 h after 1:25 dilution of an overnight culture of 
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NZ9000(pNZPnisA:usp-SCI-His). Cultures were grown statically at 30
o
C for a total of 7 h. Growth was 
determined by measuring the optical density at 600 nm over time. (C) The growth curves were fitted to a 
logistic equation K/(1 + e
-r(t-l)
), where r is the growth rate, and the doubling times were calculated from 
ln(2)/r. *P < 0.05 and **P < 0.01 for statistical comparison of doubling times after 0.5 and 3 h induction at 
each nisin concentration using a one-tailed Student’s t-test. (D, E) Effect of nisin concentration on growth 
rate of NZ9000(pNZPnisA:usp-His-Lep). Various nisin concentrations (same symbols as A, B) were added 
at (D) 1 h and (E) 2.5 h after dilution of overnight culture.  
 
6.3.2 Secretion of SCI-57 and leptin by L. lactis into supernatant 
L. lactis NZ9000(pNZPnisA:usp-SCI-His or pNZPnisA:SCI-His) were grown and 
induced with 0, 1, or 10 ng/ml nisin at 2.5 h. The 2.5-h induction start time was initially 
chosen because it seemed to balance growth rate (cultures are minimally affected even at 
10 ng/ml nisin) and total induction time (SCI-57 expression can still proceed for several 
hours in a log-phase culture, Fig. 6.2). After induction for 4 additional hours, cells were 
removed by centrifugation and secreted SCI-57 was detected via the C-terminal RGS-His 
tag using Western blotting. Bands of ≈7–8 kDa (expected: 7.5 kDa) were detected in 
cultures induced with 1 or 10 ng/ml nisin, while no signal was detected in the nisin-free 
control (Fig. 6.3A). This confirms that there is no detectable leaky expression from the 
PnisA promoter and that nisin is necessary for inducing SCI-57 expression. In addition, 
no signal was detected in the supernatant from L. lactis harboring pNZPnisA:SCI-His 
(without usp45 signal peptide), whether or not nisin was added, indicating that the usp45 
signal peptide is necessary for secretion of the downstream protein, which is in agreement 
with previous studies
36,37
. The molecular weight of RGS-His-tagged SCI-57 with the 
usp45 signal peptide is 10.3 kDa. All of our observed bands are below the 10 kDa mark, 
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indicating that the usp45 signal peptide has been cleaved, as expected, from SCI-57 
before or during secretion into the supernatant (Fig. 6.3A). Since acidification of the 
medium by L. lactis may impact cell growth and/or protein secretion, we also tested the 
effect of adding sodium hydroxide or sodium phosphates to GM17 media. There was no 
improvement in growth rate and a slight decrease in secreted SCI-57 (Fig. 6.3A). 
 
Figure 6.3. Western blot detection of SCI-57 and leptin in L. lactis supernatant. (A) Cultures of 
NZ9000(pNZPnisA:usp-SCI-His or pNZPnisA:SCI-His) were grown in GM17Cm media with or without 
50 mM sodium phosphates for 2.5 h, and then induced with 1 or 10 ng/ml nisin for an additional 4 h. For 
modulating pH with NaOH, 10% culture volume of 5 N NaOH was added at 1.5 h after induction. Anti-
RGS-His antibody was used to detect SCI-57 secreted into the supernatant. The molecular weight of RGS-
His-tagged SCI-57, after cleavage of usp45 signal peptide, is 7.5 kDa. (B) NZ9000(pNZPnisA:usp-His-
Lep) cultures were induced with 10 ng/ml nisin at 1.5, 2.5 or 3.5 h after dilution of overnight cultures and 
grown for a total of 7.5 h. Supernatants were concentrated 20-fold. The molecular weight of RGS-His-
tagged leptin is 17 kDa. 
 
Similarly, L. lactis NZ9000(pNZPnisA:usp-His-Lep) was grown and induced with 
10 ng/ml nisin at 1.5, 2.5 or 3.5 h to investigate the effect of induction time on protein 
expression. Western blotting of concentrated supernatant via the N-terminal RGS-His tag 
showed bands between 15 and 20 kDa in nisin-induced cultures, suggesting the 
successful expression of RGS-His-tagged leptin (after cleavage of usp45 signal peptide) 
with an expected size of 17 kDa (Fig. 6.3B). Delaying the induction start time from 1.5 h 
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to 3.5 h resulted in an increase in culture density, which is in agreement with Fig. 6.2. 
The increase in leptin secretion, however, is modest, possibly due to the fact that the 
increased growth rate is offset by the reduced amount of time for protein synthesis before 
the culture reaches stationary phase. 
 
6.3.3 Bioactivity of secreted SCI-57 on adipocytes 
To investigate if secreted SCI-57 is properly folded and biologically active, its ability to 
functionally signal was tested on differentiated 3T3-L1 adipocytes. Insulin signals by 
binding and activating cell-surface insulin receptors, which phosphorylates adapter 
proteins such as the insulin receptor substrate (IRS) family, which then recruit and 
activate downstream effector molecules. One such effector protein that is required for 
insulin signaling is phosphatidylinositol 3-kinase (PI 3-kinase), which phosphorylates 
Akt
38,39
. In our assay, we added conditioned L. lactis medium to differentiated 3T3-L1 
adipocytes and used p-Akt as a metric of insulin signaling. 
 Serum-starved, fully differentiated 3T3-L1 adipocytes were incubated with 1 nM 
commercial insulin solution or 100 μl 20-fold-concentrated supernatant for 15 min at 
37
o
C and p-Akt was detected by Western blotting of cell lysates. Both commercial insulin 
and supernatant from induced NZ9000(pNZPnisA:usp-SCI-His) treated with NaOH 
showed a strong p-Akt signal (Fig. 6.4A,B). Importantly, no signals could be seen in 
supernatants from uninduced NZ9000(pNZPnisA:usp-SCI-His) treated with NaOH or 
from induced cells without buffering or with sodium phosphate buffering, even though 
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these latter cultures clearly secrete the full-length polypeptide (Fig. 6.3A). These results 
indicate that functional folding of secreted SCI-57 is an important bottleneck in obtaining 
bioactive product from L. lactis, but this bottleneck is dependent on the pH and buffer 
conditions in the medium. To estimate the concentration of active RGS-His-tagged SCI-
57 in the supernatant, we quantified p-Akt signals from the Western blots of three 
independent experiments and found the signal of SCI-57 to be roughly equivalent to 1 
nM commercial insulin (Fig. 6.4B). Since 100 μl of 20-fold-concentrated supernatant was 
added to 2 ml DMEM, the original concentration of functional SCI-57 secreted by 
NZ9000(pNZPnisA:uspSCI-57his) was approximately 1 nM. 
 
Figure 6.4. In vitro biological acitivity of secreted SCI-57. (A) Representative blot of p-Akt signaling. 
Supernatant of NZ9000(pNZPnisA:usp-SCI-His) cultures were prepared as described, and concentrated 
supernatant (100 μl) was added to 2 ml DMEM on fully differentiated, serum-starved 3T3-L1 adipocytes. 
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Cell lysates were blotted for p-Akt(Ser473). (B) Quantification of p-Akt signaling from three independent 
experiments. Relative intensities are shown by normalizing to the positive control (1 nM commercial 
insulin). 
**
P < 0.01. (C) Biological activity of secreted SCI-57 without the RGS-His tag. Representative 
Western blot showing relative p-Akt signals on differentiated 3T3-L1 adipocytes stimulated by supernatant 
from NZ9000 [pNZPnisA:usp-SCI (no RGS-His tag)] cultures. (D) Quantification of p-Akt signals from 
two independent experiments. Notation for the last nine samples is: medium composition, nisin 
concentration. 
*
P < 0.05 and 
**
P < 0.01. 
 
In addition, we investigated whether the addition of the RGS-His tag, which is 
convenient for detection and assay development but not desirable for eventual in vivo 
applications, has any effect on the bioactivity of SCI-57. The p-Akt signaling 
experiments on 3T3-L1 adipocytes were repeated with conditioned media from 
NZ9000(pNZPnisA:usp-SCI) cultures. Interestingly, not only was p-Akt signaling much 
stronger for cultures treated with NaOH but it was now also detectable using untreated 
cultures or cultures with phosphate buffer (Fig. 6.4C,D). This suggests that the RGS-His 
tag adversely affects insulin receptor binding and/or SCI-57 folding. 
 
6.3.4 Bioactivity of secreted leptin and SCI-57-leptin fusions 
Leptin binds to the long-form leptin receptor (OBRb) on the cell surface, which in turn 
results in activation of the JAK/STAT signaling pathway, leading to phosphorylation and 
activation of downstream STAT3
40
. In our assay, HEK293 cells were co-transfected with 
leptin receptor (OBRb), STAT3-activated firefly luciferase (FLuc), and constitutively 
expressed renilla luciferase (RLuc). HEK293 cells were incubated with 1 nM or 10 nM 
commercial leptin or 50 μl 20-fold-concentrated supernatant for 24 h at 37oC. The 
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specific activity of leptin can be quantified by dividing the FLuc signal by the RLuc 
signal to normalize for transfection efficiency. Supernatants from the two induced 
NZ9000(pNZPnisA:usp-His-Lep and pNZPnisA:usp-Lep) cultures showed at least a 3-
fold increase in FLuc/RLuc signal compared to uninduced controls, indicating that 
secreted leptin exhibited biological activity (Fig. 6.5A). Again, the RGS-His tag seems to 
adversely affect leptin folding and/or receptor binding. Based on the controls with 0.1 nM 
and 1 nM commercial leptin, the concentrations of RGS-His-tagged leptin and untagged 
leptin secreted by L. lactis were approximately 0.2 nM and 2 nM, respectively. 
 
Figure 6.5. In vitro biological activity of secreted leptin and SCI-57-leptin fusions. (A) Commercial leptin 
or 50 μl 20-fold concentrated supernatant of NZ9000(pNZPnisA:usp-His-Lep or pNZPnisA:usp-Lep) 
cultures induced at 2.5 h for an additional 4 h were added to 2 ml DMEM on transfected HEK293 cells. 
Leptin bioactivity was determined by its downstream STAT3 transcriptional activity of firefly luciferase 
(FLuc). Results were normalized to renilla luciferase (RLuc) signal to account for differences in 
transfection efficiency. (B) Leptin bioactivity of secreted SCI-57-leptin fusion proteins was determined by 
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adding 50 μl unbuffered concentrated supernatant of NZ9000(pNZPnisA:usp-His-SCI-(linker)-Lep) or 
NaOH buffered concentrated supernatant of NZ9000(pNZPnisA:usp-SCI-(linker)-Lep) to transfected 
HEK293 cells. Notation for the samples is: linker type, RGSHis-tagged proteins or NaOH buffered culture, 
nisin concentration. (C, D) Insulin bioactivity of secreted SCI-57-leptin fusion proteins was determined by 
adding 100 μl NaOH buffered concentrated supernatant of NZ9000(pNZPnisA:usp-SCI-(linker)-Lep) to 
stimulate differentiated 3T3-L1 adipocytes. 
 
 Next, we created 6 different SCI-57-leptin fusion proteins to identify a suitable 
amino acid linker for the covalent attachment of SCI-57 and leptin. This peptide linkage 
is preferable to chemical conjugation because the entire fusion protein can then be 
synthesized by L. lactis. The C-terminus of SCI-57 was fused to the N-terminus of leptin 
because leptin contains two cysteine residues that form an essential disulfide bond 
between the middle of the protein and the C-terminus
41
. It has been shown that C-
terminal fusions of leptin adversely affect production and secretion of the protein
42
, but 
C-terminal fusions of SCI-57 in ribosome display format showed no apparent adverse 
effects in receptor binding (Chapter 5). We tested 3 glycine-serine flexible linkers GGSG 
(GS short), GAGGSGGS (GS medium), and GGGSGGAGGGSG (GS long), as well as 
an α-helical linker AEAAAKEAAAKA43 (helical), a flexible linker with resistance to 
intestinal enzymes trypsin and chymotrypsin GSPDGDIDGS
44
 (TCres), and a thrombin-
cleavable linker with trypsin/chymotrypsin resistance GSLVPRGSGS
44,45
 (TCresThrom), 
for their abilities in retaining bioactivity of the two fusion partners, SCI-57 and leptin. 
Leptin bioactivity from NZ9000(pNZPnisA:usp-His-SCI-(linker)-Lep or pNZPnisA:usp-
SCI-(linker)-Lep) culture supernatants was assayed using transfected HEK293 cells as 
described above. RGS-His-tagged SCI-57-leptin fusions gave between 2.0- and 3.9-fold 
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increases over uninduced controls, while untagged fusions with NaOH buffering gave 
slightly higher signals of between 2.6 and 5.7-fold increase (Fig. 6.5B). The leptin in the 
SCI-57-leptin fusion proteins was clearly functional, and its biological activity did not 
seem to be negatively affected by NaOH buffering (10% culture volume of 5 N NaOH 
was added 1.5 h after induction to cultures secreting untagged fusion proteins). Similarly, 
insulin bioactivity from NaOH-treated NZ9000(pNZPnisA:usp-SCI-(linker)-Lep) 
cultures was assayed on differentiated 3T3-L1 adipocytes (Fig. 6.5C, D), and all 6 SCI-
57-leptin fusion proteins showed a specific and similar p-Akt signal over uninduced 
control. Based on these in vitro bioassays, all 6 linkers were able to retain similar 
functional activity of both SCI-57 and leptin. Compared to the positive controls using 
commercial insulin and leptin, the concentrations of secreted untagged SCI-57-leptin 
fusion proteins were about 1 nM. 
 
6.3.5 Effect of pH modulation on functional SCI-57 expression 
The previous results (Figs. 6.3 and 6.4) indicate that the biological activity of SCI-57 is 
more heavily affected by the medium pH and buffering conditions than by the overall 
protein secretion level. We therefore investigated the insulin biological activity of various 
conditioned L. lactis media, each subject to a different pH profile, on 3T3-L1 adipocytes. 
Two modes of pH modulation were tested: (1) continuous control, in which 2% culture 
volume of 5 N NaOH was added hourly for 5 h; or (2) a single pulse, in which 10% 
culture volume of 5 N NaOH was added once at the indicated time after induction. In 
effect, the same total amount of NaOH was added in each case. As seen from the OD600 
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readings (Fig. 6.6A), early addition of NaOH (continuous or single dose at 0.5 h) has an 
inhibitory effect on growth. Corresponding to the lower OD600 readings, the amount of 
secreted SCI-57 detected for culture with early NaOH addition was also lower on a per-
volume basis. However, when the biological activity of these samples was tested using 
our p-Akt signaling assay on 3T3-L1 adipocytes (Fig. 6.6B, C), the observed trend was 
the opposite of that seen in Fig. 6.6A. Cultures grown with early NaOH addition secrete 
similar, if not higher, levels of functional SCI-57 than cultures grown with late NaOH 
addition. This further confirms that the biological activity of secreted SCI-57 is more 
heavily affected by buffering conditions than total secretion level and suggests that earlier 
counterbalancing of the natural medium acidification increases the fraction of functional 
SCI-57 molecules. 
 
Figure 6.6. Effect of temporal pH modulation on SCI-57 secretion and bioactivity. (A) Western blot 
showing secreted SCI-57 with different NaOH treatments, with final OD600 readings given below. Cultures 
of NZ9000(pNZPnisA:usp-SCI-His) were induced at 2.5 h with 0 or 10 ng/ml nisin for an additional 4 h. 
For continuous pH regulation with NaOH, 2% culture volume of 5N NaOH was added at 1.5, 2.5, 3.5, 4.5, 
and 5.5 h after the 1:25 dilution. For single-dose modulation with NaOH, 10% culture volume of 5 N 
NaOH was added at 0.5, 1.5, or 2.5 h after nisin induction. RGS-His antibody was used to detect the RGS-
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His-tagged SCI-57 secreted into the supernatant. (B) Representative Western blot showing relative p-Akt 
signals on differentiated 3T3-L1 adipocytes stimulated by concentrated supernatant in different buffering 
conditions. (C) Quantification of p-Akt signals, as shown in (B), from two independent experiments. 
Notation for the last eight samples is: NaOH addition time after nisin induction, nisin concentration. 
*
P < 
0.05 and 
**
P < 0.01. 
 
6.3.6 Oral delivery of SCI-57-secreting L. lactis to diabetic mice 
Finally, a pilot study was conducted to test the performance of SCI-57-secreting L. lactis 
upon oral delivery to diabetic mice. Since a constitutive expression system might offer 
advantages in vivo, we evaluated L. lactis strains with both inducible and constitutive 
expression of SCI-57; specifically, the nisin-inducible promoter PnisA was compared to 
the constitutive promoter PthyA. PthyA was chosen because it had been successfully used 
to secrete interleukin-10 in vivo
8
.  In addition, PthyA showed the highest level of SCI-57 
secretion when compared to other strong lactococcal constitutive promoters P1
46
, P23
47
, 
and P59
47
 by Western blotting (Fig. 6.7A). PthyA was able to secrete full-length untagged 
SCI-57, though at a slightly lower level compared to PnisA, (Fig. 6.7B). 
 Five streptozotocin (STZ)-induced diabetic mice were used to study the effect of 
using L. lactis as an oral delivery platform for the delivery of SCI-57. Both inducible 
(PnisA) and constitutive (PthyA) strains of L. lactis were used; in the inducible case, 10 
ng/ml nisin was used for induction 1 h prior to in vivo administration. The cultures were 
pelleted by centrifugation and resuspended in buffered minimal media (BGM9), and oral 
gavage was used for oral delivery of L. lactis. There were no noticeable differences in 
activity level before and after oral gavage, suggesting that administration of L. lactis was 
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safe to the animals. Diabetic mice that received NZ9000(pNZPnisA:usp-SCI) had 
statistically significantly reductions in blood glucose levels after 3 h compared to both 
negative controls (no treatment or oral gavage with 1 U insulin solution) (Fig. 6.7C). 
Diabetic mice that received NZ9000(pNZPthyA:usp-SCI) showed a slight reduction in 
blood glucose level compared to the no-treatment control, but no significant difference 
compared to the control with 1 U insulin solution. After 24 h, blood glucose levels in 
both groups that received L. lactis treatment returned to near-normal levels, which is not 
unexpected since most of the bacteria should be excreted by this time
5
. 
 
Figure 6.7. In vitro expression and in vivo delivery of SCI-57-secreting L. lactis to diabetic mice. (A) 
Western blot detection of SCI-57 in supernatant. Three constitutively expression strains, 
NZ9000(pNZP23:usp-SCI), NZ9000(pNZP1:usp-SCI), and NZ9000(pNZPthyA:usp-SCI) were grown for 
3.5 h in GM17Cm after overnight dilutions. The supernatants were blotted with anti-insulin antibody to 
detect the level of secreted SCI-57. (B) Comparison of level of secreted SCI-57 between 
NZ9000(pNZPthyA:usp-SCI) and an inducible expression strain, NZ9000(pNZPnisA:usp-SCI). 
NZ9000(pNZPnisA:usp-SCI) was induced at 1.5 h with 10 ng/ml nisin. (C) Blood glucose levels of STZ-
induced diabetic mice at different times after no treatment, oral gavage of 1 U insulin, or oral gavage of 
10
10
 to 10
11
 CFU of NZ9000(pNZPnisA:usp-SCI), NZ9000(pNZPthyA:usp-SCI). Results represent 
averages from 1 to 4 independent experiments with 1 or 2 mice in each group. 
*
P < 0.05 and 
**
P < 0.01. 
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6.4 Discussion 
As shown in Fig. 6.2, both nisin concentration and time of induction affect the growth 
rate. For a given induction time, a higher nisin concentration increases the doubling time 
(i.e., slows the growth rate). This is possibly due to a combination of increased burden 
from producing heterologous protein and nisin toxicity (nisin can inhibit bacterial cell 
wall biosynthesis and can kill cells by forming pores in the cytoplasmic membrane
48
). For 
a given nisin concentration, a later induction time reduces the doubling time (i.e., 
increases the growth rate). There is perhaps a critical OD600 threshold in early- to mid-log 
phase above which the burdens imposed by heterologous protein synthesis and nisin 
toxicity are offset by the faster growth rate in this phase.  
The metabolic burden from heterologous protein synthesis can be observed more 
directly in the slower growth rate (Fig. 6.3). Furthermore, Western blot signals of SCI-57 
in unconcentrated supernatant (Fig. 6.3A) are comparable to those of leptin in 20-fold 
concentrated supernatant (Fig. 6.3B), while signals of SCI-57-leptin fusion proteins in 
concentrated supernatants fell below the detection limit of Western blotting (though the 
bioassays clearly show that these proteins are present (Fig. 6.5B–D)). These observations 
reveal a further decrease in protein secretion by L. lactis, in addition to reduced growth 
rate, as the size of the heterologous produced protein is increased, although this may be 
specific to the proteins studies here. Quantification of secreted untagged SCI-57, leptin, 
and SCI-57-leptin fusions in L. lactis cultures showed around 10 nM, 2 nM, and 1 nM of 
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bioactive insulin, leptin, and insulin/leptin equivalents, respectively (Fig. 6.4 and 6.5). 
This effect is most likely due to reduced growth rate and expression, as described above, 
because there is no evidence that increasing protein size adversely affects the folding of 
protein since the usp45 signal peptide exports proteins unfolded via the secretion (Sec) 
pathway
6
. 
While leptin bioactivity was not sensitive to culture pH (Fig. 6.5B), the 
correlation between pH regulation and SCI-57 bioactivity is summarized in Table 6.3. L. 
lactis naturally acidifies the GM17 medium to pH < 5.7 when the culture is saturated. 
Regulating the pH with a base or buffering the media allows L. lactis to grow to a much 
higher density
49
 and it has also been shown to increase the stability and biological activity 
of secreted interleukin-10
10,50
. In our study, buffering the medium may increase the 
solubility, stability, and/or folding of secreted SCI-57. SCI-57 has a pI similar to native 
insulin and is most soluble at neutral pH
13
. Also, wild-type insulin is most stable near 
neutral pH, due to deamidation at low pH and aggregation at high pH
51
. However, since 
the pH during our induction experiments stays relatively close to neutral pH, deamidation 
and aggregation are unlikely to have large effects. Furthermore, SCI-57 was designed 
with amino acid substitutions in the A and B chains to prevent dimerization and higher 
order assembly
13
. Thus, we hypothesize that the marked increase in biological activity 
upon addition of NaOH is primarily due to better folding. SCI-57, like native insulin, 
requires three disulfide bonds (A6–A11, A7–B7, A20–B19) for correct folding and 
biological activity. Previous work indicated that basic pH facilitates folding of insulin by 
deprotonating thiolate moieties and thus limiting aggregation of reduced B chains, giving 
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rise to more free B chains that can form productive disulfide bonds with A chains
52,53
. 
Also, thiol-disulfide exchange, the principal mechanism by which disulfide bonds are 
formed and rearranged in proteins, proceeds via a nucleophilic attack of the thiolate anion 
and alkaline conditions facilitate this reaction
54
. In our case, the addition of NaOH could 
provide a transient alkaline environment to more efficiently facilitate formation of the 
disulfide bonds of SCI-57, thus giving rise to higher biological activity. During the 
folding of insulin, there exists a critical folding intermediate containing the single 
disulfide A20–B19, which has been suggested to form first and guide subsequent 
folding
55
. The posited initial formation of this disulfide bond may also explain why SCI- 
57 without the RGS-His tag exhibits higher biological activity even without pH 
modulation. The RGS-His tag in our experiments is fused directly to the C-terminus of 
SCI- 57 (i.e., after A21), which might impede the formation of this initial disulfide bond.  
Table 6.3. pH values during different induction conditions. 
 Starting 
pH 
Ending 
pH 
pH spike Insulin activity (with 
RGS-His tag)
a
 
Insulin activity 
(no tag) 
a
 
M17 only 6.9 5.7 No – + 
M17 with 50 mM 
sodium phosphates 
7.2 6.5 No – + 
M17 with NaOH 
addition every hour 
6.9 7–7.7 No ++ N.D. 
M17 with NaOH 
addition at 0.5 h 
6.9 7–9.17 > 9 ++ N.D. 
M17 with NaOH 
addition at 1.5 h 
6.9 6.9–7.1 > 7.7 ++ +++ 
M17 with NaOH 
addition at  2.5 h 
6.9 7.2–7.7 > 7.7 + N.D. 
 
a –: no activity; +: equivalent to < 1 nM commercial insulin; ++: equivalent to ≈ 1 nM commercial insulin; 
+++: equivalent to > 1 nM commercial insulin; N.D.: not determined. 
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One notable difference between the in vitro experiments and the actual in vivo 
environment is the pH-sensitive bioactivity. While pH decreases in in vitro experiments 
significantly hindered the bioactivity (e.g., without intervention with NaOH), the gut is 
highly pH-regulated and will not be affected by the acidification that occurs in 
unbuffered M17 medium in vitro. Furthermore, L. lactis resides in the jejunum and ileum 
of human intestine
7
, which have pH values of ~6.2 and ~6.8–8.4, respectively56. These 
pH values were closely approximated in the experiments in which we observed functional 
SCI-57. In addition, SCI-57 administered in vivo will not have an RGS-His tag, 
elimination of which should substantially increase the biological activity of the protein.  
For STZ-induced diabetic mice, subcutaneous injection of 0.5 to 1 U/kg insulin is 
usually sufficient to lower blood glucose to an acceptable level
57
. The same level of 
insulin delivered orally did not lower blood glucose (Fig. 6.7C), and the most likely 
reason is that the acidic pH and intestinal enzymes inactivated or degraded the drug
58
. 
The amount of untagged SCI-57 delivered by 10
10
 to 10
11
 CFU L. lactis was estimated to 
be the same order of magnitude, yet preliminary in vivo experiments with these doses of 
pre-induced L. lactis elicited a ~20−40% reduction in blood glucose within 2−3 hours of 
oral administration (Fig. 6.7C), suggesting an advantage in using L. lactis to deliver 
protein therapeutics rather than administrating the proteins directly. However, the trial-to-
trial variations in these experiments are great, as well as the lack of proper negative and 
positive controls.  Ideally, the mice should be fasted before and during experiments. An 
insulin-tolerance test should be carried out before the actual testing to make sure that the 
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mice respond to injected insulin. An appropriate negative control would be the oral 
gavage of uninduced bacteria. In addition, the insulin level in blood should be measured 
to ensure the reduction in blood glucose is due to insulin in the systemic circulation. 
Therefore, further optimization and in vivo studies are needed to draw more rigorous 
conclusions. 
The modest reduction in blood glucose levels also points to the need for 
improving the amount of insulin delivered by L. lactis. Two complementary strategies 
are: 1) to increase the number of protein molecules delivered by a given number of cells 
and 2) to increase the fraction of secreted bioactive proteins that reach the systemic 
circulation (i.e., improving the bioavailability). Since protein synthesis in our application 
is maximized by strong constitutive promoters (PthyA) and inducible promoters (PnisA), 
another way to increase the amount of protein delivered would be to enhance the 
secretion efficiency from L. lactis. We have investigated this possibility and our findings 
are presented in the next chapter (Chapter 7). Additionally, bioavailability can be 
improved by increasing absorption of delivered proteins, as proteins are often too large to 
readily cross the intestinal barrier
59
. To enhance absorption, a fusion partner that is able 
to cross the intestinal epithelial layer through receptor-mediated transcytosis
24
 can be 
used to conjugate the therapeutic protein of interest. In this work, leptin was chosen as 
one such potential partner, and SCI-57-leptin fusions were shown to retain bioactivity of 
both components in vitro. Another, perhaps more promising, fusion partner with better 
understood mechanisms for transcytosis is the Fc region of immunoglobulin (IgG), which 
binds to FcRn receptors present on the intestinal epithelium to cross the epithelial barrier 
220 
 
intact
60
. IgG Fc domains that were engineered to be monomeric
61
, and thus amenable to 
facile synthesis in L. lactis, were studied in Chapter 4. This remains an exciting area of 
research for furthering L. lactis as a platform for oral delivery of therapeutic proteins. 
In summary, our study demonstrates that food-grade microorganisms can be 
engineered to secrete bioactive therapeutic proteins. We have constructed a L. lactis 
strain that can efficiently secrete SCI-57, leptin, and SCI-57-leptin fusion proteins that 
are biologically active at the physiological pH in the gut. From a biomedical perspective, 
the advantages of this system for oral delivery are threefold. First, L. lactis has long been 
shown to have a safe association with humans, and thus possible adverse effects (e.g., 
using synthetic particles) can be minimized. Second, the protein can by secreted locally 
in the small intestine, minimizing loss during passage through the upper digestive tract 
and potentially enabling ‘on demand’ secretion. Third, as a live delivery vehicle, the 
pharmacokinetics can be genetically tuned to match delivery requirements. From a 
biotechnological perspective, using SCI-57- or leptin-secreting L. lactis eliminates the 
needs for laborious synthesis, expensive protein purification, and temperature-sensitive 
storage of these protein therapeutics, offering cheaper and more convenient alternatives 
to traditional insulin and leptin replacement therapies. 
 
6.5 References 
1. Morishita, M. & Peppas, N. A. Is the oral route possible for peptide and protein 
drug delivery? Drug Discov. Today 11, 905–910 (2006). 
221 
 
2. Muller, G. Oral Delivery of Protein Drugs: Driver for Personalized Medicine? 
Curr. Issues Mol. Biol. 13, 13–24 (2011). 
3. Khafagy, E.-S., Morishita, M., Onuki, Y. & Takayama, K. Current challenges in 
non-invasive insulin delivery systems: A comparative review. Adv. Drug Deliv. 
Rev. 59, 1521–1546 (2007). 
4. Balcázar, J. L. et al. Changes in intestinal microbiota and humoral immune 
response following probiotic administration in brown trout (Salmo trutta). Br. J. 
Nutr. 97, 522–527 (2007). 
5. Klijn, N., Weerkamp, A. H. & de Vos, W. M. Genetic marking of Lactococcus 
lactis shows its survival in the human gastrointestinal tract. Appl. Environ. 
Microbiol. 61 , 2771–2774 (1995). 
6. Nouaille, S. et al. Heterologous protein production and delivery systems for 
Lactococcus lactis. Genet. Mol. Res. 2, 102–111 (2003). 
7. Wells, J. M. & Mercenier, A. Mucosal delivery of therapeutic and prophylactic 
molecules using lactic acid bacteria. Nat. Rev. Microbiol. 6, 349–362 (2008). 
8. Steidler, L. et al. Biological containment of genetically modified Lactococcus 
lactis for intestinal delivery of human interleukin 10. Nat. Biotechnol. 21, 785–789 
(2003). 
9. Braat, H. et al. A Phase I trial with transgenic bacteria expressing interleukin-10 in 
Crohn’s disease. Clin. Gastroenterol. Hepatol. 4, 754–759 (2006). 
10. Steidler, L. et al. Treatment of murine colitis by Lactococcus lactis secreting 
interleukin-10. Science 289 , 1352–1355 (2000). 
11. Gordon Still, J. Development of oral insulin: progress and current status. Diabetes 
Metab. Res. Rev. 18, S29–S37 (2002). 
12. Hua, Q. Insulin: a small protein with a long journey. Protein Cell 1, 537–551 
(2010). 
13. Hua, Q. et al. Design of an active ultrastable single-chain insulin analog: synthesis, 
structure, and therapeutic implications. J. Biol. Chem. 283, 14703–14716 (2008). 
14. Rajpal, G., Liu, M., Zhang, Y. & Arvan, P. Single-chain insulins as receptor 
agonists. Mol. Endocrinol. 23 , 679–688 (2009). 
15. Auwerx, J. & Staels, B. Leptin. The Lancet 351, 737–742 (1998). 
222 
 
16. Kim, Y. B., Uotani, S., Pierroz, D. D., Flier, J. S. & Kahn, B. B. In vivo 
administration of leptin activates signal transduction directly in insulin-sensitive 
tissues: overlapping but distinct pathways from insulin. Endocrinology 141, 2328–
2339 (2000). 
17. Dardeno, T. A. et al. Leptin in human physiology and therapeutics. Front. 
Neuroendocrinol. 31, 377–393 (2010). 
18. Oral, E. A. et al. Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 
346, 570–578 (2002). 
19. Welt, C. K. et al. Recombinant human leptin in women with hypothalamic 
amenorrhea. N. Engl. J. Med. 351, 987-997 (2004). 
20. Naito, M. et al. Therapeutic impact of leptin on diabetes, diabetic complications, 
and longevity in insulin-deficient diabetic mice. Diabetes 60, 2265-2273 (2011).  
21. Wang, M. et al. Leptin therapy in insulin-deficient type I diabetes. Proc. Natl. 
Acad. Sci. U.S.A. 107, 4813–4819 (2010). 
22. Cammisotto, P. G. et al. Receptor-mediated transcytosis of leptin through human 
intestinal cells in vitro. Int. J. Cell Biol. 2010, 928169 (2010). 
23. Cammisotto, P. G., Gingras, D. & Bendayan, M. Transcytosis of gastric leptin 
through the rat duodenal mucosa. Am. J. Physiol. Gastrointest. Liver Physiol. 293, 
G773–G779 
24. Swaan, P. Recent advances in intestinal macromolecular drug delivery via 
receptor-mediated transport pathways. Pharm. Res. 15, 826–834 (1998). 
25. Mierau, I. & Kleerebezem, M. 10 years of the nisin-controlled gene expression 
system (NICE) in Lactococcus lactis. Appl. Microbiol. Biotechnol. 68, 705–717 
(2005). 
26. de Ruyter, P. G., Kuipers, O. P. & de Vos, W. M. Controlled gene expression 
systems for Lactococcus lactis with the food-grade inducer nisin. Appl. Environ. 
Microbiol. 62, 3662–3667 (1996). 
27. Kuipers, O. P., de Ruyter, P. G. G. A., Kleerebezem, M. & de Vos, W. M. Quorum 
sensing-controlled gene expression in lactic acid bacteria. J. Biotechnol. 64, 15–21 
(1998). 
223 
 
28. de Ruyter, P. G., Kuipers, O. P., Beerthuyzen, M. M., van Alen-Boerrigter, I. & de 
Vos, W. M. Functional analysis of promoters in the nisin gene cluster of 
Lactococcus lactis. J. Bacteriol. 178 , 3434–3439 (1996). 
29. Bermúdez-Humarán, L. G. et al. Controlled intra- or extracellular production of 
staphylococcal nuclease and ovine omega interferon in Lactococcus lactis. FEMS 
Microbiol. Let. 224, 307–313 (2003). 
30. van Asseldonk, M. et al. Cloning of usp45, a gene encoding a secreted protein 
from Lactococcus lactis subsp. lactis MG1363. Gene 95, 155–160 (1990). 
31. Leenhouts, K. et al. A general system for generating unlabelled gene replacements 
in bacterial chromosomes. Mol. Gen. Genet. 253, 217–224 (1996). 
32. Bahey-El-Din, M., Griffin, B. & Gahan, C. Nisin inducible production of 
listeriolysin O in Lactococcus lactis NZ9000. Microb. Cell Fact. 7, 24 (2008). 
33. Pope, B. & Kent, H. M. High efficiency 5 min transformation of Escherichia coli. 
Nucleic Acids Res. 24 , 536–537 (1996). 
34. Nakashima, N., Sharma, P. M., Imamura, T., Bookstein, R. & Olefsky, J. M. The 
tumor suppressor PTEN negatively regulates insulin signaling in 3T3-L1 
adipocytes. J. Biol. Chem. 275 , 12889–12895 (2000). 
35. Bermúdez-Humarán, L. G. et al. Effects of intranasal administration of a leptin-
secreting Lactococcus lactis recombinant on food intake, body weight, and 
immune response of mice. Appl. Environ. Microbiol. 73, 5300–5307 (2007). 
36. Le Loir, Y. et al. Signal peptide and propeptide optimization for heterologous 
protein secretion in Lactococcus lactis. Appl. Environ. Microbiol. 67, 4119–4127 
(2001). 
37. van Asseldonk, M., de Vos, W. M. & Simons, G. Functional analysis of the 
Lactococcus lactis usp45 secretion signal in the secretion of a homologous 
proteinase and a heterologous α-amylase. Mol. Gen. Genet. 240, 428–434 (1993). 
38. Jiang, Z. Y. et al. Insulin signaling through Akt/protein kinase B analyzed by small 
interfering RNA-mediated gene silencing. Proc. Natl. Acad. Sci. U.S.A. 100, 
7569–7574 (2003). 
39. Summers, S. A., Garza, L. A., Zhou, H. & Birnbaum, M. J. Regulation of insulin-
stimulated glucose transporter GLUT4 translocation and Akt kinase activity by 
ceramide. Mol. Cell. Biol. 18, 5457–5464 (1998). 
224 
 
40. Bates, S. H. et al. STAT3 signalling is required for leptin regulation of energy 
balance but not reproduction. Nature 421, 856–859 (2003). 
41. Zhang, F. et al. Crystal structure of the obese protein leptin-E100. Nature 387, 
206–209 (1997). 
42. Lo, K.-M. et al. Engineering a pharmacologically superior form of leptin for the 
treatment of obesity. Protein Eng. Des. Sel. 18, 1–10 (2005). 
43. Arai, R., Ueda, H., Kitayama, a, Kamiya, N. & Nagamune, T. Design of the linkers 
which effectively separate domains of a bifunctional fusion protein. Protein Eng. 
14, 529–32 (2001). 
44. Gasteiger, E. et al. Protein Identification and Analysis Tools on the ExPASy 
Server. The Proteomics Protocols Handbook SE - 52, 571–607 (2005). 
45. Jenny, R. J., Mann, K. G. & Lundblad, R. L. A critical review of the methods for 
cleavage of fusion proteins with thrombin and factor Xa. Protein Expr. Purif. 31, 
1–11 (2003). 
46. Waterfield, N. R., Le Page, R. W., Wilson, P. W. & Wells, J. M. The isolation of 
lactococcal promoters and their use in investigating bacterial luciferase synthesis 
in Lactococcus lactis. Gene 165, 9–15 (1995). 
47. Morello, E. et al. Lactococcus lactis, an efficient cell factory for recombinant 
protein production and secretion. J. Mol. Microbiol. Biotechnol. 14, 48–58 (2008). 
48. McAuliffe, O., Ross, R. P. & Hill, C. Lantibiotics: structure, biosynthesis and 
mode of action. FEMS Microbiol. Rev. 25, 285–308 (2001). 
49. Tremillon, N. et al. Production and purification of staphylococcal nuclease in 
Lactococcus lactis using a new expression-secretion system and a pH-regulated 
mini-reactor. Microb. Cell Fact. 9, 37 (2010). 
50. Schotte, L., Steidler, L., Vandekerckhove, J. & Remaut, E. Secretion of 
biologically active murine interleukin-10 by Lactococcus lactis. Enzyme and 
Microb. Technol. 27, 761–765 (2000). 
51. Brange, J. & Langkjaer, L. Chemical stability of insulin. 3. Influence of excipients, 
formulation, and pH. Acta Pharm. Nord. 4, 149–158 (1992). 
52. Hua, Q. et al. Mechanism of insulin chain combination: asymmetric roles of a-
chain α-helices in disulfide pairing. J. Biol. Chem. 277, 43443–43453 (2002). 
225 
 
53. Weiss, M. A. Proinsulin and the genetics of diabetes mellitus. J. Biol. Chem. 284, 
19159–19163 (2009). 
54. Rudolph, R. & Lilie, H. In vitro folding of inclusion body proteins. FASEB J. 10, 
49–56 (1996). 
55. Yan, H., Guo, Z.-Y., Gong, X.-W., Xi, D. & Feng, Y.-M. A peptide model of 
insulin folding intermediate with one disulfide. Protein Sci. 12, 768–775 (2003). 
56. Charman, W. N., Porter, C. J. H., Mithani, S. & Dressman, J. B. Physicochemical 
and physiological mechanisms for the effects of food on drug absorption: The role 
of lipids and pH. J. Pharm. Sci. 86, 269–282 (1997). 
57. Cho, H. et al. Insulin resistance and a diabetes mellitus-like syndrome in mice 
lacking the protein kinase Akt2 (PKB β). Science  292, 1728–1731 (2001). 
58. Carino, G. & Mathiowitz, E. Oral insulin delivery. Adv. Drug Deliv. Rev. 35, 249–
257 (1999). 
59. Lee, V. H. L. & Yamamoto, A. Penetration and enzymatic barriers to peptide and 
protein absorption. Adv. Drug Deliv. Rev. 4, 171–207 (1990). 
60. Dickinson, B. L. et al. Bidirectional FcRn-dependent IgG transport in a polarized 
human intestinal epithelial cell line. J. Clin. Invest. 104, 903–911 (1999). 
61. Ying, T., Chen, W., Gong, R., Feng, Y. & Dimitrov, D. S. Soluble monomeric 
IgG1 Fc.  J. Biol. Chem. 287, 19399–19408 (2012).  
 
226 
 
CHAPTER 7 
Engineering signal peptides for enhanced protein secretion 
from Lactococcus lactis 
7.1 Introduction 
 Lactococcus lactis, traditionally used in the food fermentation industry for the 
production of cheese and buttermilk
1
, has great potential as an oral delivery vehicle for 
the clinical delivery of therapeutic molecules. This bacterium has generally regarded as 
safe (GRAS) status in humans and has been used as a mucosal delivery vehicle because it 
can survive passage through the stomach acid and contact with bile
2,3
. L. lactis has been 
engineered to express and secrete a variety of therapeutic proteins, including interleukin-
10 for treatment of inflammatory bowel disease
4, and bovine β-lactoglobulin for 
immunity against this cow milk allergen
5
. In the previous chapter, we demonstrated 
successful secretion of a single-chain insulin analog, leptin, and their fusions from this 
bacterium. However, although preliminary in vivo studies on oral delivery of insulin-
secreting L. lactis to diabetic mice showed encouraging results, the level of glucose 
reduction was relatively modest and showed variability among the limited number of 
trials performed. The amount of insulin secreted by a feasible number of ingested bacteria 
was estimated to be approximately the same as which would be needed in a subcutaneous 
injection to lower blood glucose to an acceptable level, which would thus be insufficient 
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for oral delivery given the additional bottlenecks in delivery. Therefore, it is extremely 
important to enhance the secretion capability of L. lactis. Even in other biomedical 
applications in which a reasonable therapeutic dose can be achieved, maximizing 
secretion of the recombinant protein of interest would be desirable since the dose and/or 
administration frequency of L. lactis can be reduced. 
In addition to clinical delivery of therapeutic proteins, there also has been 
increasing interest over the past two decades in the use of this bacterium for the 
biotechnological production of heterologous proteins. A major advantage of using L. 
lactis or other Gram-positive bacteria rather than Gram-negative bacteria (e.g., 
Escherichia coli) for protein production is that proteins can be easily secreted into the 
medium, which streamlines the often expensive and inefficient downstream purification 
process
6
. In contrast to many commonly used Gram-positive bacteria (e.g., Bacillus 
species), laboratory strains of L. lactis possess only one exported housekeeping protease, 
HtrA
7
, and secrete only one major extracellular protein, Usp45
8
, thus minimizing protein 
degradation by the extracellular proteolytic system and further simplifying downstream 
purification. Given its simple and well-known metabolism, its completely sequenced 
genome
9,10
, and the availability of various genetic tools
11
, L. lactis is an attractive host for 
many biotechnological applications. Enhancing the secretion capabilities of this host can 
reduce cost and maximize the production of heterologous proteins. 
 In L. lactis, most proteins are secreted unfolded via the secretion (Sec) pathway
12
. 
Proteins are synthesized as precursors containing the mature moiety of the protein with 
an N-terminal signal peptide. The signal peptide plays an important role in targeting the 
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protein to the cytoplasmic membrane, where the protein precursor is subsequently 
translocated by the Sec machinery
13
. Following cleavage of the signal peptide, the mature 
protein is released extracellularly
14
. The lactococcal signal peptides follow the common 
tripartite structure, including a positively charged N terminus (n-region), a central 
hydrophobic core (h-region), and a more polar C terminus (c-region) containing the 
signal peptide cleavage site
15
. The most widely used signal peptide for L. lactis secretion 
is that from Usp45 (Usp45sp), which has the best secretion efficiency
16
. Other reported 
lactococcal signal peptides, both natural (e.g., SP310
17
, SPExp4
18
, and AL9
19
) and 
engineered (e.g., SP310mut2
20
), have secretion efficiencies only as good as, and often 
worse than, that of Usp45sp
6,20,21
. Although improvements in secretion have been 
achieved by either introducing a synthetic propeptide
22
 or complementing the lactococcal 
translocation machinery with SecDF
23
, the inherent limitations of Usp45sp itself have not 
been addressed. Thus, optimization of this widely used signal peptide should not only 
directly lead to enhancements in the secretion efficiencies of a wide range of proteins but 
may also be combined with other improvements, such as those mentioned above, to fully 
exploit the secretion potential of L. lactis. 
 As the signal peptide of the only major secretory protein in L. lactis, it is 
unknown whether Usp45sp has been subjected to stringent evolutionary pressures that 
have maximized its secretory efficiency. Here, we screened libraries of silent and targeted 
mutations in Usp45sp and demonstrated that the secretion efficiency of this signal peptide 
can indeed be improved. We first showed that silent mutations of Usp45sp alone can give 
an increase of up to 16% in the activity of secreted α-amylase. We then used a simple 
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mathematical model to provide a quantitative explanation for this observed effect based 
on the free energy of the mRNA secondary structure around the ribosome binding site 
(RBS) and its consequent effect on protein translation. We further introduced nonsilent 
mutations in Usp45sp using a targeted mutagenesis approach and achieved an increase of 
up to ~50% in the activity of secreted α-amylase at the maximum induction level. Using 
the best clone from the targeted mutation library, we introduced silent mutations into this 
sequence and identified clones that also increase secretion levels at lower concentrations 
of inducer. Analyzing these silent mutation clones with our mathematical model, we 
show that the effect of optimizing the amino acid sequence is more dominant than that of 
relaxing mRNA folding in enhancing secretion levels. In summary, we have used two 
complementary directed evolution approaches to achieve progressive improvements in L. 
lactis secretion efficiencies solely by engineering the signal peptide; this work represents 
the first successful effort in achieving secretion yields higher than that attainable with 
Usp45sp and also provides general strategies for enhancing protein secretion in bacterial 
hosts. 
 
7.2 Materials and methods 
7.2.1 Bacterial strains, plasmids, and growth conditions 
The strains and. E. coli and L. lactis used, and their respective growth conditions, were 
described in Section 6.2.1. Solid media were prepared by adding agar (15 g/liter) to the 
corresponding broths. For the nuclease plate assay, brain heart infusion (BHI) agar 
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(Acumedia, Lansing, MI) was used to grow L. lactis. When needed, chloramphenicol 
(Cm) was used at a final concentration of 10 μg/ml. Plasmids used in this work are listed 
in Table 7.1 
Table 7.1. Plasmids used in this study.  
 Characteristics Sources 
pNZPnisA:usp-SCI-His Modified pNZ8048 containing PnisA promoter with 
Usp45sp fused with downstream RGS-His-tagged SCI-
57 gene; Cm
r
 
Chapter 6 
pNZ8048m:usp45sp-MazF Modified pNZ8048 containing PnisA promoter with 
Usp45sp fused with downsream RGS-His-tagged E. coli 
MazF gene; Cm
r
 
This work 
pNZ8048m:usp45sp-Nuc Modified pNZ8048 containing PnisA promoter with 
Usp45sp fused with downstream RGS-His-tagged S. 
aureus nuclease gene; Cm
r
 
This work 
pNZ8048m:usp45sp-AmyE Modified pNZ8048 containing PnisA promoter with 
Usp45sp fused with downstream RGS-His-tagged B. 
subtilis α-amylase gene (with internal EcoRI silent 
mutation); Cm
r
 
This work 
pNZ8048m:SP310-Nuc Modified pNZ8048 containing PnisA promoter with 
SP310 signal peptide fused with downstream RGS-His- 
tagged S. aureus nuclease gene; Cm
r
 
This work 
pNZ8048m:SP310-AmyE Modified pNZ8048 containing PnisA promoter with 
SP310 signal peptide fused with downstream RGS-His- 
tagged B. subtilis α-amylase gene (with internal EcoRI 
silent mutation); Cm
r
 
This work 
 
7.2.2 DNA manipulations and plasmid construction 
Isolation of plasmid DNA from E. coli and L. lactis was performed as described in 
Section 6.2.2. Phusion high-fidelity DNA polymerase, restriction enzymes, and T4 DNA 
ligase were purchased from NEB (Ipswich, MA) and were used as recommended by the 
manufacturer. Primers used for DNA amplification (Integrated DNA Technologies, 
Coralville, IA) are listed in Table 7.2. pNZ8048m:usp45sp-MazF was constructed by 
isolating the mazF gene from E. coli K-12 (GenBank accession no. NC000913) by 
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colony PCR with primers 1 and 2, digesting with BspEI and BamHI, and ligating into 
similarly cut pNZPnisA:usp-SCI-His (Usp45sp from GenBank accession no. M60178 but 
with two silent mutations to introduce a BspEI site, as described in 6.2.2). To incorporate 
an NcoI site at the junction between the coding sequences for Usp45sp and mazF, 
pNZ8048m:usp45sp-MazF was PCR amplified with primers 3 and 2, digested with BspEI 
and BamHI, and ligated into similarly cut pNZ8048m:usp45sp-SCI57his, giving rise to 
pNZ8048m:usp45sp-MazF. pNZ8048m:usp45sp-Nuc (Fig. 7.1A) was constructed by 
isolating the nuclease gene from Staphylococcus aureus (GenBank accession no. 
AM990992; courtesy of Dr. Mark Goulian, University of Pennsylvania) by colony PCR 
with primers 4 and 5, digesting with NcoI and BamHI, and ligating into similarly cut 
pNZ8048m:usp45sp-MazF. pNZ8048m:usp45sp-AmyE was constructed using the same 
method as described above after isolating Bacillus subtilis α-amylase (GenBank 
accession no. FJ643607; courtesy of Dr. Mark Goulian) with primers 6 and 7, except that 
an internal EcoRI site was eliminated by a silent mutation to facilitate subsequent library 
construction. This was done by PCR amplification of the α-amylase with primers 6 and 9 
and primers 8 and 7, fusion of the two fragments by assembly PCR, digestion of the full-
length product with NcoI and BamHI, and ligation into NcoI- and BamHI-digested 
pNZ8048m:usp45sp-MazF. To replace Usp45sp with the SP310 signal peptide, SP310 
was constructed by extension PCR with primers 10 and 11 followed by digestion with 
EcoRI and NcoI and ligation into similarly cut pNZ8048m:usp45sp-Nuc and 
pNZ8048m:usp45sp-AmyE to yield pNZ8048m:SP310-Nuc and pNZ8048m:SP310-
AmyE, respectively. All ligation mixtures were transformed into chemically competent 
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E. coli EC1000, sequenced, and electroporated into electrocompetent L. lactis NZ9000 as 
described previously in Section 6.2.2. 
 
Figure 7.1. Schematics of the expression constructs and screening process. (A) Plasmid map of 
pNZ8048m:usp45sp-Nuc, showing promoter PnisA, usp45 signal peptide sequence, S. aureus nuclease 
gene, and RGS-His tag in the modified pNZ8048 backbone. (B) Flow diagram of the mutagenesis and 
screening process. The signal peptide mutations were encoded by degenerate PCR primers. Nucleotide 
libraries were constructed, digested, and ligated into the pNZ8048m vector backbone via the EcoRI and 
NcoI sites. After plasmid transformation into L. lactis NZ9000, the resulting library was plated and 
screened by carefully overlaying a toluidine blue-DNA agar (TDA) mixture with inducer (10 ng/ml nisin) 
onto the agar plates. Since the size of the pink halo around each colony corresponds to the amount of 
nuclease secreted, clones could be quickly screened by eye and subjected to further analyses (sequencing, 
amylase secretion assays, Western blotting, etc.). Subsequent libraries were designed based on data 
collected in the initial screen. 
 
Table 7.2. Primers used in this study. 
Primer 
Number 
Primer Name Nucleotide Sequence (5’  3’) a 
1 MazF_BspEI_f CTTACGTCCGGAGTTTACGCTATGGTAAGCCGATACGTAC 
2 MazF_BamHI_r TACGTTGGATCCTCTCCCAATCAGTACGTTAATTTTG 
3 Usp45NcoIMazF-
BspEI_f 
TTCAGCTCCGGAGTTTACGCCATGGTAAGCC 
4 SaurNuc_NcoI_f TTTACGCCATGGTTTCACAAACAGATAATGGCGTAAATAG 
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5 SaurNuc_BamHI_r ATGGTGGGATCCTCTTTGACCTGAATCAGCGTTGTCTTC 
6 BsubAmy_NcoI_f TTTACGCCATGGTTCTTACAGCACCGTCGATCAAAAG 
7 BsubAmy_BamHI_r ATGGTGGGATCCTCTATGGGGAAGAGAACCGCTTAAGC 
8 BsubAmy_EcoRImut_f CACGCAGAACTCATTGCTCG 
9 BsubAmy_EcoRImut_r CGAGCAATGAGTTCTGCGTG 
10 SP310_EcoRI_f CTCAAAGAATTCATGAAATTTAATAAAAAAAGAGTTGCAATAG 
11 SP310_NcoI_r TTGTCGCCATGGCATTAGTTTGGTTATCTTGGATTGATG 
12 pNZ_EcoRI_f TTATAAGGAGGCACTCAAAGAATTCATG 
13 NucB_NcoI_r CATTATCTGTTTGTGAAACCATGG 
14 Usp45SM_NcoI_r CACTTTCCATGGCRTANACNCCNGAYAANGGNGCNGCNGCNGAN 
AGDATNACNGTNGACATYAADATNGCNGADATDATYTTYTTYTT 
CATGAATTCTTTGAGTGCCTCCTTATAA 
15 Usp45TM_NcoI_r ATCGGCTTACCATGGCMNNAACMNNGGAMNNCGGGGCTGCMNNM 
NNAAGMNNCACMNNMNNMNNTAAMNNAGCMNNMNNMNNCTTTTT 
TTTCATGAATTCTTTGAGTGCCTCCTTATAA 
16 TM8SM_NcoI_r 
b
 GTGAAACCATGGCYTTNACRTTNGADATNGGNGCNGCNGTNGTN 
AGCATNACNACNACNGCNAARTGNGCYTTNAGNACYTTYTTYTT 
CATGAATTCTTTGAGTGCCTCCTTATAA 
 
a
 Restriction sites are underlined. 
b
 The bolded N should be a Y to encode for only silent mutations of leucine. Nevertheless, all clones 
selected for characterization in this work contained only silent mutations at this position. 
 
7.2.3 Library construction and selection procedures 
The selection procedure is outlined in Fig. 7.1B. To construct the mutation libraries for 
Usp45sp silent mutations, Usp45sp targeted mutations, and Usp45TM8 silent mutations, 
three separate extension PCRs were performed with forward primer 12 and degenerate 
reverse primers 14, 15, and 16, respectively. The constructs were digested with EcoRI 
and NcoI and ligated with a 1:1 molar ratio into > 1 µg similarly digested 
pNZ8048m:SP310-Nuc. The ligation products were electroporated directly into L. lactis 
NZ9000 and plated onto 10 150-mm-diameter petri dishes with BHI agar containing Cm. 
Colonies were allowed to grow overnight at 30°C. 
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 Toluidine blue-DNA agar (TDA) was made with 36 mg toluidine blue O (Sigma-
Aldrich, St. Louis, MO), 4 g NaCl, 4 g agar, 0.12 g salmon DNA (EMD Chemicals, 
Billerica, MA), and 0.4 ml of 0.01 M CaCl2 dissolved in 400 ml of 0.05 M Tris (pH 9)
24
. 
Molten TDA (13 ml) containing 10 ng/ml nisin (Sigma-Aldrich) was carefully overlaid 
on each BHI agar plate and allowed to solidify. After incubation at 30°C for 1 h, colonies 
were evaluated by the size of their pink halos. Single colonies were picked, inoculated 
into 5 ml GM17Cm, and grown overnight at 30°C. Plasmids in selected clones were 
isolated and analyzed by DNA sequencing. To clone the selected signal peptide upstream 
of α-amylase, signal peptides were PCR amplified with primers 12 and 13, digested with 
EcoRI and NcoI, and ligated into similarly digested pNZ8048m:usp45sp-AmyE. 
 
7.2.4 Nuclease plate assay 
To evaluate the secretion efficiency and activity of nuclease secreted by individual 
clones, 10 ml molten TDA was spread into each 100-mm-diameter petri dish and allowed 
to solidify. Wells were created in the TDA with P1000 pipet tips (USA Scientific, Ocala, 
FL). Overnight cultures of L. lactis NZ9000 containing pNZ8048m:usp45sp-Nuc (or 
similar constructs with other signal peptides) were diluted 1:25 into fresh GM17Cm. 
Cultures were grown for 1.5 h and induced with the appropriate amount of nisin for 
another 2 h. The optical density at 600 nm (OD600) was measured on a plate reader 
(Infinite M200; Tecan, Männedorf, Switzerland) to ensure that different cultures had 
similar growth rates. Cells were removed from the supernatant by a 5-min centrifugation 
235 
 
at 5,000g, 1 µl supernatant was added to each TDA well, and the plates were incubated at 
30°C for 1 h. The size of the pink halo around each clone was measured. 
 
7.2.5 α-Amylase activity assay and Western blotting 
To evaluate the secretion efficiency and activity of α-amylase secreted by individual 
clones, starch azure assays were carried out as previously described
16
 but with 
modifications. Cultures of L. lactis were grown, induced with nisin, and centrifuged as 
mentioned above. The supernatant (100 µl) was incubated with 20 mg starch azure 
(Sigma-Aldrich) and 900 µl α-amylase buffer (50 mM Tris-HCl [pH 7.5], 50 mM NaCl, 
5 mM CaCl2) at 37°C for 1 h with shaking. Centrifugation was carried out at 15,000 x g 
for 5 min, and supernatant absorbance at 595 nm was measured on a plate reader. α-
Amylase activity was calculated from a standard curve (Fig. 7.2). The standard curve was 
obtained by incubating 0.0038 to 3.8 units of purified B. subtilis α-amylase (Sigma-
Aldrich) with starch azure under the conditions described above.  
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Figure 7.2. Standard curve of α-amylase starch azure test. B. subtilis α-amylase (100 µl of 0.0001 mg/ml to 
0.1 mg/ml solution) was mixed with 20 mg starch azure, and then 900 µl α-amylase buffer was added. 
Samples were shaken horizontally at 37
o
C for 1 h, and absorbance of the supernatant was measured at 595 
nm. The data represent the mean ± standard errors of the means (SEM) of two independent experiments.  
 
For Western blotting, the supernatant was passed through a 0.22-µm-pore-size 
filter (Millipore, Billerica, MA) to remove any cells, and 13 µl supernatant (adjusted with 
phosphate-buffered saline as needed to achieve equivalent cell densities) was mixed with 
2 µl 500 mM dithiothreitol and 5 µl lithium dodecyl sulfate sample buffer for analysis by 
SDS- PAGE in a 4–12% NuPAGE Bis-Tris gel (Invitrogen, Carlsbad, CA). Proteins were 
transferred and blotted as described previously in Chapter 6. 
 
7.2.6 mRNA structure analysis and mathematical modeling 
The mRNA sequence from the transcription start site to 6 nucleotides after the end of the 
signal peptide-coding region (135 bases total) was analyzed using the mfold web server
25
. 
The structure with the lowest (most negative) folding energy was used to calculate the 
free energy (ΔG) of the ribosome binding site (RBS). ΔGRBS was calculated by adding up 
the ΔG contributions of the 6 bases in AGGAGG and an initiation ΔG of 3.4 kcal/mol26. 
 We developed a mathematical model to quantitatively explain the differences in 
secretion due to silent mutations in the signal peptide. The model relates the stability of 
mRNA secondary structure around the ribosome binding site to translation and secretion 
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efficiencies based on a previous model with modifications
27
 (Fig. 7.3). Nomenclature and 
parameter values are provided in Table 7.3. 
 
Figure 7.3. Schematic of the mathematical model. The model predicts that translational efficiency 
correlates with ribosome binding to accessible RBSs, which depends on the fraction of RBSs in the 
unfolded state, which, in turn, is determined by the ΔG of the RBS for a given mRNA sequence. Secretion 
efficiency is determined as a fraction of the total amount of translated protein and is specific to a particular 
amino acid sequence. 
 
Table 7.3. Nomenclature and parameter values used in the mathematical model. 
Symbol Description Value Reference 
F mRNA with secondary structure around the 
RBS (folded) 
Calculated from fsolve N/A 
U mRNA with exposed RBS (unfolded) Calculated from fsolve N/A 
Rb Free ribosomes Calculated from fsolve N/A 
Rb•U Ribosomes bound to unfolded mRNA Calculated from fsolve N/A 
Kf Equilibrium association constant for mRNA 
folding around the RBS 
Calculated from ΔGRBS Reference
25,26
 
ΔGRBS Free energy of mRNA secondary structure 
around the RBS 
Varies from -8.5 to -0.5 
kcal/mol (calculated from 
mfold with initiation term) 
Reference
25,26
 
Krb Equilibrium association constant for binding 
of 30S ribosomal subunit to unfolded mRNA 
Calculated from ΔGrb Reference
27
 
ΔGrb Free energy of binding of 30S ribosomal -14 kcal/mol Reference
27
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subunit to unfolded mRNA 
Rbtot Total concentration of ribosomes in the cell 40 µM (assumed to be 
equivalent to E. coli with 
the same doubling time) 
Reference
28,29
 
RNAtot Total concentration of mRNA transcripts 
(depending of induction level) 
0.08 Rbtot, 0.8 Rbtot, and 8 
Rbtot for 0.1, 1, and 10 
ng/ml nisin, respectively 
This work 
C Peptide-specific proportionality constant 
relating protein expression to secretion 
efficiency 
Usp45SM: 1.01; 
Usp45TM8_SM: 1.45 
This work 
R Gas constant 1.986 cal/K mol N/A 
T Temperature (in Kelvin) 303.15 K (L. lactis was 
grown at 30
o
C) 
N/A 
 
First, we modeled translation as a process initiated by a ribosome recognizing the 
ribosome binding site and unfolding of the initiation region in the mRNA
30,31
. The 
folding/unfolding equilibrium of mRNA is based specifically on the free energy of 
mRNA secondary structure around the ribosome binding site (RBS) (ΔGRBS). 
U Kf F 
where Kf = [F]/[U]  and ΔGRBS = - RT ln(Kf)     (1) 
The 30S subunit of the ribosome binds to the unfolded mRNA with association 
constant Krb. 
 Rb + U Krb Rb•U 
where Krb = [Rb•U]/[Rb][U]  and ΔGrb = - RT ln(Krb)   (2) 
Since initiation is the rate-limiting step in translation
32
, translation was set to be 
proportional to the amount of ribosome-bound mRNA ([Rb•U]). Finally, since L. lactis 
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only secretes a fraction of the expressed protein
14
, secretion rate was calculated as a 
fraction of the total amount of protein translated: 
 secretion ∝ protein expression ∝ [Rb•U] 
so, secretion = C [Rb•U]/Rbtot       (3) 
where C is a constant that is unique to the amino acid sequence of a specific signal 
peptide. 
 Together with the two mass balance equations: 
 [U] + [F] + [Rb•U] = RNAtot       (4) 
and [Rb] + [Rb•U] = Rbtot,        (5) 
the system of equations, (1), (2), (4) and (5), was solved in Matlab using fsolve to obtain 
the unknowns [U], [F], [Rb], and [Rb•U]. The C values for the Usp45sp and Usp45TM8 
silent mutation libraries were determined experimentally from the secretion levels of 
wild-type Usp45sp and Usp45TM8, respectively, and Equation (3) was used to calculate 
the final normalized protein secretion. 
 
7.3 Results 
7.3.1 Signal peptide screening with nuclease and α-amylase reporters 
To allow efficient screening of a large library of signal peptides, the Staphylococcus 
aureus nuclease was used as the reporter protein
33
. Secretion of S. aureus nuclease from 
L. lactis colonies can be easily detected by overlaying the library transformants with 
toluidine blue-DNA agar (TDA)
24
; the size of the pink halo indicates nuclease activity, 
which corresponds directly to secretion efficiency. For better quantification of secretion 
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efficiency, selected signal peptides were fused upstream of Bacillus subtilis α-amylase. 
Activity of secreted α-amylase in liquid culture can be easily quantified by incubation 
with starch azure
16
 (Fig. 7.2). Furthermore, the use of two different heterologous proteins 
to evaluate secretion efficiencies can elucidate any protein-specific dependence on 
secretion and increase the likelihood that the best signal peptide selected would improve 
secretion of other useful proteins. These two proteins, S. aureus nuclease and B. subtilis 
α-amylase, were evaluated for their abilities to report secretion efficiencies of two known 
signal peptides, Usp45sp
16
 and SP310
17
. A TDA plate test, carried out on L. lactis 
cultures secreting nuclease fused to either signal peptide, showed a larger pink halo with 
Usp45sp, indicating secretion levels qualitatively higher than those of SP310 (Fig. 7.4A). 
A more quantitative starch azure activity test on cultures secreting α-amylase also 
demonstrated that secretion with SP310 was only ~62% of that achieved with Usp45sp 
(Fig. 7.4B), in agreement with previous results
20
. We therefore used Usp45sp as the 
starting sequence for directed evolution to probe any inherent sequence limitations in 
using this signal peptide and to identify and alleviate bottlenecks to improve protein 
secretion in L. lactis. The signal peptide mutagenesis and screening process was 
performed as shown in Fig. 7.1B. To construct silent mutation libraries, we used primers 
with appropriate degeneracies in the third nucleotide of each codon, giving a maximum 
theoretical diversity of ~10
12
. For the targeted mutation library, degenerate codons 
(NNK) were used to fully randomize specific amino acid residues, giving a maximum 
diversity of ~10
19
. Our actual library sizes were limited by the transformation efficiency 
in L. lactis (~10
6
 CFU/µg DNA). A TDA-nisin overlay allowed us to rapidly screen a 
large number of nuclease-secreting colonies by visualizing the sizes of the pink halos and 
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selecting individual clones for more quantitative testing with α-amylase. The maximum 
subinhibitory concentration of nisin (10 ng/ml) was used for all screens
34
. 
 
Figure 7.4. Nuclease plate test and α-amylase starch azure test of the two control signal peptides, Usp45sp 
and SP310. (A) The size of the pink halo on Toluidine blue-DNA-agar corresponds to the activity of 
secreted nuclease. (B) The starch azure test gives a more quantitative measure of α-amylase secretion (Fig. 
7.2). Blue bar: no nisin induction; red bar: 10 ng/ml nisin induction. In both cases, the secretion efficiency 
of Usp45sp is higher than that of SP310. In the starch azure test, SP310 secretion was ~62% of Usp45sp 
secretion, in agreement with previous results
20
.  
 
7.3.2 Silent mutations in Usp45sp modestly increase secretion 
First, a Usp45sp silent mutation library was constructed to examine if mRNA secondary 
structure, independent of amino acid sequence, has an effect on secretion and if secretion 
can be improved by relaxing mRNA structure, assuming that translation and secretion are 
directly correlated. It is known that silent mutations in the gene itself can alter mRNA 
folding and translation initiation, thus influencing gene expression
35
. Wild- type Usp45sp 
is predicted to have a considerable amount of mRNA folding and secondary structure, 
especially around the RBS (Fig. 7.5), and preliminary studies on signal peptides with 
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very highly folded mRNAs revealed that secretion was completely abolished. We 
therefore created a library to allow all possible silent mutations of Usp45sp and screened 
for (i) clones with representative low, medium, and high secretion levels to further probe 
the correlation between secondary structure and secretion rate and (ii) clones with 
secretion levels significantly higher than that of wild-type Usp45sp. Individual silent 
mutation clones were assayed for secretion of nuclease or α-amylase and were ordered by 
their ΔG values around the RBS (Table 7.4), which we hypothesized to be a major 
determinant of translation initiation and, thus, protein expression and secretion
27
. The 
majority of both nuclease and α-amylase secretion levels follows the ΔG trend: signal 
peptides with ΔGRBS values that are more negative generally exhibited worse secretion 
than Usp45sp, and those with ΔGRBS values that were less negative generally yielded 
better secretion than Usp45sp. To visualize putative mRNA folding, secondary structure 
predictions for Usp45sp, Usp45SM2, and Usp45SM3 — representing the wild-type 
sequence, a worse secreting sequence, and a better secreting sequence, respectively — 
were computed using mfold
25
 (Fig. 7.5). As shown, Usp45SM2 has greater secondary 
structure around the RBS, which would be expected to hinder ribosome binding and lead 
to lower expression and secretion. On the other hand, Usp45SM3 shows a more relaxed 
mRNA conformation around the RBS, which would more readily allow translation 
initiation and, thus, result in higher secretion. Three of the best clones, Usp45SM10, 
Usp45SM5, and Usp45SM3, showed a small (~15%) but significant increase in secretion 
of α-amylase. 
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Figure 7.5. Representative mRNA structures, showing the differences in secondary structure and ΔG 
around the ribosome binding site (RBS) for wild-type Usp45 signal peptide, Usp45SM2, and Usp45SM3. 
mRNAs from the transcript start site to 6 nucleotides after the end of the signal peptide sequence were 
entered into mfold to obtain the secondary structures
25. Structures with the lowest ΔG values are shown, 
with the RBS (AGGAGG) circled. 
 
Table 7.4. mRNA folding energies of the AGGAGG ribosome binding site and activities of secreted 
nuclease and α-amylase for selected clones from the Usp45sp silent mutation library a. 
Usp45sp silent 
mutation clone 
ΔG of ribosome binding 
site (AGGAGG) 
Secreted nuclease activity 
(compared to Usp45sp) 
b
 
Secreted α-
amylase activity 
(% of Usp45sp) 
c
 
Usp45SM2 -8.4 – 79 ± 5† 
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Usp45SM14 -8.4 – – 83 ± 13 
Usp45SM11 -6.1 – – 85 ± 3†† 
Usp45sp -6.1 * 100 
Usp45SM16 -5.9 – 91 ± 12 
Usp45SM19 -5.9 + 106 ± 16 
Usp45SM4 -5.7 + 107 ± 6 
Usp45SM10 -3.8 + 116 ± 5† 
Usp45SM20 -3.7 + + 103 ± 15 
Usp45SM5 -3.7 + 113 ± 5† 
Usp45SM8 -3.3 + 92 ± 5 
Usp45SM15 -3.3 + 100 ± 6 
Usp45SM9 -3.3 + 114 ± 7 
Usp45SM7 -3.2 + 105 ± 14 
Usp45SM6 -2.5 + + 99 ± 12 
Usp45SM12 -1.6 + + 96 ± 12 
Usp45SM3 -0.6 * 114 ± 3†† 
 
a
 Nuclease and α-amylase secretion levels are reported for cultures induced with 10 ng/ml nisin for2 h at 
mid-log phase. ΔG, mRNA folding energy. Nucleotide sequences are given in Table 7.5.  
b
 Data represent levels of nuclease secretion. *, secretion similar to Usp45sp level; –, secretion slightly (< 
10%) lower than Usp45sp level; – –, secretion much (> 10%) lower than Usp45sp level; +, secretion 
slightly (< 10%) higher than Usp45sp level; + +, secretion much (> 10%) higher than Usp45sp level.  
c
 α-Amylase secretion data represent the means ± SEM of the results of three independent experiments. †, P 
< 0.05; ††, P < 0.01 (for statistical comparison of α-amylase activities of the respective clone and Usp45sp 
using one-tailed Student’s t test). 
 
Table 7.5. Nucleotide sequences of selected clones from the Usp45sp silent mutation library. 
Usp45sp silent Nucleotide sequence (5’  3’) 
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mutation clone 
Usp45sp ATGAAAAAAAAGATTATCTCAGCTATTTTAATGTCTACAGTGATACTTTCTGCTGCAG
CCCCGTTGTCCGGAGTTTACGCC 
Usp45SM2 ATGAAGAAAAAGATCATATCCGCCATCTTGATGTCAACAGTCATTCTATCGGCCGCCG
CCCCCTTATCAGGCGTGTATGCC 
Usp45SM3 ATGAAGAAGAAGATCATTTCTGCCATTTTGATGTCAACAGTTATTCTTTCCGCAGCCG
CTCCGTTATCCGGAGTGTACGCC 
Usp45SM4 ATGAAGAAGAAAATCATTTCAGCGATATTAATGTCCACGGTCATCCTTTCTGCGGCCG
CTCCGTTGTCTGGTGTCTACGCC 
Usp45SM5 ATGAAGAAGAAAATCATCTCAGCCATATTAATGTCCACAGTGATCCTCTCCGCGGCAG
CGCCATTGTCCGGCGTGTACGCC 
Usp45SM6 ATGAAGAAGAAGATCATCTCCGCCATATTAATGTCCACTGTGATACTGTCAGCAGCTG
CGCCGTTGTCAGGTGTATATGCC 
Usp45SM7 ATGAAAAAAAAAATCATTTCAGCCATCTTGATGTCCACAGTTATCCTCTCAGCAGCAG
CTCCCTTATCGGGAGTTTACGCC 
Usp45SM8 ATGAAGAAGAAGATCATATCCGCGATCTTGATGTCGACAGTAATACTTTCGGCCGCGG
CGCCGTTATCGGGGGTATATGCC 
Usp45SM9 ATGAAAAAGAAGATCATCTCTGCCATATTAATGTCCACCGTAATCCTCTCCGCCGCCG
CGCCCTTATCCGGAGTCTACGCC 
Usp45SM10 ATGAAAAAGAAGATCATCTCAGCCATTTTGATGTCTACGGTTATTCTTTCTGCAGCAG
CTCCATTGTCCGGCGTATACGCC 
Usp45SM11 ATGAAGAAGAAAATCATCTCCGCAATATTAATGTCCACCGTGATACTATCTGCAGCTG
CCCCGTTATCTGGAGTGTACGCC 
Usp45SM12 ATGAAGAAGAAAATAATTTCCGCGATCTTAATGTCAACAGTGATCCTATCGGCAGCGG
CGCCATTATCAGGAGTGTACGCC 
Usp45SM14 ATGAAAAAGAAGATCATATCCGCCATCTTGATGTCTACAGTAATCCTTTCCGCGGCCG
CCCCCTTATCAGGTGTGTATGCC 
Usp45SM15 ATGAAGAAAAAGATCATCTCCGCAATTTTGATGTCGACAGTCATCCTCTCGGCTGCAG
CACCTTTGTCGGGAGTCTACGCC 
Usp45SM16 ATGAAGAAGAAGATAATATCCGCCATCTTAATGTCGACCGTGATACTTTCGGCAGCTG
CTCCTTTATCGGGAGTATATGCC 
Usp45SM19 ATGAAAAAAAAAATCATCTCTGCCATCTTAATGTCAACGGTTATTCTCTCCGCCGCTG
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CGCCTTTATCAGGGGTTTATGCC 
Usp45SM20 ATGAAAAAGAAGATCATTTCGGCGATATTGATGTCCACCGTCATTCTATCCGCGGCTG
CACCTTTGTCCGGGGTATACGCC 
 
7.3.3 Mathematical model captures secretion levels based on ΔG around the RBS 
To more quantitatively link predicted ΔGRBS values and experimentally measured 
secretion levels, we developed a mathematical model based on modifications of previous 
work
27
. The model considers translation to be initiated once the ribosome binds to the 
RBS, which is assumed to occur only when the initiation region of the mRNA is 
unfolded
30,31
 and is therefore determined by ΔGRBS. In the model, translation is 
proportional to the amount of ribosome-bound mRNA and secretion is a fraction of the 
total translated protein. We plotted α-amylase secretion versus ΔGRBS for three different 
nisin induction levels (0.1, 1, and 10 ng/ml) (Fig. 7.6A to C) and compared these 
experimental findings to model simulations with three analogously different mRNA 
transcript levels (all 10-fold apart) (Fig. 7.6D to F). Model predictions of protein 
secretion for all three transcript amounts show good agreement with experimental results. 
At all induction levels, tightly folded mRNA around the RBS yields low secretion. 
Secretion gradually increases as the mRNA structure around RBS is relaxed, but it 
eventually plateaus at high ΔGRBS when either the mRNA transcripts or ribosomes 
become limiting. The agreement between experiment and model further supports the 
notion that the mRNA conformation around the RBS can explain differences in secretion 
among the Usp45sp silent mutation clones. The relaxation of the mRNA structure alone 
in this context can augment secretion by a ~15% increase at the maximum induction 
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level. This modest improvement is consistent with the model, since the value determined 
for Usp45sp (-6.1 kcal/mol) is close to the plateau region of the curve (Fig. 7.6F). 
 
Figure 7.6. Secretion efficiencies of clones selected from the Usp45sp silent mutation library and 
comparison to results from a mathematical model. α-Amylase activity was plotted against the folding 
energy (ΔG) of the ribosome binding site (RBS) for induction at (A) 0.1 ng/ml, (B) 1 ng/ml, and (C) 10 
ng/ml nisin. α-Amylase activity was normalized to the amount secreted by Usp45sp culture induced with 
10 ng/ml nisin. ΔGRBS was calculated for the AGGAGG RBS sequence from the mRNA structure with the 
lowest overall ΔG. The data represent the means ± SEM of the results of three independent experiments. 
Simulation results show protein secretion levels plotted against ΔG for (D) low (3.2 µM), (E) medium (32 
µM), and (F) high (320 µM) mRNA transcript levels. Parameter values used in the model are given in 
Table 7.3. 
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7.3.4 Amino acid mutations in Usp45sp more significantly augment secretion of both 
nuclease and α-amylase 
Since our experimental and modeling results suggest that the mRNA structure of 
Usp45sp is not a major bottleneck in achieving enhanced protein secretion, we 
constructed another signal peptide library consisting of targeted amino acid substitutions 
in Usp45sp. The length and tripartite structure of wild-type Usp45sp were kept: 27 amino 
acids in total, with 7, 13, and 7 residues in the n-, h-, and c-regions, respectively. 
Residues that were considered significant in maintaining the identities of the three 
regions were kept as follows: (i) charged lysines in the n-region, (ii) hydrophobic 
residues in the h-region, and (iii) residues important for structure and cleavage of the 
signal peptide in the c-region. The resulting library had 13 possible positions at which 
amino acid mutations could occur (Fig. 7.7A). After screening for library members with 
nuclease secretion, little to no conservation was observed in the 13 randomized positions 
(Fig. 7.7A). Five selected clones (Usp45TM8, -TM11, -TM12, -TM13, and -TM14) had 
increased positive charge in the n-region (from + 3 to + 4 or + 5), but only two of these 
clones (Usp45TM8 and -TM11) exhibited significantly higher secretion for both nuclease 
and α-amylase (Fig. 7.7A and B). The poorer performances of Usp45TM12 and -TM13 
may be due to the fact that these sequences newly introduced a positive charge in the 
stretch of hydrophobic residues in the h-region. Comparing nuclease and α-amylase 
secretion across all clones, there was clearly a protein-specific effect on secretion for 
signal peptides Usp45TM13, -TM14, and-TM29 (Fig. 7.7A and B), but the two best 
clones from the nuclease screen, Usp45TM8 and -TM11, also exhibited enhanced 
secretion of α-amylase at both 1 and 10 ng/ml nisin induction (Fig. 7.7B). Western 
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blotting showed no differences among wild-type Usp45sp, Usp45TM8, and Usp45TM11 
signal peptides in the size of the secreted α-amylase, indicating no change in the cleavage 
pattern when the engineered signal peptides were used (Fig. 7.7C). The best clone, 
Usp45TM8, gave a ~45% increase in α-amylase secretion, 30% higher than what was 
achieved by silent mutations alone. 
 
Figure 7.7. Secretion efficiencies of clones selected from the targeted mutagenesis library of the Usp45 
signal peptide. (A) Amino acid sequences and secreted nuclease activity for cultures induced at 10 ng/ml 
nisin. Amino acid mutation positions, indicated by red Xs in the Usp45TM library sequence, were encoded 
by degenerate NNK nucleotides. *, –, – –, +, and + + indicate secretion levels similar to and < 10% lower, 
> 10% lower, < 10% higher, and > 10% higher than Usp45sp levels, respectively. Blue and green residues 
indicate positively and negatively charged residues, respectively. Nucleotide sequences are given in Table 
7.6. (B) α-Amylase activity of different clones normalized to the amount secreted by Usp45sp culture 
induced with 10 ng/ml nisin. Red bars represent induction at 1 ng/ml nisin, and green bars represent 
induction at 10 ng/ml nisin. The data represent the means ± SEM of the results of two independent 
experiments. (C) Western blot showing secreted α-amylase in the supernatant detected by anti-RGS-His 
antibody. The different targeted mutations did not alter the size of the secreted protein, indicating that the 
signal peptide cleavage site had been maintained. 
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Table 7.6. Nucleotide sequences of selected clones from the Usp45sp targeted mutation library. 
Usp45sp targeted 
mutation clone 
Nucleotide sequence (5’  3’) 
Usp45sp ATGAAAAAAAAGATTATCTCAGCTATTTTAATGTCTACAGTGATACTTTCTGCT
GCAGCCCCGTTGTCCGGAGTTTACGCC 
Usp45TM6 ATGAAAAAAAAGCTTGTTACTGCTCAGTTATATGGGAGTGTGATTCTTCTGTCT
GCAGCCCCGTATTCCTGTGTTAATGCC 
Usp45TM7 ATGAAAAAAAAGAGTTGTACGGCTGGTTTACAGTTGATGGTGACGCTTTTGACT
GCAGCCCCGTTTTCCTATGTTAATGCC 
Usp45TM8 ATGAAAAAAAAGGTGCTGAAGGCTCATTTAGCTGTGGTTGTGATGCTTACGACG
GCAGCCCCGATTTCCAATGTTAAGGCC 
Usp45TM11 ATGAAAAAAAAGCCGAGGCGGGCTTTGTTATGTATGCTTGTGGGTCTTGCTCTG
GCAGCCCCGATGTCCAATGTTACGGCC 
Usp45TM12 ATGAAAAAAAAGCGGCGGATGGCTTGGTTACGTATGATGGTGGCTCTTGGGGTT
GCAGCCCCGCCTTCCGATGTTCTTGCC 
Usp45TM13 ATGAAAAAAAAGCGTGCGTCTGCTTTGTTAAAGCTGACTGTGCTGCTTACTACG
GCAGCCCCGTGGTCCGTGGTTGGGGCC 
Usp45TM14 ATGAAAAAAAAGTCGGCGCGTGCTGCTTTAATGCTTTCTGTGAATCTTTTTTTG
GCAGCCCCGGCGTCCAATGTTAATGCC 
Usp45TM28 ATGAAAAAAAAGCCGTCGAGTGCTGTGTTATTGTGTTGTGTGATGCTTGGTATT
GCAGCCCCGTGTTCCTTTGTTATGGCC 
Usp45TM29 ATGAAAAAAAAGCCGTGTACTGCTCTTTTACTTTGGGGTGTGGCTCTTGCGATT
GCAGCCCCGAAGTCCTTTGTTCATGCC 
 
7.3.5 Silent mutations in Usp45TM8 further increase secretion 
Finally, another round of silent mutation was performed on the best targeted mutation 
clone to combine the benefits of the two mutation strategies. We constructed a library 
with silent mutations in Usp45TM8 in order to determine if relaxing the mRNA 
secondary structure encoding this new signal peptide would have any consequent effect 
on secretion efficiency. In addition, comparison of Usp45TM8 and Usp45sp silent 
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mutation clones with highly folded mRNA structures could reveal if any secretion 
enhancement achieved by amino acid substitution could be eliminated by tighter mRNA 
folding. We again screened for representative low-, medium-, and high-secretion clones 
and analyzed them individually for α-amylase secretion. Table 7.7 shows Usp45TM8 
silent mutation clones ordered by ΔGRBS. All analyzed clones had an increase in secretion 
of at least 30% compared to wild-type Usp45sp, even though the lowest ΔGRBS 
(Usp45TM8_SM15) was as low as those for the most poorly secreting Usp45sp silent 
mutation clones (Usp45SM2 and -SM14). This shows that the secretion enhancement 
brought about by the amino acid sequence of Usp45TM8 is more dominant than any 
inhibition of translation initiation due to mRNA folding (at least in this range of ΔGRBS). 
As in the Usp45sp silent mutation library, α-amylase secretion generally increased (up to 
~50%) when ΔGRBS increased, which is consistent with our hypothesis that tight mRNA 
folding around the RBS inhibits translation initiation and subsequent secretion. We then 
plotted α-amylase secretion against ΔGRBS for both the Usp45TM8 and Usp45sp silent 
mutation clones for comparison (Fig. 7.8A to C). At all induction levels, clones from the 
two silent mutation libraries exhibited the same trend, with low secretion at more-
negative ΔGRBS and higher saturated secretion at less-negative ΔGRBS. Usp45TM8 silent 
mutation clones generally exhibited higher secretion than Usp45sp silent mutation clones 
at comparable ΔGRBS values, with more pronounced differences observed at higher levels 
of induction. We also simulated secretion using the same mathematical model as 
described above, except we used a higher secretion constant for the Usp45TM8 amino 
acid sequence (see Discussion and Table 7.3), and there is good agreement between our 
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modeling and experimental results (Fig. 7.8). Our best clones, Usp45TM8_SM14 and 
TM8_SM25, yielded a ~50% increase in α-amylase secretion compared to Usp45sp. 
 
Table 7.7. mRNA folding energies of the AGGAGG ribosome binding site and activities of secreted α-
amylase of selected clones from the Usp45TM8 silent mutation library 
a
. 
Usp45TM8 silent 
mutation clone 
ΔG of ribosome binding site (AGGAGG) Secreted α-amylase 
activity (% of Usp45sp) 
b
 
Usp45TM8_SM15 -8.2 135 ± 2 
Usp45TM8_SM7 -6.1 137 ± 6 
Usp45TM8_SM22 -6.1 140 ± 2 
Usp45TM8_SM25 -6.1 151 ± 3 
Usp45TM8_SM9 -3.3 145 ± 5 
Usp45TM8_SM10 -3.0 143 ± 9 
Usp45TM8_SM14 -3.0 147 ± 5 
Usp45TM8 -2.1 145 ± 10 
 
a
 α-Amylase secretion levels are reported for cultures induced with 10 ng/ml nisin for 2 h at mid-log phase. 
ΔG, mRNA folding energy. Nucleotide sequences are given in Table 7.8.  
b
 α-Amylase secretion data represent the means ± SEM of the results of three independent experiments. For 
each value in this column, P < 0.01 (for statistical comparison of α-amylase activities of the respective 
clone and Usp45sp using one-tailed Student’s t test). 
 
Table 7.8. Nucleotide sequences of selected clones from the Usp45TM8 silent mutation library. 
Usp45TM8 silent 
mutation clone 
Nucleotide sequence (5’  3’) 
Usp45TM8 ATGAAAAAAAAGGTGCTGAAGGCTCATTTAGCTGTGGTTGTGATGCTTACG
ACGGCAGCCCCGATTTCCAATGTTAAGGCC 
253 
 
Usp45TM8_SM7 ATGAAAAAAAAGGTCCTTAAAGCACACTTGGCCGTGGTAGTGATGCTAACG
ACTGCTGCCCCGATTTCTAATGTAAAAGCC 
Usp45TM8_SM9 ATGAAAAAGAAGGTGCTCAAAGCACATTTAGCTGTGGTGGTGATGCTTACA
ACTGCTGCTCCCATTTCTAACGTTAAAGCC 
Usp45TM8_SM10 ATGAAAAAAAAGGTCCTCAAGGCTCACTTGGCAGTGGTGGTAATGCTTACC
ACAGCGGCCCCTATCTCTAATGTCAAGGCC 
Usp45TM8_SM14 ATGAAAAAGAAGGTCCTCAAGGCCCACTTGGCCGTAGTCGTTATGCTAACC
ACGGCTGCTCCAATATCTAACGTAAAAGCC 
Usp45TM8_SM15 ATGAAAAAGAAGGTACTCAAAGCACATTTAGCTGTTGTCGTAATGCTCACA
ACGGCCGCTCCTATATCGAATGTCAAAGCC 
Usp45TM8_SM22 ATGAAAAAGAAGGTCCTTAAGGCACATTTAGCTGTAGTCGTTATGCTAACT
ACGGCAGCCCCAATCTCAAATGTGAAAGCC 
Usp45TM8_SM25 ATGAAAAAGAAGGTCCTCAAGGCCCACTTAGCAGTTGTTGTGATGCTCACC
ACAGCTGCCCCTATCTCGAATGTTAAAGCC 
 
 
Figure 7.8. Secretion efficiencies of clones selected from Usp45TM8 silent mutation library compared to 
clones from Usp45sp silent mutation library. α-Amylase activity (normalized to the amount secreted by 
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wild-type Usp45sp at 10 ng/ml nisin) was plotted against ΔG of the RBS for induction at (A) 0.1 ng/ml, (B) 
1 ng/ml, and (C) 10 ng/ml nisin for Usp45TM8 silent mutation clones (color squares; Usp45sp silent 
mutation clones as described for Fig. 7.6 are shown as gray diamonds for comparison). The data represent 
the means ± SEM of the results of three independent experiments. Simulation results show protein 
expression levels against folding energy for (D) low (3.2 µM), (E) medium (32 µM), and (F) high (32 µM) 
mRNA transcript levels. Color lines represent Usp45TM8 silent mutation clones, and dashed gray lines 
represent Usp45sp silent mutation clones (data from Fig. 7.6). 
 
7.4 Discussion 
Using directed evolution, we have systematically explored the mRNA and amino acid 
sequence space of Usp45sp to achieve enhanced protein secretion in L. lactis (Fig. 7.9). A 
minor limitation of wild-type Usp45sp lies in its significant mRNA secondary structure, 
which may lead to less-efficient translation initiation. By relaxing mRNA folding around 
the RBS (-6.1 kcal/mol for Usp45sp and -3.8 kcal/mol for Usp45SM10), we could 
slightly improve secretion (up to 16%). The modest nature of this effect could be 
quantitatively captured by a mathematical model that relates the free energy of folding 
around the RBS to protein secretion. A more significant limitation lies in the actual 
amino acid sequence of Usp45sp, which likely impacts the efficacy of the physical 
process of protein secretion. By mutating nonconserved positions in the tripartite signal 
peptide, we significantly improved secretion yields (by 41% and 45% for Usp45TM11 
and Usp45TM8, respectively). As quantitatively predicted by our mathematical model 
and confirmed by additional directed evolution experiments, introducing silent mutations 
into the best amino acid sequence (Usp45TM8) minimally improved protein secretion at 
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maximum induction (6% additional enhancement for Usp45TM8_SM14 compared to 
Usp45TM8).  
 
Figure 7.9. Progressive improvements in L. lactis secretion achieved by directed evolution. (A) Nucleotide 
sequence alignment of selected clones (only differences from Usp45sp are shown). (B) α-Amylase activity 
of selected clones at 0.1 ng/ml (blue), 1 ng/ml (red), and 10 ng/ml (green) nisin induction. The data 
represent the means ± SEM of the results of three independent experiments. Arrows below the graph show 
the evolutionary relationships between the different selected clones. 
 
Intriguingly, the best silent mutation clones for Usp45TM8 were able to enhance 
secretion at lower induction levels. The Western blot in Fig. 7.7C and the starch azure 
assay in Fig. 7.9B show that secretion of α-amylase by Usp45TM8 and -TM11 at 0.1 
ng/ml nisin is lower than that by wild-type Usp45sp despite enhancing secretion at higher 
nisin concentrations (1 and 10 ng/ml). Silent mutations in Usp45TM8 were able to restore 
wild-type secretion levels at 0.1 ng/ml nisin, and Usp45TM8_SM14 is shown as an 
illustrative example (Fig. 7.9B). Although the mechanism by which silent mutations 
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enhance submaximal secretion is not entirely clear, combining amino acid and silent 
mutation strategies has enabled us to augment the maximum secretion enhancement of 
51% without jeopardizing secretion at lower induction level.  
Our mathematical model is most successful in explaining the relationship between 
mRNA folding and protein secretion at a high nisin induction level (e.g., 10 ng/ml nisin) 
(Fig. 7.6 and 7.8). In this regime, the availability of ribosomes is limiting and translation 
rate is at its maximum. At lower nisin concentrations (1 or 0.1 ng/ml nisin), the number 
of mRNA transcripts becomes limiting and other factors not considered by the model 
(e.g., degradation of mRNA
36
) might become more important. Thus, it is possible that 
Usp45TM8, while as efficient as Usp45TM8_SM14 in translation and secretion, is 
subjected to a higher rate of mRNA degradation. This effect may be negligible at the high 
induction levels but becomes more pronounced when the mRNA transcript level becomes 
limiting. The importance of such secondary effects at lower induction levels (0.1 and 1 
ng/ml nisin) may account for the disparity between the experiments and model 
simulations at more-negative ΔGRBS. Clones with stronger folding around the RBS also 
tend to have a higher level of secondary structure overall, which might reduce mRNA 
degradation. By neglecting the counterbalancing effect of reduced mRNA degradation in 
the model, the simulations should underestimate secretion at low ΔGRBS and this is 
indeed what is seen (Fig. 7.6 and 7.8). Another assumption in the model is that the 
mRNA transcript level varies linearly with nisin concentration for the range of inducer 
used in our experiments.  
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In analyzing our experimental results, we initially attempted to use ΔG of the 
entire translation initiation region to predict expression, as has been done in other 
work
35,37
, but we did not see any correlations even when different mRNA windows were 
used. In our study, small windows could not capture the contributions of the entire signal 
peptide region (81 nucleotides from the start codon), while large windows included 
significant, but distal mRNA secondary structures that did not affect translation initiation. 
It was also not possible to use ΔG of the untranslated region around the RBS27 because 
our silent mutations are contained in the coding region. Therefore, we simulated folding 
of the mRNA sequence from the transcription start site to six nucleotides after the signal 
peptide to capture all silent mutation contributions, but the relevant ΔG was calculated 
only from base pairing involving the RBS. These values were computed using ΔG data 
from mfold
25, but since ΔG contributions of individual base pairs were parsed from the 
overall mRNA structure, an initiation term of 3.4 kcal/mol was added
26. The ΔG for 
unfolded mRNA binding to the 30S ribosomal subunit was -14 kcal/mol
27
. This value is 
consistent with experimentally measured values
38
 with the additional consideration of 
translational standby sites
39
.  
With a limited number of targeted mutation clones, it is difficult to present a 
comprehensive picture of the molecular determinants in Usp45sp that govern protein 
secretion. Nevertheless, two of the best clones in our study, Usp45TM8 and -TM11, 
appeared to increase the overall positive charge in the n-region without introducing 
destabilizing charges in the hydrophobic h-region (Fig. 7.7). It has been suggested that 
positive charges in the n-region are responsible for interacting with the Sec translocation 
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machinery and the negatively charged phospholipids in the membrane during 
translocation
40
. Increasing the positive charge in this region has been shown to improve 
secretion efficiency in E. coli and B. brevis
20,41,42
. In the hydrophobic h-region, 
Usp45TM8 has an increased number of polar residues (four) and Usp45TM11 has a 
decreased number (two) compared to wild-type Usp45sp (three). Previous studies 
investigating the effect of introducing hydrophobic residues such as leucines in this 
region have given contradictory results; secretion has been shown to increase in E. coli 
and B. brevis but has been shown to decrease in L. lactis
20,41,42
. In the light of these 
findings and our own results, it is possible that the specific amino acid identities and their 
actual positions within the h-region are important factors in regulating secretion. For 
example, in Usp45TM11, a glycine is found in position 8 of the h-region, and this helix-
breaking residue is commonly present in the middle of the hydrophobic core to allow the 
signal peptide to form a hairpin-like structure to facilitate membrane insertion
40
. Given 
our library design, mutations in the c-region should have relatively minor influences on 
the overall secretion efficiency since most of the important residues (proline and serine 
favoring β-turns; -3 and -1 residues for signal peptidase cleavage)43 were held constant 
(Fig. 7.7A). Overall, the best signal peptides from our screens preserve the tripartite 
structure of the signal peptide but increase the positive charge of the n-region.  
Many other factors, such as the overall charge balance, hydrophobicity profile, 
and interactions among the n-, h-, and c-regions, can influence secretion efficiency, so 
further design of signal peptides may still necessitate extensive trial-and-error. The lack 
of a blueprint for signal peptide engineering motivated us to use a directed evolution 
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approach to discover sequences that enhance secretion. In designing our targeted 
mutation library, we attempted to retain features that appear to be generally conserved in 
signal peptides while allowing for full randomization in the remaining positions. This 
library was far from exhaustive, but nevertheless, our simple screen, requiring only a 
transformation step and a plate assay, was successfully used to identify signal peptide 
mutants with an increase of up to 51% in secretion relative to the most efficient natural 
signal peptide in L. lactis.  
 Future work should include examining the potential context dependence of 
selected signal peptides, since it is possible, even likely, that the optimal signal peptide 
will change with different expression systems or coding sequences. In our screens, we 
found that signal peptides can exhibit different secretion efficiencies at different 
expression levels (e.g., low vs. high nisin concentration in Fig. 7.9B). Our screen was 
designed to select the best signal peptide at the highest expression level; however, if a 
promoter with an attenuated expression level were preferred, a different signal peptide 
might be optimal. We have also observed protein-specific effects on secretion by 
comparing nuclease and α-amylase secretion for the selected clones (Table 7.4 and Fig. 
7.7). To address these concerns and to use this selection system for finding the optimal 
signal peptide for secretion of therapeutic or recombinant proteins of interest (e.g., insulin 
from Chapter 6), a signal peptide library can be built downstream of the desired promoter 
and upstream of a therapeutic-nuclease fusion reporter. The same nuclease screen can be 
employed, but any effects on secretion arising from construct-specific interactions within 
the upstream portion of either the encoding mRNA or the corresponding amino acid 
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sequence can now be accounted for. The protein of interest is fused directly to the signal 
peptide, which is an important consideration, as our work and previous work
44
 have 
shown dependence of the 5’ end of the encoding mRNA on expression. In fact, a toxic 
protein(MazF)-nuclease fusion reporter assay has been successfully used to select for L. 
lactis signal peptides with increased secretion, which reduced intracellular levels of the 
toxic protein and resulted in cell survival (Fig. 7.10). 
 
Figure 7.10. Selection results for Usp45sp silent mutation library fused to MazF-NucB reporter gene. (A) 
Growth curves of MazF-NucB cultures with Usp45sp (blue ♦: no nisin, red ◊: 1 ng/ml nisin), Usp45_MN_2 
(green ▲: no nisin, green ∆: 1 ng/ml nisin), and Usp45_MN_4 (red ●: no nisin; red ○: 1 ng/ml nisin) 
showed improvements in cell survival in Usp45_MN_2 and Usp45_MN_4 variants, potentially due to 
greater toxin secretion. (B) Secreted nuclease activity for MazF-NucB cultures induced with 1 ng/ml nisin. 
* and ++ indicate secretion levels similar to and > 10% higher than Usp45sp levels respectively. 
 
Additional studies are also needed to determine whether even greater 
improvements in secretion can be achieved solely by engineering the signal peptide, since 
other steps in the secretion process such as translocation efficiency
23
, modification by 
chaperones
14
, and transportation across the cell wall
45
 might become limiting. Indeed, 
protein secretion in L. lactis has been improved by introduction of a synthetic 
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propeptide
22
 or by complementation with the SecDF machinery
23
. Thus, other natural or 
engineered bacterial species with higher levels of protein secretion may serve as better 
fundamental models for studying inherent limitations of signal peptides. Nonetheless, this 
study produced signal peptides that can replace wild-type Usp45sp in many 
biotechnological and clinical applications of L. lactis and it also highlights the potential 
of directed evolution as a general approach for signal peptide engineering in bacteria. 
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CHAPTER 8 
Conclusions and future directions 
8.1 Summary of work 
In this work, we have sought to develop the next generation of therapeutics in two major 
ways: through molecular engineering approaches guided, when possible, by mathematical 
models, and through cellular engineering approaches to create a microorganism-based 
oral delivery platform. Our molecular engineering efforts have led to the development of 
two robust in vitro directed evolution protocols for mRNA display (Chapter 4) and 
ribosome display (Chapter 5), which were then employed to display and study a variety 
of interesting scaffold proteins and agonists. Through in vivo directed evolution, namely 
an Escherichia coli display system (Chapter 2) and a Lactococcus lactis platform 
(Chapter 7), proteins and peptides with new and useful properties have been evolved and 
these properties have been linked to desired responses through mathematical models that 
provide new mechanistic insights. In the area of antibody engineering, we successfully 
employed a CDR grafting strategy for scFv stabilization and humanization. Our work on 
Fc domain engineering identified specific binding properties of aglycosylated Fc mutants 
that enhance tumor cell phagocytosis; in a separate but related study, we altered a 
monomeric Fc domain by introducing mutations that stabilize and improve serum half-
life, and this variant retained FcRn binding. For protein therapeutics from 
267 
 
nonimmunoglobulin domains, we elucidated stability determinants for a DARPin, as well 
as two important agonists, insulin and leptin. Throughout this work, mathematical 
modeling was critical for guiding directed evolution efforts and understanding outcomes. 
The molecular insights generated from the mechanistic models on aglycosylated Fc and 
signal peptide engineering can inform future engineering efforts. The thermodynamic 
ligation model and related software (Chapter 3) provide an easy way to rationally 
optimize ligation reactions for DNA library construction. 
Complementary to our molecular engineering work, we have also proposed a 
novel cell-based platform for oral delivery of protein therapeutics based on Lactococcus 
lactis (Chapter 6). Single-chain insulin and leptin have been used as model agonists in 
this platform. We further improved the therapeutic potential of L. lactis through signal 
peptide engineering (Chapter 7). Our results open up the possibility of systemic delivery 
of protein therapeutics using live microorganisms. 
 
8.2 Future directions in molecular engineering studies 
A direct extension of this work would be the molecular evolution of some of the proteins 
already functionally displayed in either the ribosome display or mRNA display platform. 
With ribosome display, randomized internal repeats and/or capping repeats could be 
added to the truncated Off7 fragments and selected for MBP binding. The resulting 
binders could then be compared to wild-type Off7 to examine differences in sequence 
and affinity arising from different evolutionary paths. Single-chain insulin, leptin, and the 
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disulfide-free leptin variant could be evolved for higher stability or reduced proteolysis, 
particularly in the gut. 
A new generation of hR6.5 with alternative stable frameworks could be tested for 
human ICAM-1 binding. If successful, the next step would be to evolve hR6.5 or hYN1 
for cross-species binding. In particular, there is interest in an scFv capable of binding to 
rat ICAM-1, which is important for translational research since it will allow the study of 
in vivo biodistribution and protective effects in small animal models (C. Greineder, 
personal communication). In order to meet this evolutionary objective, DNA shuffling of 
hR6.5 and hYN1, coupled with additional point mutations introduced through random 
mutagenesis, may make a good starting library for ribosome display. 
The bacterial display platform used to screen aglycosylated full length antibodies 
can be used to evolve Fc domains to enrich for FcγRIIa-H131/FcγRIIb selectivity since 
our mathematical model clearly suggested a dominant role for FcγRIIa-H131 in effector 
activation. Evolving more avid and selective binders to this new engineering target 
should lead to an even greater enhancement in antibody-dependent cellular phagocytosis. 
The availability of a new streamlined mRNA display protocol, which utilizes 
highly stable, covalently assembled selection particles, should facilitate the development 
of novel selection methodologies that transcend simple binding and enrich for more 
complex behaviors directly on cells. One such function is transcytosis, where a new 
selection method with mRNA display utilizing cultured polarized epithelial cells can be 
investigated. Monolayers of Caco-2 or HT-29 cells grown on a permeable support (e.g., a 
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Transwell plate) differentiate and form tight junctions, resembling the intestinal 
epithelium
1,2
. In each round of mRNA display, the mRNA-protein complexes could be 
added to the apical side of the monolayer and selection particles that display transcytosis 
properties would be recovered on the basolateral side through RT-PCR of the mRNAs in 
the medium. Although there may be concerns about mRNA stability during this process, 
preliminary studies using ribosome display for selection of human leptin across Caco-2 
monolayers showed that at least some of the mRNA from the ternary complexes added to 
the apical side can be recovered from the basolateral side (Fig. 8.1), suggesting that 
selection via transcytosis is in principle possible using in vitro display methods. For 
future studies, mRNA display might represent a better strategy because the covalently 
linked mRNA-protein complex is much more stable than the mRNA-ribosome-protein 
ternary molecule. A protein with greater potential than leptin for transcytosis in the gut 
might also be considered in developing this cell-based mRNA display protocol. A 
convenient choice would be mFc.67, since Fc/FcRn has more established mechanisms for 
transcytotis in the gut
3
 and since mFc.67 has already been shown to specifically bind to 
FcRn in mRNA display format (Chapter 4). Overall, the idea that assays can be designed 
to directly select for protein functions in the context of a cell is extremely exciting as it 
can eliminate disparities that commonly arise between affinity engineering against a 
purified target and resulting cellular activity of such engineered variants. 
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Figure 8.1. Transcytosis of human leptin across Caco-2 monolayer assessed by ribosome display. Caco-2 
cells were grown on a 6-well Transwell plate and differentiated. Ternary complexes of human leptin were 
added to the apical side of the monolayer. “+” represents wells with only cells and “com.” represents wells 
with cells in the presence of excess leptin competitor (5×10
14
/well). Panning was performed for 1 h at 37°C 
or 4°C with shaking; then, 200 µl solution from the basolateral or apical side was taken to isolate mRNA 
according to protocols described in Chapters 4 and 5. Products after RT and 25 cycles of PCR were shown. 
 
Extending this idea even further, another interesting molecule that displays high 
transcytotic potential is botulinum neurotoxin B (BoNT/B). This food toxin is generally 
regarded as one of the most potent poisons
4
. After ingestion of the toxin, BoNT/B binds 
to receptors on the mucosal side of the intestinal epithelium and undergoes transcytosis to 
reach systemic circulation, where it acts on peripheral cholinergic nerve endings to block 
acetylcholine release
5
. Fortunately, its binding and translocation domains are distinct 
from the catalytic domain that is responsible for its toxicity
6
. Upon removal of the toxic 
subunit, the BoNT/B binding subunit can potentially provide unique advantages over 
other carrier molecules for certain transcytosis applications (see next section). 
 
8.3 Future directions in cell-based oral delivery studies 
A more comprehensive study is needed to evaluate the in vivo efficacy of delivering SCI-
57 orally to diabetic mice via L. lactis. However, our completed preliminary mice 
experiments suggest several areas for improvement of the platform. It is therefore prudent 
to first maximize the delivery potential of L. lactis before proceeding to further in vivo 
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testing. One significant issue is the dosage of therapeutic proteins in systemic circulation 
following oral delivery of L. lactis. Two challenges need to be addressed in this regard: 
1) maximizing the amount of protein secreted by L. lactis in the intestinal lumen and 2) 
maximizing the fraction of this secreted protein that reaches systemic circulation. 
To partially address the first challenge, we have evolved signal peptides capable 
of increasing the secretion level of L. lactis. However, since the library used was far from 
exhaustive and the selection was carried out with a generic reporter protein, further 
optimization of the signal peptide may be possible. The newly evolved signal peptides 
can then be fused to the therapeutic protein of interest to enhance secretion. Another 
strategy to improve secretion would be to overexpress the translocation machinery or 
complement missing members (SecDF)
7
 to maximize the intrinsic secretion capacity of L. 
lactis. A third strategy would be to engineer stronger promoters so that more protein 
molecules can be synthesized. A library of PnisA (the strongest promoter tested so far) 
can be synthesized by keeping the transcription initiation site, -35 and -10 sites before the 
transcription initiation site, and ribosome binding site sequences constant while 
introducing stretches of randomized sequences around them; the fixed motif sequences 
ensure promoter function, while the random bases modulate efficiency
8
. The promoter 
library can then be introduced upstream of a reporter gene (e.g., green fluorescence 
protein) and stronger promoters can be enriched by fluorescence-activated cell sorting. In 
fact, the reagents needed for such promoter engineering have already been acquired. All 
of these strategies could eventually be combined to significantly increase the amount of 
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protein expressed and secreted by L. lactis, which would correspond to enhanced 
therapeutic delivery during treatment. 
To address the second issue of bioavailability, mechanisms for efficient 
absorption of the delivered proteins are needed. Carrier-mediated transcytosis remains a 
promising approach for increasing absorption of bulky protein molecules. We briefly 
investigated this strategy using leptin as a transcytosis fusion partner, and we successfully 
secreted functional SCI-57-leptin fusion proteins from L. lactis. However, preliminary 
ELISA experiments assessing for transcytosis of leptin across Caco-2 cells gave a low 
yield on the basolateral side. Moreover, although there is some evidence of leptin 
transcytosis
9,10
, there are other candidates with more well-characterized properties for 
intact transcytosis. Specifically, transcytosis partners such as mFc.67, mFc.67 variants, or 
BoNT/B might elicit greater success in enhancing intestinal absorption. 
While molecular engineering can increase the proteolytic stability of the delivered 
protein, cellular engineering of L. lactis itself might improve the survival of the bacteria 
in harsh environments. For example, trehalose can be co-expressed by L. lactis to 
improve its viability after freeze-drying (for formulation) and survival in the gastric 
environment
11
. An evolutionary approach similar to the one described in Dekel and 
Alon
12
 could also be used to evolve L. lactis strains that better adapt to the gastric or 
intestinal environment by serial dilution of a culture through hundreds of generations in 
progressively more unfavorable environments. 
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Further extensions to this work could include construction of a glucose sensor in 
L. lactis to express proteins when glucose is present. The L. lactis strain MG5267 can be 
used to allow growth with lactose as the carbon source
13
. In the presence of glucose, the 
constitutively expressed carbon catabolite control protein A (ccpA) activates the cre-
containing promoter of the las operon and upregulates its downstream genes
14
. It might 
be possible to mimic these existing interactions to create a synthetic “glucose-sensing” 
promoter to trigger therapeutic protein production autonomously. 
Although this work has mainly focused on systemic delivery of protein 
therapeutics, L. lactis could also be used for systemic delivery of vaccines
15
. It would be 
interesting to use the transcytosis fusion partner BoNT/B for this application since the 
fusion partner would be highly immunogenic and could serve as a potent adjuvant to 
maximize the immune response against the fused antigen. In addition, mucosal delivery 
of therapeutics using L. lactis, which does not depend on transcytosis, is a very exciting 
area of research
15
. For example, mucosal delivery of insulin was used to induce antigen-
specific tolerance for treatment of Type I diabetes
16
. This mode of antigen delivery to the 
gut for induction of immune tolerance could be further exploited with other antigens. 
Moreover, other deliverables which act on cells in the gastrointestinal tract can also be 
easily delivered by L. lactis. In short, this simple and inexpensive cell-based platform has 
the potential to be used for oral delivery of a wide range of important protein 
therapeutics. 
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